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EVALUATION OF EFFECTS OF CYP450 DERIVED EICOSANOIDS IN 
CEREBRAL ISCHEMIA 
Jafar Sadik Bhasha Shaik, M. Pharm., Ph.D. 
University of Pittsburgh, 2013 
Stroke and cardiac arrest (CA) both are characterized by severe fall in the cerebral blood flow 
(CBF) locally or globally at the onset of the event with subsequent prolonged reductions observed 
after initiation of reperfusion. These CBF derangements may lead to secondary neuronal damage 
and worse functional outcomes. Currently there is limited understanding of the causative factors 
of CBF dysregulation after cerebral ischemic injury. Among the many known vasoactive 
substances, CYP450 derived metabolites of arachidonic acid (AA), called CYP eicosanoids were 
shown to act as potent regulators of microvascular tone. The main objective of this research was 
to investigate the role of CYP eicosanoids in the cerebral ischemic injury using in vitro and in vivo 
models of ischemia. In order to characterize the regional and temporal distribution of CYP 
eicosanoids in the brain after ischemic injury, sophisticated lipidomics based analytical methods 
were developed and validated.  
Studies in in vitro neuronal cultures indicated that 11,12-EET (vasodilatory) exhibited 
concentration-dependent neuroprotective effects whereas 20-HETE (vasoconstrictive) exhibited 
concentration-dependent toxic effects in a hypoxia-reoxygenation injury model. We have used two 
pharmacological inhibitors of CYP eicosanoid pathway for in vivo studies namely t-AUCB, an 
inhibitor of soluble epoxide hydrolase (sEH) that converts EETs to inactive DHETs 
(dihydroxyeicosatrienoic acid), and HET0016 that inhibits 20-HETE synthesis. The in vivo studies 
iv 
in animal model of focal ischemia with t-AUCB showed the following key findings: i) significant 
reduction in the infarct size by specifically increasing the ratio of EET/DHET in the cortex; ii) 
significant improvement in the short-term functional outcome after acute administration; iii) 
marginal improvement in CBF around the infarcted area during the post-ischemic reperfusion, and 
iv) dose-dependent significant increase in the neuronal survival in a hypoxia-reoxygenation injury
model of primary rat cortical neuronal cultures. 
Our studies in animal model of global ischemia showed a specific pattern of CBF dysregulation 
during the reperfusion phase that is dependent on the duration of the initial injury itself. Our 
lipidomics analysis of regional and temporal distribution of AA metabolites in the rat brain 
revealed a significant imbalance in the tissue levels of these metabolites, and their association with 
the pathological changes in CBF in the cortex post resuscitation from different durations of CA. 
The studies with acute administration of HET0016 showed improvement in the cortical CBF 
during the early reperfusion phase after 12 min CA by selectively inhibiting 20-HETE levels in 
the cortex. Further, we showed significant reduction in neuronal death, and improved short-term 
behavioral performance after a single low dose administration of HET0016. 
In conclusion, these results showed the evidence that CYP eicosanoids are associated with CBF 
dysregulation after ischemic injury in both focal and global ischemia, and that alteration of CYP 
eicosanoids levels in brain tissue with pharmacological inhibitors  improves short-term functional 
outcome through vascular and non-vascular mechanisms. Further research is warranted in order to 
design an effective therapeutic strategy for administering pharmacological inhibitors of CYP 
eicosanoid pathway to rectify the CBF dysregulation and improve the long-term functional 
outcomes after stroke injury. 
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1.0 INTRODUCTION AND BACKGROUND 
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1.1 STROKE AND CARDIAC ARREST 
Stroke is the leading cause of long-term disability and third leading cause of death in the 
United States (Goldstein et al., 2001; Young et al., 2007). Each year almost 130,000 Americans 
die due to stroke. On average, one American dies from stroke every 4 minutes. Every year, more 
than 795,000 people in the United States have an incidence of stroke. About 610,000 of these are 
first or new strokes (Roger et al., 2012). Stroke costs the United States an estimated $38.6 
billion each year, which includes the cost of health care services, medications, and missed days of 
work. Common stroke warning signs and symptoms include sudden numbness or weakness of the 
face, arm, or leg especially on one side of the body, sudden confusion, trouble speaking or 
understanding, sudden trouble seeing in one or both eyes, walking, dizziness, loss of balance or 
coordination, and sudden severe headache with no known cause. The risk of having a stroke varies 
with race, ethnicity, gender, and age. In general, stroke incidence and mortality rates are lower in 
premenopausal women relative to men of same age indicating that differences may exists in stroke 
risk and outcomes between men and women. However, some of these differences may be unrelated 
to sex hormones, and are inherent to gender differences at cellular level (Golomb et al., 2009; 
Lloyd-Jones et al., 2009). Key risk factors for stroke include high blood pressure, high LDL 
cholesterol, smoking, and lifestyle disorders such as diabetes, overweight and obesity, physical 
inactivity, and excessive alcohol use (Centers for Disease et al., 2011).  
 
Out-of-hospital cardiac arrest (OHCA) is a leading cause of death among adults in the United 
States. Each year, approximately 300,000 persons in the United States experience an OHCA and 
approximately 92% of persons who experience an OHCA event die. An OHCA is defined as 
cessation of cardiac mechanical activity that occurs outside of the hospital setting and is confirmed 
2 
 
by the absence of signs of circulation. An OHCA can also occur from non-cardiac causes such as 
trauma, drowning, overdose, asphyxia, electrocution, primary respiratory arrests, and other non-
cardiac etiologies (McNally et al., 2011). However, the most common cause of cardiac arrest (CA) 
in adults is ventricular fibrillation (VF). The majority of persons who experience an OHCA event 
do not receive bystander-assisted cardiopulmonary resuscitation (CPR) or other timely 
interventions that are known to improve the likelihood of survival to hospital discharge. It is 
estimated that 16,000 American children suffer a CA each year. Only 5% to 10% of patients 
survive OHCA and often with severe neurological complications whereas 27% of in-hospital arrest 
patients survive to discharge with 65% of them leaving with good neurological outcomes (Topjian 
et al., 2008). Pediatric arrests often occur as a complication of, or progression of respiratory failure, 
circulatory shock, or both (Sahu et al., 2010), which is one of the most common causes of non-
traumatic brain injury in children. Return of spontaneous circulation (ROSC) is achieved in 
approximately 30% of children who suffer out-of-hospital CA, but only 12% of these survive to 
hospital discharge, and only 4% of these children have favorable neurologic outcome (Donoghue 
et al., 2005). In case of in-hospital CA the prognosis is comparatively better with 52% of the 
patients achieving ROSC, 27% survive to hospital discharge, and 15% have favorable neurological 
outcomes. Although respiratory failure is the major cause of CA in pediatric patients, ventricular 
fibrillation can also occur in 10 – 15% of the pediatric cases (Donoghue, et al., 2005; Young et al., 
2004). Since pediatric CA are secondary to asphyxia rapid initiation of CPR to restore circulation 
is very crucial in improving survival as recommended by  The International  Liaison Committee 
on Resuscitation (ILCOR) (Herlitz et al., 2005; Hickey et al., 1995). 
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1.1.1 Classification and characterization  
Approximately 15% of the stroke occurrences are of hemorrhagic nature due to rupture of 
a cerebral blood vessel in parenchyma or subarachnoid space, and 85% are of ischemic nature due 
to either thrombotic or embolic occlusion of a cerebral artery. There is a graded evolution of lesion 
in the tissue that is supplied by the occluded artery in ischemic stroke based on the residual blood 
cerebral blood flow (CBF). A focal or central region of rapid death called core (infarct) is 
characterized by marked reduction in CBF to less than 10% of baseline. It is surrounded by 
penumbral region (peri-infarct) with residual blood flow between 15 and 40% of baseline supplied 
from collateral arteries. Infarct region represents irreversible cell death whereas penumbral region 
represents cells at risk of death and is salvageable if blood flow is restored to normal levels in a 
timely manner. CA leads to global cessation of blood flow to brain causing global brain ischemia, 
which progressively changes the cellular architecture and physiology, rendering the cells 
susceptible to further damage following reperfusion. This condition of reduced nutritive supply of 
oxygen and glucose to brain due to decreased blood flow is termed as cerebral ischemia. Ischemia 
of cerebral tissue and cell death is common underlying mechanism in all forms of stroke including 
focal ischemia (embolic and/or thrombotic), and global ischemia (as in cardiac arrest). In addition, 
ischemia also overlaps with the underlying injury mechanisms of vascular complications in 
traumatic brain injury (TBI) and subarachnoid hemorrhage (SAH). Interestingly, there are 
remarkable differences in the underlying mechanisms of cell death between global and focal 
ischemia, and within the focal ischemia there are unique processes in the tissue that undergoes 
reperfusion (Smith, 2004). Understanding these injury type specific cell death mechanisms is 
critical in developing new therapeutic strategies for effectively reducing the ischemic 
complications of stroke and cardiac arrest.  
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1.1.2. Pathophysiology of cerebral ischemic injury  
The energy needs of the brain are provided by metabolism of glucose and oxygen for the 
phosphorylation of ADP to ATP. Most of the ATP thus generated is used in the brain to maintain 
intracellular homeostasis and transmembrane ionic gradients. Cerebral ischemic injury 
mechanisms were well described in the literature. Although exact sequence of events is not 
determined, the sequence of events that follow after the injury are distinct and unique in different 
regions of the brain due to which they exhibit varied degrees of tolerance to ischemia. During 
ischemia within minutes brain tissue is deprived of glucose and oxygen. In the core infarct region, 
loss of glucose, and decrease in the pH due to accumulation of acidic products of metabolism 
severely decreases ATP production due to suppression of mitochondrial electron transport chain 
activity. Rapidly declining ATP levels affect energy dependent pumps like Na+/K+ ATPase, 
perturbing ionic gradients across membrane resulting in persistent depolarizations. This is 
exacerbated further due to high influx of Ca2+ owing to the failure of Na+/Ca2+ exchanger resulting 
in massive sequestration of intracellular Ca2+. At this point neurons in the infarct core region begin 
to fire repetitively releasing the excitatory neurotransmitters in the synapses such as glutamate, 
which was observed to increase in both focal (Hillered et al., 1989; Takagi et al., 1993) and global 
ischemia (Benveniste et al., 1984). A massively high intracellular Ca2+ is a key contributor of 
ischemic cell death as it initiates several events including activation of proteases that affect 
structural integrity of cytoskeleton, activation of phospholipases that affect membrane integrity. 
Increased intracellular Ca2+ also induces of nitric oxide synthase (NOS), which produces highly 
reactive free radical peroxynitrate capable of causing single stranded DNA breaks. This induces 
poly (adenosine diphosphate ribose) polymerase (PARP) activity, and together with other parallel 
mechanisms detailed above neurons eventually die due to necrosis.  
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However, depending on the degree and duration of ischemia these events describe above may be 
minimal and short lived resulting in temporary cellular dysfunction (Smith, 2004). In the 
penumbral region, cellular damage is mediated by different mechanisms. Since ATP levels and 
blood flow are marginally reduced in penumbra, ionic homeostasis, and transmembrane gradients 
are not fully impaired thus rendering neurons in this region functionally viable but electrically 
inactive. Increased levels of extracellular glutamate released from dying neurons of core region 
was found to be toxic to penumbral neurons, a phenomenon termed as excitotoxicity (Hugon et 
al., 1996; Kirino, 1994; Whetsell, 1996). Glutamate acts on ionotropic and metabotropic glutamate 
receptors, N-methyl-D-aspartate (NMDA), and α-amino-3-hydroxy-5-methyl-4-isoxazole 
propionic acid (AMPA) receptors resulting in elevated intracellular calcium [Ca2+i]. As shown in 
the Figure 1-1, moderate increases in Ca2+ activates phospholipases, cause lipid peroxidation, 
release fatty acids into cytosol, and increases release of cytochrome C from mitochondrial 
transition pore, which initiates apoptotic cell death by activating caspase activity.  
 
Adding to the complexity, during reperfusion more free radicals are generated by mitochondria, 
creating oxidative stress, which accounts for much of neuronal damage. As such brain is 
particularly vulnerable to oxidative stress due to high concentrations of polyunsaturated fatty acids 
(PUFA), which are susceptible to lipid peroxidation and lower antioxidant defense compared to 
other organs. Specifically, neurons are more susceptible to damage by oxidative stress as they have 
lower levels of reduced glutathione (Dringen, 2000). These free radicals bind covalently to cellular 
proteins, nucleic acids, lipids and alter their function. Further, they also contribute to the 
inflammatory response by increasing the expression of cytokines, which in turn up-regulate 
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adhesion molecules, leukocytes, platelets that deposit over endothelium eventually damaging 
capillaries and worsening the ischemic injury. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-1. Pathways of cell death in cerebral ischemia 
 
1.1.3. Phospholipases and free fatty acids in cerebral ischemia 
1.1.3.1. Lipids and free fatty acids:   
The central nervous system (CNS) has high concentration of lipids next to adipose tissue. Brain 
lipids are complex and consists of glycerophospholipids, sphingolipids, gangliosides, cholesterol, 
7 
 
and cholesterol esters. Glycerophospholipids are composed of two fatty acids (FA) attached to a 
glycerol backbone. A saturated FA is usually bound to sn-1 position, a polyunsaturated fatty acid 
(PUFA) in the sn-2 position, and a phosphate in the sn-3 position, covalently linked to a base group 
such as choline, serine, inositol, and ethanolamine (Tassoni et al., 2008). These phospholipids are 
important component of cell structure as they form bilayers that provide membrane fluidity, and 
structural integrity (Lenaz, 1979). In addition, they also serve as energy reservoirs, precursors to 
various secondary messengers such as arachidonic acid (AA), docosahexanoic acid (DHA), and 
phosphatidic acid. Lipids in the CNS plays a crucial role in cell signaling and tissue physiology.  
Knowledge of the phospholipid metabolism is critical to our understanding of the role they play in 
cell physiology under normal, and pathophysiological conditions since altered lipid metabolism in 
the CNS contributes to a variety of disorders of neurological origin such as stroke, Alzheimer’s, 
schizophrenia, and Parkinson’s (Adibhatla et al., 2006). Indeed, altered lipid metabolism is 
believed to be a key contributor to CNS injuries such as stroke.  
One mechanism contributing to neuronal death after ischemic injury is the release of bioactive free 
fatty acids (FFA) from membrane phospholipids. Bazan et al first described the release of FFAs 
in brain during ischemia (Abe et al., 1987; Bazan, 1970; Bazan, 1976; Gardiner et al., 1981). Two 
pathways control release of FFA from membrane phospholipids. The first pathway is direct release 
from the hydrolysis of glycerophospholipids by various phospholipases, and the second pathway 
is the degradation of phosphatidylinositol by phospholipase C followed by formation of 
diacyglycerol, which is further metabolized to FFA by lipases such as diacylglyceride lipase (Sun 
et al., 1979). Accumulation of the saturated and polyunsaturated FFA (PUFA) may indicate 
regional lipid membrane damage, which further leads to progressive infarction after cerebral 
ischemia. It has been shown that the accumulation of FFAs after cerebral ischemia correlates 
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locally with the severity of the insult (Baskaya et al., 1996). In a study by Pilitsis, concentrations 
of FFAs measured in the cerebrospinal fluid (CSF) collected from ischemic and/or hemorrhagic 
stroke patients within 48 h of insult were found to be significantly higher than in the controls 
(Pilitsis et al., 2003; Pilitsis et al., 2001). Higher concentrations of PUFA in CSF obtained within 
48 h of insult were correlated with lower admission Glasgow scores and worse outcomes at 
discharge. Of all the PUFA released in CSF of the patients, AA was released in the highest 
proportion followed by DHA. Initial elevation of FFA early after ischemic injury appear to return 
to control levels during the early phase of reperfusion. Particularly, levels of AA have been found 
to decrease faster than those of other FFA after recirculation (Shohami et al., 1982). Interestingly, 
a delayed increase in the FFA levels were also observed after three days of reperfusion in a gerbil 
model of ischemia (Nakano et al., 1990). It is postulated that decrease in the levels of all FFA 
during reperfusion phase is due to either vascular washout, reesterification or diffusion in to CSF. 
The cascade of events leading to ischemic-injury associated secondary brain damage due to 
accumulation of FFAs is mediated by direct and indirect mechanisms. Direct mechanisms include 
disruption of cellular energy metabolism, induction of blood-brain barrier breakdown, and edema 
formation (Chan et al., 1984; Rehncrona et al., 1979; Unterberg et al., 1987). Indirect mechanisms 
include generation of active oxygenated metabolites of liberated FFA that effect CBF and vascular 
tone. (Dempsey et al., 1986; Moncada et al., 1978). 
1.1.3.2. Phospholipases:  
In neural membranes, saturated fatty acids such as palmitic or stearic are usually esterified at sn-1 
position of the glycerol backbone whereas PUFA such as arachidonic acid are esterified at the sn-
2 position. The PLA2 pathway is the primary pathway through which AA is released from 
phospholipids (Kudo et al., 2002; Perez-Chacon et al., 2009; Sun et al., 2004). PLA1 and PLA2 
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acts on the fatty acid ester bond at sn-1 and sn-2 positions respectively liberating a free fatty acid 
and a lysophospholipid. Lysophospholipids perturb membrane homeostasis and increase 
membrane fluidity and permeability (Caro et al., 2006). There are other types of phospholipases 
like PLB, PLC, and PLD as shown in Figure 1-2, that differ in their action on phospholipid 
hydrolysis position and subsequent lysophospholipid formed. 
 
Figure 1-2. Free fatty acid release from membrane by phospholipases 
PLA1, A2, C and D are all expressed in multiple forms in the brain tissue (Phillis et al., 2004). 
Within the brain, PLA2 has been identified in different cell types such as neurons, astrocytes, 
microglial, and neuroblastoma cells. The PLA2 can be categorized into three different families 
namely i) secretory (sPLA2), ii) cytosolic or calcium dependent (cPLA2), and iii) calcium 
independent (iPLA2). Secretory PLA2 does not exhibit specificity for any particular FA. 
Significant increases in the expression of sPLA2 were observed in the hippocampus, and 
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neocortical areas in a transient forebrain ischemia model (Lauritzen et al., 1994). Calcium 
dependent PLA2 exhibits specificity for arachidonic acid and its expression was identified in 
various brain regions including olfactory cortex, hippocampus, thalamus, and cerebellum. 
Increased intracellular Ca2+ (~ 100 – 500 nM) promotes translocation of cPLA2 to intracellular 
membranes but Ca2+ as such is not needed for its catalytic activity. iPLA2 represents dominant 
PLA2 activity in the cytosol and function as housekeeping genes for the maintenance of membrane 
phospholipids. Similar to sPLA2, it does not exhibit any particular substrate specificity and its 
expression was identified in all brain regions. cPLA2 is implicated in various pathophysiological 
conditions such as ischemia/reperfusion injury (Hornfelt et al., 1999a; Hornfelt et al., 1999b; 
Kishimoto et al., 1999; Pepicelli et al., 2002).  
In a rat model of focal ischemia, a biphasic increase in FFA was observed one early during 
ischemia and another at 16 h after reperfusion. FFA accumulation in early phase of focal ischemia 
was attributed to the action of cPLA2 whereas in the late reperfusion phase it was attributed to 
upregulation of sPLA2 in the reactive astrocytes of penumbral region (Zhang et al., 1995).  
Similarly, in global cerebral ischemia model also upregulation of cPLA2 was observed (Pilitsis et 
al., 2002; Walton et al., 1997). Thus neuronal damage due to ischemic injury may activate cPLA2, 
sPLA2 depending on the cell type, time course, and type of ischemic insult. Neuronal excitation 
resulting from depolarization due to high concentrations of potassium, and stimulation with 
various excitatory neurotransmitter agonists such as AMPA, NMDA, glutamate, as well as 
muscarinic cholinergic agonists can stimulate release of AA, which plays an important role in 
cellular death by necrotic or apoptotic processes. Glutamate mediated excitotoxicity is 
accompanied with accumulation of intracellular Ca2+, degradation of membrane phospholipids, 
and accumulation of FFA such as AA, and lipid peroxides implying the involvement of 
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phospholipases such as cPLA2 (Lipton, 1999; Verity, 1993; Whetsell, 1996). AA can itself 
modulate ion channels (Kim et al., 1995), increase the mitochondrial permeability transition pore 
open time, affect release, uptake, and transport of several neurotransmitters, and activate many 
signaling pathways such as PKA, PKC, ERK, JNK,  p38 MAPK, NADPH oxidase, diacylglycerol 
kinase, and Na+/K+ ATPase  (Alexander et al., 2001; Katsuki et al., 1995). Different preclinical 
and clinical studies indicated that cytokines such as tumor necrosis factor-α (TNF-α), IL-1, and 
IL-6 are upregulated after stroke, which may be related to the release of AA during the initial 
periods of ischemia (Adibhatla et al., 2008).  
 
1.1.4. Arachidonic acid metabolism 
Arachidonic acid (C20:4, ω-6; AA) is one of the physiologically important PUFA that is 
required as a constituent of cell membrane phospholipids (Caro, et al., 2006). AA is accessible 
from dairy products and meat or can be synthesized de novo from linoleic acid, which is abundant 
in vegetable oils.  As shown in Figure 1-3, Free AA release from phospholipid membranes is 
metabolized to various structurally different and biologically active products by cyclooxygenase 
(COX), lipoxygenase (LOX), and cytochrome P450 (CYP450) pathways (Liu et al., 2004; 
Panigrahy et al., 2010).  
 
 
 
 
12 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 1-3. Pathways of arachidonic acid metabolism 
Cyclooxygenase (COX): COX enzymes consists of a constitutive isoform (COX-1) and an 
inducible form (COX-2). Arachidonic acid is transformed into the cyclic endoperoxides by COX 
also known as prostaglandin endoperoxide synthase (PES). PES exhibit both cyclooxygenase and 
peroxidase activities (Samuelsson, 1987). The cyclooxygenase component of the enzyme 
introduces two molecules of oxygen into AA to yield a highly unstable endoperoxide product 
PGG2, which is reduced by the peroxidase activity of the enzyme to form unstable PGH2. PGH2 is 
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further metabolized by various terminal tissue specific synthases, reductases, and isomerases to 
form prostaglandins (PG), prostacyclin (PGI2), or thromboxanes (TXA2) collectively referred as 
prostanoids. Isomerases catabolize PGH2 into either PGD2 or PGE2. A- and B-series 
prostaglandins are derived from PGE2 by sequential dehydration and isomerization. Prostaglandin 
F2α (PGF2α) is generated via reduction of PGH2. Prostacyclin and thromboxane (TX) synthases 
form PGI2 and TXA2, respectively. Hydrolysis of PGI2 and TXA2 yields inactive by-products (6-
keto-PGF1α and TXB2) of much greater stability. Additional enzymes can interconvert the 
prostaglandins; for example, PGE2 can be modified to PGF2α by the action of PGE2-9-
ketoreductase.  
Lipoxygenase (LOX): These cytosolic dioxygenases transform AA to hydroperoxides by 
introducing one molecule of oxygen at specific carbon position (e.g.: 5, 12, or 15) on AA. 
Leukocytes and mast cells are rich in 5-lipoxygenase. The 12-, and 15-lipoxygenase are 
predominant in platelets and respiratory tissues, respectively. Leukotrienes (LTs) are formed by 
the 5-lipoxygenase (5-LOX) pathway. AA is first metabolized by 5-LOX to 5-
hydroperoxyeicosatetraenoic acid (5-HPETE), which is then either converted by a competing 
peroxidase to 5-HETE, or dehydrated into an unstable epoxide intermediate, LTA4. Leukotriene 
A4 is either hydrolyzed to form a dihydroxy derivative, LTB4, or is linked with glutathione to 
create LTC4. Further enzymatic process of LTC4 yields LTD4 and LTE4. The other two LOX 
metabolizes AA into 12-HPETE, and 15-HPETE by 12-LOX, and 15-LOX respectively. These 
hydroperoxy products are rapidly reduced to their hydroxy analogues, 12-HETE and 15-HETE. 
15-HETE is further subjected to the successive action of 5-LOX to form the tetraene trihydroxy 
lipoxins (LXs) (Samuelsson, 1987).  
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1.1.4.1 CYP450 enzymes: AA metabolism by COX and LOX enzymes were well characterized 
and studied for their role in various physiological and pathophysiological processes such as 
inflammation, vasoconstriction, vasodilation, thrombosis, mitogenesis, and allergic reactions. In 
the last few decades, CYP450 pathway emerged as third yet an important pathway of AA 
metabolism and ever since the interest in delineating the physiological significance of AA 
metabolites from this pathway has been steadily increasing in the lipid research field. Cytochrome 
P450 enzymes (CYP450) are members of a superfamily of membrane bound, heme-containing 
monooxygenases in a multienzyme system that also includes flavoprotein containing nicotinamide 
adenine dinucleotide phosphate (NADPH)-cytochrome P450 reductase, and cytochrome b5. 
CYP450 enzymes originally considered as pigments were later discovered to contain iron-
protoporphyrin IX complex. The reduced CO complex of this pigment absorbed light at 450 nm, 
which is unusual for heme containing proteins, thus they were named CYP450 (Omura et al., 1964; 
Omura et al., 1962). CYPs are membrane bound proteins, which are mainly found either in 
endoplasmic reticulum (ER) or in mitochondrial membrane (Hedlund et al., 2001). CYP450 
enzymes metabolize cholesterol, steroids, fatty acids, vitamins, and numerous structurally diverse 
xenobiotics in an oxygen and NADPH-dependent manner. As shown in Figure 1-4, CYP450 
typically introduces one oxygen atom to the substrate from molecular oxygen and incorporates the 
other incorporated into water. The first step in the process of catalysis is binding of the substrate 
to the apoprotein, which is non-covalently linked to the heme-protoporphyrin IX complex 
containing iron. The binding of substrate displaces the water molecule bound to iron above the 
plane of protoporphyrin-heme complex, facilitating the transfer of one electron from NADPH-
CYP450 reductase and subsequent reduction of iron from ferrous (Fe3+) to ferric (Fe2+) state.  This 
is in turn followed by binding of molecular oxygen forming [Fe3+-O2∙ ] complex. Then another 
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electron is transferred either from NADPH-CYP450 reductase or cytochrome b5 to the activated 
molecular oxygen forming a highly reactive nucleophilic iron-peroxo complex [Fe3+-O2−]. This is 
followed by protonation from surrounding water to form reactive iron-hydroperoxo [Fe3+-OOH∙] 
complex. At this point molecular oxygen is dissected with the addition of one more proton forming 
one water molecule and electrophilic iron-oxo complex [Fe5+-O] or [Fe4+-OH]. The substrate, 
which is in the vicinity of this reactive electrophilic complex is oxidized to form monooxygenated 
metabolite, leaves the enzyme returning it back in Fe3+ state bound to water molecule (Meunier et 
al., 2004).  
 
 
 
 
 
 
 
 
 
 
Fig 1-4.  Cytochrome P450 catalytic cycle 
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CYP450 cycle can produced reactive oxygen species (ROS) like hydrogen peroxide, superoxide 
anion either by decomposition of the ferrous-dioxygen complex or by release from peroxyferric 
intermediates. The generation of ROS considerably varies depending on the P450, the presence or 
absence of substrate, nature of the substrate, and the action of cytochrome b5 (Zangar et al., 2004). 
CYP expression in the brain is relatively lower than that of liver and kidney yet CYP enzymes in 
the brain perform specific function in fatty acid metabolism, which exerts diverse array of 
pharmacological actions (Warner et al., 1988). CYP enzymes from the family of CYP2B, CYP2C, 
CYP2D, CYP2E1, CYP2J, CYP4A, 4B, and 4F were shown to be involved in AA metabolism, 
and various orthologous isoforms in different species are expressed in liver, heart, lung, kidney, 
and brain with tissue specific expression profiles. For example, CYP2B, CYP2C11, CYP2E1, and 
CYP2J3 were found to have higher expression in the heart, while in the lung, CYP2B1, CYP2J3, 
and CYP4Fs were found to be highly expressed in rat (Zordoky et al., 2008). Genes encoding 
CYP1-4 families can be regulated at transcriptional level through one of the four receptor-
dependent mechanisms. They are aryl hydrocarbon (AhR), constitutively active receptor (CAR), 
pregnane X receptor (PXR), and peroxisome proliferator activated receptor (PPAR). CAR, PXR, 
and PPAR belong to nuclear receptor superfamily, and they initiate transcription usually by 
binding as heterodimers with retinoid X receptor (RXR) to the respective response elements in 
target genes. Glucocorticoids, mineralocorticoids, progesterone, and fibrates activate PPARα 
inducing CYP4A and some CYP2C isoforms but downregulates the expression of CYP4F and 
CYP2C11 (Roman, 2002).  
 
1.1.4.2. CYP450 eicosanoids:  CYP450 enzymes metabolize AA by catalyzing 
hydroxylation, epoxidation or allylic oxidation reactions (Capdevila et al., 2000; Oliw et al., 1996) 
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producing an array of structurally diverse and physiologically active metabolites referred to as 
“CYP eicosanoids”. Hydroxylation of AA results into a series of regioisomeric metabolites termed 
as hydroxyeicosatetraenoic acids (HETEs). Hydroxylation at subterminal positions forms 16-, 17-
, 18-, and 19-HETE, which can occur as R- or S-enantiomers due to asymmetrical carbon atom 
whereas hydroxylation at terminal position forms 20-HETE.  CYP isoforms 1A1, 1A2, and 2E1 
are capable of carrying out ω-1 hydroxylation predominantly. However, in addition to 19-HETE 
these isoforms also can generate 18-HETE (CYP2E1) or 16-, 17-, and 18-HETE (CYP1A1 and 
1A2) as minor products. CYP4A and 4F subfamilies predominantly carry out terminal 
hydroxylation of AA forming 20-HETE as major product.in the liver, kidney, brain, and 
cardiovascular system (Hardwick et al., 1987; Kroetz et al., 2005; Powell et al., 1998; Simpson, 
1997). In rat, CYP4A1, 4A2, 4A3, and 4A8 are expressed in kidney, liver, and cerebral blood 
vessels (Gebremedhin et al., 2000; Helvig et al., 1998; Ito et al., 1998). CYP4F2, 4F3, 4F11, 4F12, 
and 4A11 are expressed in the liver and kidney of humans (Kikuta et al., 2000; Lasker et al., 2000). 
Among these, CYP4F2, CYP4A11, and CYP4F3B are the major 20-HETE synthesizing enzymes. 
However, these isoforms are also capable of ω-1 hydroxylation and form 19-HETE as a minor 
product. The orthologous isoforms of different species exhibit varied degree of regioselectivity in 
forming different HETEs for example, human CYP4A11 produces 20-HETE and 19-HETE in a 
ratio of 90:10, whereas mouse CYP4a12a forms in 87:13, and rat CYP4A1 forms in 93:7 
proportions. Similarly, regioselectivity was also observed with the human CYP4F isoforms 4F2, 
4F3A, and 4F3B (Konkel et al., 2011). In addition to the most common hydroxylation reactions at 
terminal and subterminal carbons of AA, certain CYP450 isoforms such as 2C8, 2C9 and 3A4 are 
also capable of performing allylic oxidation reactions, which form six regioisomeric hydroxy 
metabolites 5-, 8-, 9-, 11-, 12-, and 15-HETE containing a cis-trans conjugated dienol (Bylund et 
18 
 
al., 1998; Hornsten et al., 1996; Oliw, et al., 1996). These are referred to as mid-chain HETEs, 
which resemble the metabolites produced by lipoxygenases. 
Epoxidation of AA at four unsaturated double bonds produces four regioisomeric cis-
epoxyeicosatrienoic acids (5,6-, 8,9-, 11,12-, and 14,15-EET) , which can be either R,S- or S,R- 
enantiomers. Several mammalian CYP isoforms such as CYP1A, 2B, 2C, 2D, 2G, 2J, 2N, and 
CYP4A can produce EETs. They differ in selectivity for regioisomers, catalytic efficiency, 
inducibility, species, and organ distribution (Spiecker et al., 2005). CYP2C isoform produce the 
majority of EETs in human liver and kidney whereas CYP2J isoforms are predominant in EETs 
biosynthesis in rat and human heart. CYP2C and 2J isoforms also like CYP4A, 4F exhibit varied 
degree of regioselectivity in different species. For example, human CYP2C8 produces exclusively 
14,15- and 11,12-EET in a ratio of 1.3:1 whereas CYP2C9 shows less regio and stereoselectivity. 
CYP2C3 in rat kidney produces 8,9-, 11,12-, and 14,15-EET in a ratio of 1:2:0.7. Similarly, regio 
and stereoselectivity was also observed with mouse CYP2C44, human CYP2J2.  
1.1.4.3. CYP eicosanoids metabolism:  Once produced the CYP eicosanoids (HETEs, EETs, 
and DHETs) are either reincorporated into membranes through esterification at sn-2 position by 
coenzyme A (CoA), forming membrane stores, which are readily released by the action of PLA2 
in response to the signaling pathways of hormones, cytokines, and growth factors or undergo 
further metabolism. CYP eicosanoids being fatty acid derivatives bind strongly to plasma proteins, 
which limit their biological activity in the circulation and restrict their distribution to plasma when 
administered directly through intravenous routes.  
EETs:  EETs are highly reactive and unstable. EETs are predominantly metabolized in vivo 
to less active dihydroxyeicosatrienoic acid (5,6-, 8,9-, 11,12- and 14,15-DHET) by soluble epoxide 
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hydrolase (sEH) enzyme (Chiamvimonvat et al., 2007; Newman et al., 2005; Spector et al., 2004), 
which is encoded by EPHX2 gene. sEH expression was found in neurons, astrocytes, 
oligodendrocytes, endothelial cells, and VSM cells (Iliff et al., 2010). 5,6-EET is a poor substrate 
and 14,15-EET is a preferred substrate of sEH. sEH functions as a homodimer with each subunit 
consisting of two domains of different enzymatic activities. The carboxy terminal domain exhibits 
epoxide hydrolase activity and the amino terminal domain exhibits Mg2+ dependent lipid 
phosphatase activity. These two domains function independently, and inhibition of one activity 
does not affect the catalytic function of the other (Newman et al., 2003). EETs can bind to fatty 
acid binding protein (FABP), which modulates EETs incorporation into phospholipids and its 
availability to sEH for metabolism (Spector, et al., 2004; Spector et al., 2007). EETs can undergo 
β-oxidation forming 16-carbon epoxy derivatives, which accumulate in the extracellular fluid and 
they can also be chain-elongated to form 22-carbon derivatives that are incorporated into 
phospholipids. These two pathways take precedence in cells with low availability or activity of 
sEH. The other less common pathways of EETs metabolism include the terminal hydroxylation by 
ω-hydroxylases to form 20-hydroxy EETs, conjugation by glutathione-S-transferase, and 
metabolism by COX enzymes (Spector, et al., 2007).  
HETEs: In an in vitro study of porcine coronary artery endothelial cells, 20-HETE was 
found to be esterified and stored in the phospholipids by the action of acylcoenzyme A synthase. 
20-HETE is metabolized in the endothelial cells by β-oxidation to form short-chain 16-carbon 
derivatives, and by ω-oxidation to form 20-carboxy-arachidonic acid (20-COOH-AA) (Kaduce et 
al., 2004). 20-HETE is also metabolized to 20-hydroxy-PGG2 and 20-hydroxy-PGH2 by COX 
enzymes in the endothelium (Schwartzman et al., 1989). 
20 
 
1.1.5 Pharmacological effects and molecular mechanisms of CYP eicosanoids 
CYP eicosanoids serve as lipid signaling molecules. They not only play a critical role in 
regulation of vascular, renal, and cardiac function (Hao et al., 2007; Imig, 2012) but also participate 
in various pathological conditions such as inflammation and ischemia/reperfusion injury. The 
extensively studied and characterized effects of CYP eicosanoids are their actions on vasculature 
of different organs as they regulate the vascular tone. Interestingly, some of the pharmacological 
actions of HETEs and EETs on vascular beds of different organs are diametrically opposite to each 
other.  
1.1.5.1 HETE:  20-HETE, is most potent vasoconstrictor of HETEs in most vascular beds 
except for pulmonary and coronary circulation where it exhibits vasodilatory response in an 
endothelium and cyclooxygenase dependent manner (Birks et al., 1997; Pratt et al., 1998). 
Vasoconstrictive actions of angiotensin II, endothelin, and norepinephrine are mediated through 
20-HETE signaling mechanism (Maier et al., 2001). 20-HETE induces vasoconstriction by 
inhibiting calcium activated large conductance potassium channels (BKCa), activating Rho-kinase, 
protein kinase C (PKC), and allowing Ca2+ entry by opening L-type Ca2+ channels (Kroetz, et al., 
2005). Interestingly, 20-HETE though a potent vasoconstrictor of small arteries, and arterioles (< 
100 µm) has little or no effect on the larger arteries (Roman, 2002). Vascular overproduction of 
20-HETE is detrimental to endothelial function as it uncouples endothelial nitric oxide synthase 
(eNOS), and activates pro-inflammatory transcription factor NF-κB (Cheng et al., 2008; Ishizuka 
et al., 2008). Excessive formation of 20-HETE is also detrimental in ischemic organ injury in heart 
and brain (Miyata et al., 2005; Nithipatikom et al., 2004). 20-HETE mediates the signaling of 
mitogenic actions of growth factors and vasoactive agents (Muthalif et al., 1998), and promotes 
angiogenesis (Amaral et al., 2003) suggesting its important role in vascular cell growth. In addition 
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to controlling renal tone, 20-HETE also affects electrolyte excretion by inhibiting Na+/K+-ATPase, 
and Na+/K+-2Cl- cotransporter in the kidney (Maier, et al., 2001). In humans, increased urinary 
excretion of 20-HETE is associated with endothelial dysfunction. Several recent studies indicated 
that genetic polymorphisms in the genes encoding CYP4A11, 4F2 isoforms that form 20-HETE 
are associated with hypertension, coronary endothelial dysfunction, and stroke (Ding et al., 2010; 
Fava et al., 2008; Fu et al., 2008a; Fu et al., 2008b; Gainer et al., 2005; Zordoky et al., 2010).  
20-HETE metabolite 20-COOH-AA also exhibits moderate vasodilatory effect in the porcine 
coronary microvessels (Kaduce, et al., 2004). The COX derived metabolites of 20-HETE also have 
shown vasoconstrictive effect in the rat aorta (Schwartzman, et al., 1989). Surprisingly, other 
subterminal hydroxylated AA metabolites such as 16-, 17-, 18-, and 19-HETE exert opposite 
pharmacological actions to that of 20-HETE. 19-HETE stereoselectively inhibits 20-HETE 
induced vasoconstriction and endothelial dysfunction (Alonso-Galicia et al., 1999). The 
pharmacological actions of mid-chain HETEs are less characterized and largely remain unknown.  
 
1.1.5.2. EETs:  EETs are potent vasodilators in most vascular beds except for pulmonary 
circulation where they exert opposite effects. Intracellular EETs can bind to FABP, interact with 
ion channels or transcription factors whereas EETs in membrane bound phospholipids can interact 
with other membrane proteins or phospholipid mediated signaling pathways. In several vascular 
beds, they function as the major endothelium derived hyperpolarizing factor (EDHF) because of 
their ability to dilate arteries (Campbell et al., 2007). EETs exert paracrine effects on vascular 
smooth muscle (VSM) by activating BKCa channels causing hyperpolarization of VSM cells and 
eventual relaxation and dilation. In addition, EETs also activate transient receptor potential (TRP) 
V4 channels, L-type Ca2+, ATP sensitive potassium (KATP) and Na+ channels, tyrosine kinase, 
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ERK1/2, p38 MAPK, and PI3 kinase signaling pathways in endothelial cells (Chen et al., 1998; 
Chen et al., 1999; Hoebel et al., 1998; Lee et al., 1999; Loot et al., 2008; Lu et al., 2001a). EETs 
unlike 20-HETE suppress the activation of NF-κB thus exerts anti-inflammatory properties 
(Spector, et al., 2007). They also promote endothelial cell growth but inhibit migration of VSM 
cells indicating their roles in angiogenesis and prevention of uncontrolled vascular remodeling 
(Fleming, 2007; Spiecker, et al., 2005).  In humans, polymorphisms in genes encoding EET 
forming CYPs (CYP2C8, 2C9, and 2J2) and EET metabolizing sEH enzyme have been associated 
with increased risks for the development of hypertension, stroke, coronary artery disease, and 
myocardial infarction (Imig et al., 2009; Zordoky, et al., 2010). In various different studies looking 
at vasodilatory, anti-inflammatory, antioxidative, anti-migratory, and pro-fibrinolytic properties of 
EETs, 11,12-EET was found to be more efficacious than other regioisomers (Node et al., 1999; 
Sun et al., 2002; Wu et al., 1997).  
 
1.1.5.3. DHET and sEH:  DHETs are usually considered less active than EETs. Thus, 
inhibiting sEH is generally presumed not to be detrimental to any vital physiological processes. 
This view is supported by various studies that employed either genetic deletion of sEH (Sinal et 
al., 2000) or pharmacological inhibitors (Imig et al., 2005; Yu et al., 2000) reporting no toxicity 
associated with its inhibition or deletion. However, in recent studies vasodilatory activity of DHET 
in coronary circulation has been reported (Campbell et al., 2002; Lu et al., 2001b; Oltman et al., 
1998). It is possible that they may be important in exerting vasodilatory effects under conditions 
of rapid EET metabolism to DHET. So far there is no conclusive evidence that any of the effects 
of DHET are essential in normal physiological function.  
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Although pharmacological actions and the underlying downstream mechanisms of CYP 
eicosanoids are well characterized, their primary targets on cells, which elicit these actions are not 
identified yet. Several explanations were proposed for the possible mode of action of CYP 
eicosanoids. Possibility of a membrane bound G-protein coupled receptor (GPCR) cannot be ruled 
out although unlike prostaglandins and leukotrienes, a putative receptor for CYP eicosanoids is 
yet to be identified. Another possible mode is direct interaction of CYP eicosanoids with 
intracellular or membrane bound targets. For example, EETs bind to and activate nuclear receptors 
PPAR, which are expressed endothelial cells and blood vessels (Cowart et al., 2002; Fang et al., 
2006; Ng et al., 2007).  
 
1.1.6. Animal models of cerebral ischemia 
Various animal models were developed in the past in both small and large animals (e.g.: 
mice, rats, gerbils, rabbits, cats, dogs, pigs, sheep, and monkeys) to evaluate cerebral ischemia 
(Ahmed et al., 2000). Larger animals are easier to work with imaging techniques, physiological 
monitoring, measurement of CBF, and they have structural and functional similarity to human 
brain but on the down side they are very costly, labor intensive, need usage of different anesthetic 
regimens that may impact outcome. On the other hand, small animals especially rodents are less 
costly, genetically homogenous (especially mice), and sophisticated neurosensory and motor 
behavior assessments are well established to use with them. Despite of the many advantages they 
offer, the structural and functional differences to human brain limit their benefit in successfully 
translating the findings to humans. Yet they are routinely used as they can be physiologically 
controlled to get reproducible injury, studied for careful dissection of potential mechanisms of 
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injury, and neuroprotection, which greatly advance our understanding of the pathophysiology of 
the disease progression (Traystman, 2003).  
Cerebral ischemia models can be characterized as global, focal, and multifocal ischemia models 
based on the extent of the tissue injured and as incomplete or complete based on the extent of 
reduction of CBF. In global model, CBF is reduced throughout most or all of the brain whereas in 
focal models CBF reduction occurs in specific region of the brain. In multifocal models, there is a 
patchy pattern of reduced CBF in the regions of the brain. With complete ischemia, global blood 
flow ceases completely whereas in incomplete it reduces severely to a level that is not sufficient 
enough to maintain cerebral metabolism and function. Most commonly used focal ischemia model 
for studying mechanisms of cell injury, and neuroprotection is middle cerebral artery occlusion 
(MCAO) using an intraluminal filament or suture (Longa et al., 1989). Reperfusion can be easily 
achieved in this model by withdrawing the suture, and the animals may survive for days to months 
depending on the severity of injury, enabling the functional outcome measures to be recorded 
thoroughly. Other commonly used models include MCAO + carotid occlusion, photochemical 
thrombosis, blood clot embolization, and electrocoagulation of MCA. Most commonly used global 
ischemia model is asphyxial cardiac arrest (Katz et al., 1995). Other routinely used models include 
neck cuff inflation, ventricular fibrillation, decapitation, forebrain ischemia models of 4-vessel 
(common carotid and vertebral arteries) occlusion, and 2-vessel occlusion. However, it is 
important to note that these models differ in terms of the extent and pattern of injury based on the 
strain and species used. Permanent and reperfusion models of ischemic stroke in animals are more 
relevant to human ischemic stroke. In animals region of the brain injured, termed as infarction is 
estimated through histological staining procedures whereas in human it can be visualized with 
diffusion-weighted magnetic resonance imaging (MRI) (Kelly et al., 2001).  
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1.2 CEREBRAL BLOOD FLOW REGULATION  
1.2.1 Cerebral circulatory system 
Arterial circulation can be broadly classified into macrocirculation and microcirculation 
based on the vessel size or intrinsic and extrinsic based on the location relative to parenchyma of 
brain. Large conductance arteries such as middle cerebral and pial arteries constitute 
macrocirculation and extrinsic system whose main function is conductance of blood whereas 
penetrating arterioles, capillaries, and venules constitute microcirculation and intrinsic system 
whose main function is regulation of flow, although definitive role of capillaries in regulation of 
flow is less characterized (Kulik et al., 2008). Neurons exert direct influence on CBF. Nerve fibers 
associated with cerebral vessels have been identified within both the macro and micro circulation 
(Hamel, 2006). Vascular reactivity of the vessels is conferred due to the contractile nature of VSM 
cells, which are not found in the capillaries. Capillaries instead contain specialized contractile cells 
pericytes. Regulation of flow at capillary level is dependent on the regulation at arteriole level 
(Kontos et al., 1978). Under physiological conditions, a significant proportion of cerebrovascular 
resistance (CVR) is located in the pial and penetrating arterioles. Thus in order to increase flow to 
intrinsic circulatory bed, the extrinsic vessels must dilate, otherwise a vascular shunting might 
occur.  
A special feature of CNS is its redundancy of arterial supply (collateral circulation), which can 
protect brain in the event of focally restricted blood flow in a larger conductance vessel. Another 
unique feature of CNS is blood-brain barrier (BBB), which is formed by tight gap junctions of 
vascular endothelium. The BBB serves important regulatory function in maintaining ionic balance, 
transport of micro and macro nutrients and preventing toxic substances from blood to diffuse into 
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the parenchyma. The large conductance arteries, pial arteries, and penetrating arterioles all have a 
BBB (Roggendorf et al., 1977). Ischemic injury affects both smaller and larger arteries. In 
ischemic injury, leukocytes adherence to endothelial cell wall and platelet rupture leads to 
irreversible injury of BBB. During reperfusion phase injury is further aggravated as leukocytes 
interact with damaged abluminal endothelial wall and plug microvasculature causing a no-reflow 
phenomenon. In addition, release of inflammatory factors, cytokines, and free radicals worsen the 
injury (Chan, 2001).  
 
1.2.2 Cerebral autoregulation of blood flow 
The human brain comprises only 2% of the body mass yet it consumes 20% of the energy 
produced by the body at resting state. Since brain requires constant supply of glucose and oxygen, 
regulation of blood flow throughout the brain is vital for maintaining normal cognitive and motor 
functions. CBF varies directly with cerebral perfusion pressure (CPP), which is classically defined 
as difference between mean arterial pressure (MAP) and intracranial pressures (ICP), and inversely 
with the total CVR. Further, hemodynamics of blood flow is also affected by hematocrit, platelet 
aggregation, and plasma viscosity (Kee et al., 1984). The contribution of any given vessel to 
overall CBF is determined by its radius, length, blood viscosity, and pressure. Under physiological 
conditions, tissue perfusion in brain ranges from 50 to 55 mL/100 g/min. As blood perfusion 
decreases like in the example of ischemia, oxygen extraction from hemoglobin gradually increases 
so the decrease in oxidative metabolism can be less than the fall in CBF (Frykholm et al., 2000). 
Brain naturally develops autoregulatory mechanisms to maintain normal CBF in the face of rising 
blood pressure (myogenic tone) (Panerai, 2008). CBF is autoregulated over a range of arterial 
pressure from 70 to 120 mm Hg in normal brain. Autoregulation is governed by myogenic 
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regulation of precapillary blood vessels such as pial arteries and metabolic regulation at the level 
of small precapillary arterioles (Imig et al., 2011). In response to increases in arterial blood 
pressure, smooth muscle cells in vessels depolarize through the action of vasoconstrictive factors 
that increase intracellular Ca2+ resulting in vasoconstriction, thereby increasing the total CVR to 
maintain a constant CBF globally. Cerebral arteries originating from the circle of Willis and pial 
arteries on the surface of brain are highly myogenically active. The autoregulatory capacity is 
influenced by factors such as hematocrit, hemoglobin concentration, and blood levels of CO2, O2, 
H+, brain temperature, cardiac output, and altitude. In certain chronic disease states such 
hypertension autoregulatory mechanisms may become dysfunctional due to which CBF passively 
changes with the changes in the MAP and ICP causing extreme fluctuations in the CBF eventually 
leading to vascular and organ damage over time. 
1.2.2.1. Endothelium dependent relaxation:   
Endothelium is involved in controlling the balance between vasoconstrictors (ET-1, PGF2α, 
and TXA2), and vasodilators (NO, PGE2, PGI2, and EDHF) to help maintain a resting tone. In 
addition, it also plays important role in regulating local inflammatory and cell adhesion process, 
in vascular remodeling, platelet aggregation, and coagulation. A functioning endothelium is very 
essential in vascular adopting to the changes in the blood flow. Endothelial dysfunction is the 
underlying cause in the pathophysiology of many cerebrovascular and cardiovascular diseases (Cai 
et al., 2000; Iadecola et al., 2004; McIntyre et al., 1999; Widlansky et al., 2003). Circulating 
substances such as acetylcholine, bradykinin, and ATP that bind to specific endothelial surface 
receptors as well as mechanical stimuli such as fluid shear stress and pulsatile stretch activate the 
endothelium, which releases various vasoactive factors. Endothelium derived nitric oxide (NO) 
and prostacyclin (PGI2) are well characterized endothelium derived relaxing factors that affect the 
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vascular tone. Despite the inhibition of NO and PGI2 pathways, an endothelium dependent 
relaxation effect persisted in most vascular beds, which led to the identification of yet another 
endothelium derived hyperpolarizing factor (EDHF) (Chen et al., 1988; Taylor et al., 1988).  
EDHF plays important role in the control of cerebral artery tone. EDHF exerts autocrine and 
paracrine effects by hyperpolarizing endothelial and VSM cell eventually leading to 
vasorelaxation. The underlying mechanisms include activation of BKCa on VSM cells promoting 
K+ efflux and membrane hyperpolarization. Other mechanisms include activation of endothelial 
KCa channels of small (SKCa) and intermediate (IKCa) conductance, which release K+ in to 
myoendothelial space. The released potassium either causes endothelial hyperpolarization, which 
is electrically transmitted through myoendothelial gap junctions into the smooth muscle cell 
(SMC) layer or activates the Na+/K+ ATPase and the inward rectifying potassium channels (KIR) 
on the SMC inducing K+ release, hyperpolarization of VSM and subsequent relaxation (Bellien et 
al., 2008). Though EDHF dependent relaxation is observed in both resistance and conduit arteries, 
its contribution appears to be prominent in small arteries and decreases inversely with the vessel 
size (Nagao et al., 1992). NO interacts with EDHF pathways by exerting a constant inhibition. 
Thus EDHF mediated relaxations are usually masked in the larger arteries and are evident only in 
the presence of NO inhibition or in conditions of low vascular availability of NO (Bauersachs et 
al., 1996).  
 
1.2.3. Neurovascular coupling 
As opposed to cerebral autoregulation of maintaining constant flow globally, in instances 
of increased neuronal activity blood flow is increased locally to match the metabolic demands of 
neurons through a phenomenon called neurovascular coupling or functional hyperemia (Filosa et 
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al., 2007; Imig, et al., 2011). Locally, cerebral blood vessels respond to changes in their physical 
(intraluminal pressure, longitudinal shear) and chemical (pH, partial pressures of O2, and CO2) 
environments but they can also sense and respond to increases in neuronal activity via a specialized 
system comprised of neurons, astrocytes, and blood vessels. Astrocytes, most abundant glial cell 
population in brain, serve as a key player in coupling neuronal activity to cerebral vessels. Fine 
perisynaptic processes extending from astrocyte cell body cover most synapses whereas terminal 
portion of large processes (endfeet) cover a major proportion of the abluminal vascular surface of 
capillaries, intracerebral arterioles, and penetrating arterioles (Simard et al., 2003). Thus they are 
ideally placed for sensing neuronal activity, and relaying that information to surrounding cerebral 
vessels by releasing vasodilatory mediators such as EETs. Thus together astrocytes, neurons, and 
cerebral blood vessels form a neurovascular (NV) unit (Attwell et al., 2010).   
1.2.3.1. Neurogenic regulation: Neurovascular control of the cerebral circulation varies 
depending on the location and capacity of the vessels. Extracerebral vessels are in general 
innervated by peripheral nerves (extrinsic innervation) of sympathetic, parasympathetic, and 
sensory origin (Bleys et al., 2001). In contrast, parenchymal microvessels are primarily regulated 
by afferent fibers from subcortical pathways, local interneurons, and neuronal terminals from 
central origin (intrinsic innervation) (Hamel, 2006).  Glutamate released from neuronal synapses 
during increased activity acts on ionotropic glutamate receptors or NMDA receptors on neurons 
increasing the intracellular Ca2+. This in turn activates neuronal nitric oxide synthase (nNOS), 
which releases NO that is shown to dilate cerebral vessels in both in vitro and in vivo studies 
(Busija et al., 2007). However, in a study with mice deficient in eNOS, and nNOS no abnormalities 
in the normal CBF response to whisker stimulation were observed (Koehler et al., 2009; Lindauer 
et al., 1996; Ma et al., 1996) indicating that neurogenic control through NO may not be the only 
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mechanism in neurovascular coupling and that other compensatory mechanisms involving other 
vasodilators of neurogenic or non-neurogenic origin might be contributing to the hyperemic 
response.  
1.2.3.2. Astrocyte regulation:   Glutamate released from neurons also acts on the 
metabotropic glutamate receptors on astrocytes leading to an increase in intracellular Ca2+. This 
transient increase in calcium levels either opens BKCa in astrocyte endfeet, which release K+ onto 
microvessels or activate cPLA2. Activated cPLA2 increases free AA levels in cytosol, which is 
metabolized to form prostaglandins such as PGE2 and EETs that dilate nearby arterioles (Peng et 
al., 2004; Zonta et al., 2003). However, an increase in intracellular Ca2+ in astrocytes also releases 
wide range of different vasoconstrictors (e.g. 20-HETE, PGF2α, thromboxane A2, and endothelins) 
and vasodilators (e.g. NO, ATP, PGE2, and EETs) depending on the type and duration of stimuli 
(Filosa, et al., 2007). Therefore, whether a rise in intracellular Ca2+, causes dilation or constriction 
may in part be determined by the pre-existing tone of the vessel (Blanco et al., 2008). The relative 
importance of neuronal and astrocytic pathways in vasodilation remains unclear and is likely to 
differ across brain regions. It appears that NO, cyclooxygenase, and epoxygenase products are all 
important in mediating functional hyperemia in the cortex whereas NO is more dominant in the 
cerebellum (Yang et al., 1999). This implies that therapeutic modulation of the signaling pathways 
controlling CBF may have different effects in different brain regions and on different neuronal 
pathways in the same region. Adding to the complexity, interaction between different signaling 
pathways of vasodilation were also reported in the literature. For example, NO inhibits enzymes 
that forms 20-HETE and EETs, which explains the cyclic GMP independent vasodilatory effect of 
NO (Sun et al., 2000).  
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1.2.3.3. Endothelial regulation: Although the primary role of endothelium is to establish a 
resting tone of cerebral vessels through basal release of NO and set that tone as a background for 
other dilators and constrictors, its precise role in neurovascular coupling has not been clearly 
defined. However, it is speculated that neurogenic and astrocytic mediators released in response 
to increased neuronal activity, could traverse the VSM to stimulate receptors on the abluminal side 
of the endothelium to release various vasodilatory agents (Andresen et al., 2006). This was tested 
experimentally in different studies by applying dilator agents to the abluminal side of the 
endothelium although not in connection with neuronal activation (Dietrich et al., 1996; Faraci et 
al., 2004). Dilation of larger upstream arterioles and arteries along with the dilation of arterioles 
directly supplying to the capillary bed is required for maximizing the vascular control. Indeed, 
neuronal stimulation can dilate large upstream cerebral vessels. Vascular endothelium could play 
an important role in mediating upstream dilations by conducting a dilator response along the vessel 
to upstream arterioles possibly communicating via specialized gap junctions. In support of this, 
local application of ATP to penetrating arterioles induced both a local vasomotor response as well 
as an upstream dilation indicating that vascular endothelium could play an important role in 
mediating upstream dilations (Dietrich, et al., 1996; Horiuchi et al., 2002).  
1.2.3.4. Regulation in disease states:  Interestingly, impaired autoregulation and altered 
neurovascular coupling are both evident in several disease states and the interactions between the 
systems is poorly understood (Girouard et al., 2006; Krizanac-Bengez et al., 2004). In ischemia, 
functional hyperemia is observed in certain regions during the early reperfusion period, which is 
followed by long lasting periods of hypoperfusion. This inadequate matching of flow to the 
neuronal activity may produce damage to cells beyond that is caused by initial ischemic injury. 
This decreased flow or no-reflow phenomenon was attributed to different mechanisms. The first 
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one is reduction in the capillary diameter as a result of astrocyte endfoot swelling causing capillary 
blockage by blood cells and fibrin (Ames et al., 1968) whereas the other mechanism was failure 
of arteriole vasodilatory mechanisms (Kagstrom et al., 1983a; Wagerle et al., 1988). 
 
1.2.4. CYP eicosanoids in CBF regulation 
1.2.4.1. Role in cerebral autoregulation: 
HETE:  In an in vitro study with rat middle cerebral arteries, Gebremedhin et al., showed 
that elevating transmural pressure from 20 – 140 mm Hg produced a fourfold increase in 20-HETE 
levels. Inhibition of 20-HETE synthesis or antagonizing the vasoconstrictive actions of 20-HETE 
with synthetic structural analog 20-HEDE blocked pressure induced contraction of these vessels 
indicating that 20-HETE may be an essential component of the myogenic response in cerebral 
arteries. They also indicated that 20-HETE plays a critical role in determining the efficiency of 
autoregulation of CBF in vivo. Activation of PK C and Rho-kinase appears to be the key signaling 
mechanisms contributing to the myogenic response (Gebremedhin, et al., 2000; Strandgaard et al., 
1984). It appears that endothelium derived factors could modulate the myogenic contraction by 
interfering with the actions of 20-HETE. For example, NO inhibits formation of 20-HETE by 
binding to CYP4A, 4F enzymes and it is reported in different studies that non cGMP dependent 
vasodilatory response of NO is due to the fall in 20-HETE levels in cerebral arteries (Sun, et al., 
2000; Yu et al., 2002).  
EETs:  Exogenous application of EETs has been shown to dilate cerebral arteries in both 
in vitro (Gebremedhin et al., 1992) and in vivo (Ellis et al., 1990) studies. Alkayed et al., showed 
that inhibition of CYP epoxygenase decreases baseline blood flow suggesting that tonic release of 
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EETs participates in the maintenance of basal vascular tone in rat brain microcirculation (Alkayed 
et al., 1996). However, they measured EETs from cultured rat astrocytes and not from endothelium 
of cerebral vessels. In the previous section 1.2.2.1, I have described the role of endothelium, and 
especially EDHF in maintenance of basal vascular tone. Though, CYP derived EETs have been 
identified as EDHF in different vascular beds (Archer et al., 2003; Bellien et al., 2006; Fischer et 
al., 2007; Hillig et al., 2003) their role as EDHF in cerebral vasculature is not conclusively proved 
due to the limited evidence on expression of CYP epoxygenases in the cerebral blood vessels (Iliff, 
et al., 2010). Different studies showed that cerebral tone is markedly affected by EET production, 
although not from endothelium but astrocytes (Alkayed et al., 1997; Harder et al., 2000). However, 
EETs can functionally antagonize actions of 20-HETE by increasing the open state probability of 
KCa channels and activating Na+-K+-ATPase. In a study Imig et al., showed that inhibiting 
epoxygenase activity enhances arteriolar constriction when perfusion pressure is increased from 
80 to 120 mm Hg (Imig et al., 1999). Thus, EETs can potentially impact the myogenic tone of 
cerebral arteries by counterbalancing the actions of 20-HETE in the blood vessels.  
 
1.2.4.2. Role in neurovascular coupling: 
EETs:  In section 1.2.3.1, I have mentioned that the mice deficient in eNOS, and nNOS 
showed no abnormalities in the normal CBF response to whisker stimulation suggesting that NO 
may not be an essential component in neurovascular coupling (Koehler, et al., 2009). Consistent 
with this view different studies have showed that in response to glutamate released by neurons, 
astrocytes release EETs consequently increasing the CBF. EET antagonists or EET synthesis 
inhibitors were also shown to attenuate the increase in CBF on activation of the cerebral cortex 
(Filosa, et al., 2007; Koehler et al., 2006). These evidence prove that within neurovascular unit 
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EETs released from astrocytes function as sensors of neuronal activity in a feed forward manner 
and elicit functional hyperemia.  
However, the role of EETs in neurogenic control of blood flow, especially in the large conduit 
arteries-perivascular nervous system was not elucidated until recently. Iliff et al, produced first 
evidence of CYP2J and sEH expression in the perivascular nerve fibers innervating the cortical 
surface vasculature including middle cerebral and basilar artery. This extrinsic perivascular 
innervation has population of vasodilatory neurons including parasympathetic fibers originating 
in the sphenopalatine ganglia (SPG), and otic ganglia, and sensory afferents that project to the 
trigeminal ganglia (TG). Expression of CYP2J and sEH in the sensory TG and parasympathetic 
SPG neurons (Iliff et al., 2009b) indicates that EETs may serve as a nerve derived vasodilatory 
factor in large cerebral conduit arteries. Electrical stimulation of efferent nerve fibers and chemical 
stimulation by capsaicin both showed EET mediated increase in cortical CBF, which was 
abolished by pretreatment of EET antagonist 14,15-EEZE. However, these fibers also release NO, 
vasoactive intestinal peptide (VIP) from parasympathetic nerve fibers, and calcitonin gene-related 
peptide (CGRP) from sensory fibers to mediate their vasodilatory effects. Based on their findings, 
Iliff et al postulated that EETs may interact with these other vasomotor pathways in three possible 
modes. One possible mode is release of EETs from nerves in additive manner with other 
neurotransmitters in response to stimuli to regulate vascular tone. A second possibility is that 
neurogenic EETs exert autocrine effects in releasing other neurotransmitters as VIP or CGRP. A 
third possible mode of interaction is that one or more releasable factors from parasympathetic or 
sensory perivascular neurons exert vasoactive effects via a vasomotor pathway dependent on 
endothelial EET signaling (Iliff, et al., 2009b). 
35 
 
20-HETE: 20-HETE does not exert any appreciable impact on the increase in cortical CBF in 
response to whisker barrel stimulation in rats or mice. Interestingly, an interaction between 20-
HETE and EETs was observed when nNOS is inhibited whereby 20-HETE reduced the effects of 
EET in eliciting functional hyperemia (Liu et al., 2008).  
 
1.2.5. Small molecule inhibitors of CYP eicosanoid pathway 
Small molecule chemical inhibitors are best studied tools for delineating the 
pharmacological actions of CYP eicosanoids in various disease models. In this section, various 
pharmacological inhibitors used for studying the role of CYP eicosanoids in different in vitro and 
in vivo studies are summarized.   
1.2.5.1. ω-hydroxylase pathway:   
Mechanism based inhibitors:  A single intraperitoneal injection of suicidal substrate 1-
aminobenzotriazole (ABT) (50 mg/kg) selectively inhibited renal cortical 20-HETE formation in 
rats. However, chronic treatment with ABT inhibited both 20-HETE and EET formation in the rat 
kidney (Dos Santos et al., 2004; Su et al., 1998). A series of terminal acetylenic monocarboxylic 
fatty acids of varying length from 10 [10-undecynoic acid (10-UDYA)] to 17 [17-octadecynoic 
acid (17-ODYA)] carbons were tested as inhibitors of 20-HETE formation (Ortiz de Montellano 
et al., 1984; Reich et al., 1986). Of these, 17-ODYA was potent inhibitor of AA metabolism 
inhibiting both HETE and EET forming enzymes. Yet 17-ODYA was used in different in vitro 
and in vivo studies.  A single dose administration of 10-undecynyl sulfate (10-SUYS), a structural 
analog of 10-UDYA decreased 20-HETE formation and reduced mean arterial blood pressure in 
spontaneously hypertensive rats (SHR) (Xu et al., 2002a).  
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Competitive and non-competitive inhibitors: An olefinic acyclic dibromide compound, N-
methylsulfonyl-12,12-dibromododec-11-enamide (DDMS) reduced the pressure-induced 
vasoconstriction of isolated rat cerebral vessels, resulting in 24% increase in vessel diameter 
compared to control. In an in vivo study DDMS abolished the autoregulatory response in rat and 
increased the CBF corresponding to increases in arterial pressure (Gebremedhin, et al., 2000). A 
higher cerebrovascular 20-HETE levels were shown to contribute to oxidative stress and 
endothelial dysfunction, and increased susceptibility to ischemic brain damage (Dunn et al., 2008).  
Brain 20-HETE levels were found to be increased after ischemic stroke and chronic administration 
of a potent, selective 20-HETE synthesis inhibitor, N-hydroxy-N`-(4-butyl-2-methylphenyl)-
formamidine (HET0016) decreased brain 20-HETE levels, attenuated the decrease in CBF during 
the reperfusion period, and reduced the infarct volume in a rat temporary MCAO model (Poloyac 
et al., 2006). Similarly, acute administration of HET0016 also reduced infarct size in a rat model 
of focal ischemia (Renic et al., 2009). HET0016 was also effective in reducing 20-HETE levels in 
CSF, and prevent the acute fall in CBF in the rat model of SAH (Cambj-Sapunar et al., 2003; Kehl 
et al., 2002). N-(3-Chloro-4-morpholin-4-yl) phenyl-N`-hydroxyimido formamide (TS-011), the 
most potent inhibitor of 20-HETE synthesis to date, has shown protection from hemorrhagic and 
ischemic stroke in rats by significantly reducing brain 20-HETE levels and improving functional 
outcomes (Marumo et al., 2010; Miyata, et al., 2005; Renic, et al., 2009). Recently, TS-011 was 
shown to improve defects in cerebral microcirculatory autoregulation near the infarct site thereby 
reducing cerebral damage following ischemia (Marumo, et al., 2010). 
20-HETE antagonists: A stable structural analog of 20-HETE, 20-hydroxyeicosa-
6(Z),15(Z)-dienoic acid (20-HEDE) blocked 20-HETE induced vasoconstriction of rat middle 
cerebral and basilar arteries, and attenuated 20-HETE mediated increases in intracellular Ca2+ in 
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an in vitro study and reduced the acute fall in CBF in a rat model of SAH (Gebremedhin, et al., 
2000; Yu et al., 2004). 20-HETE antagonist also showed reduction in infarct size in a rat temporary 
MCAO model (Renic, et al., 2009).  
1.2.5.2 Epoxygenase and sEH pathway: Miconazole and 17-ODYA have been used as 
epoxygenase inhibitors in the coronary and cerebral circulations (Harder et al., 1998). Miconazole 
significantly decreased baseline blood flow in the brain of rats (Alkayed, et al., 1996) and reduced 
glutamate induced increases in CBF (Harder, et al., 1998). Miconazole and N-methylsulfonyl-6-
(2-propargyloxyphenyl) hexamide (MS-PPOH), a selective epoxygenase inhibitor blocked the 
functional hyperemic response to the activation of the whisker barrel cortex in rats (Bhardwaj et 
al., 2000). .  
Since administering EETs is not a viable pharmacological approach as they rapid bind to plasma 
proteins or metabolized to less active DHETs, more metabolically stable analogs of EET (Sodhi 
et al., 2009) were developed in the past but most widely used approach for studying the effects of 
EETs has been increasing endogenous EET levels by inhibiting or genetically deleting sEH , which 
metabolizes EETs (Iliff et al., 2009a; Imig, et al., 2009). Different genetic studies have tested the 
association between the genetic polymorphisms in EPHX2 encoding sEH and the risk for ischemic 
stroke (Fornage et al., 2005; Gschwendtner et al., 2008; Koerner et al., 2007; Lee et al., 2010; 
Zhang et al., 2008a). There were conflicting findings in terms of the association with increased 
risk for stroke and/or cardiovascular diseases. However, pharmacological inhibition of sEH has 
consistently demonstrated effectiveness in reducing ischemic damage in rats and mice (Dorrance 
et al., 2005; Simpkins et al., 2009; Zhang et al., 2007; Zhang et al., 2008b). Different potent and 
specific sEH inhibitors were developed with better physicochemical properties (Kim et al., 2004; 
Morisseau et al., 1999; Morisseau et al., 2002). sEH inhibitor 12-(3-adamantan-1-yl-ureido) 
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dodecanoic acid (AUDA) protected against cerebral ischemia in spontaneously hypertensive and 
Wistakr-Kyoto rats. Both acute and chronic inhibition of sEH showed protection from ischemic 
injury irrespective of the time of administration of inhibitors and the protective effects appeared 
to be mediated by EETs as CYP epoxygenase inhibition by MS-PPOH abolished the protective 
effect of sEH inhibition (Zhang, et al., 2007; Zhang, et al., 2008b).  
Despite the development of various chemical inhibitors targeting specific CYP450 eicosanoid 
pathways, most of the existing pharmacological inhibitors do not possess all favorable 
characteristics such as solubility, and permeability across BBB. Thus, there is a growing need to 
design new compounds with not just chemical stability but with selectivity and specificity to the 
CYP isoforms in the target organ, and with improved pharmacokinetic profile to achieve desired 
therapeutic concentrations in the brain, to test in animal models of cerebrovascular disease in order 
to develop effective therapeutic strategies to treat the debilitating neurological consequences of 
stroke and ischemic brain injury. 
1.3. NEUROPROTECTIVE THERAPIES 
1.3.1 Neuroprotective agents  
Drugs used for acute ischemic stroke can be broadly classified into drugs that improve 
hemodynamics (thrombolytics, antiplatelet drugs, anticoagulants, and fibrinogen depleting agents) 
and others that target molecular and cellular pathways that mediate the injury, which are known as 
neuroprotective agents. In section 1.1.2 pathophysiology of cerebral ischemic injury was 
discussed. In this section, I will briefly review various therapeutic agents tested in clinical trials 
for ischemic stroke that target different cellular and molecular pathways of injury.  
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NMDA receptor antagonists were developed in the past as a putative neuroprotective therapy since 
they are primarily involved in mediating the excitotoxicity associated with glutamate release in 
ischemia. NMDA receptor competitive and non-competitive antagonists can reduce experimental 
ischemic volume as much as 30 – 50% (Lipton, 1999). MK-801, a potent non-competitive NMDA 
antagonist failed in the clinical trials due to unwanted serious side effects such as psychosis, 
hallucinations, and hypotension. A primary reason for the failure of many NMDA receptor 
antagonists was the therapeutic time window, which was as late as 6 h after stroke. This may be 
too late as glutamate release is highest in the initial few hours of ischemic injury. Ca2+ channel 
blockers were another class of drugs that attracted attention as they aim to decrease intracellular 
Ca2+, which is key contributor in initiating many cell death pathways. However, these agents also 
reduce systemic blood pressure, and hypotension can increase infarct size by affecting the 
collateral flow, which can worsen the clinical outcome. Nimodipine, a calcium channel antagonist 
has only been effective in preventing ischemia from SAH associated vasospasm but not in focal 
ischemia. During reperfusion phase there is increased production of free radicals in penumbra. 
Free radical inhibitors were thought to be more beneficial as they offer longer therapeutic window 
than glutamate pathways. Spin-trap free radical inhibitors can dramatically reduce infarct volume 
in reperfusion models (Marshall et al., 2001; Sydserff et al., 2002). Free-radical inhibitors offer 
longer time window than that of glutaminergic pathways. Tirilazad, and NXY-059 both have failed 
in the clinical and currently Ebselen, an antioxidant that can react with peroxynitrite is undergoing 
phase III trials. Several other drugs were developed and tested in clinical trials that work through 
various known and unknown pathways (Table 1-1) but have not been successful (Smith, 2004; Xu 
et al., 2013). Currently the only approved medication by Food and Drug Administration (FDA) for 
improving clinical outcome in ischemic stroke is recanalization of the vessels using tissue 
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plasminogen activator (tPA) and even that has a narrow therapeutic index and must be 
administered within 3 hours of stroke onset (Fisher et al., 2003).  
Table 1-1 List of neuroprotective agents tested for stroke (www.strokecenter.org/trials) 
Mechanism Agent / Trial Phase  Status 
Free radical scavenger / Antioxidant Ebselen III On going 
 Tirilazad II Completed 
GABA agonist Clomethiazole II Completed 
Ca2+ channel blocker Nimodipine III Completed 
 Flunarizine III Completed 
Ca2+ chelator Dp-b99 II On going 
Glutamate antagonist    
AMPA antagonist Zonampanel II Completed 
 MPQX II Completed 
Competitive NMDA antagonist Selfotel III Completed 
NMDA channel blocker Aptiganel III Completed 
 Traxoprodil III On going 
 Magnesium III On going 
Glycine site antagonist Licostinel I On going 
 Gavestinel III Completed 
Growth factor Fibroblast GF III Completed 
Leukocyte adhesion inhibitor Enlimomab III Completed 
 Rovelizumab III Completed 
Nitric oxide inhibitor Lubeluzole III Completed 
Opiod antagonist Cervene III Completed 
Phosphatidyl choline precursor  Citicoline III On going 
Seretonin agonist Repinotan III Completed 
Sodium channel blocker Fosphenytion III Completed 
Potassium channel agonist BMS-204352 III Completed 
Unknown mechanism Piracetam III On going 
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There are probably several reasons for failure of most of the clinical trials that otherwise showed 
promise in preclinical testing. The reasons for the failure are complex and many including timing 
of administration of drug, window of opportunity, duration of ischemia, dose of the drug given, 
species, gender differences, age, and underlying diseases. There is a definite need to reassess the 
research paradigm in both preclinical and clinical stroke studies in order to improve successful 
translation of the animal studies to human. Perhaps appropriate model selection that accounts for 
factors like age, comorbid conditions; choice of anesthetics that have less confounding effects on 
neuroprotection; monitoring of physiological variables; assessing neurological damage in both 
permanent and temporary MCAO models; longer therapeutic time window; drugs that cross BBB 
may be some of the useful strategies. Further, as it is difficult to intervene early in stroke, 
preventing the ischemic cell death at later times by targeting the pathways leading to delayed 
ischemic cell death such as free radical damage may be useful as an adjuvant therapy along with 
recanalizing the vessels. 
 
1.3.2 STAIR Recommendations 
 Lack of translation of therapies to human after ischemia has led to formation of an 
academy/industry joint roundtable “Stroke Therapy Academy Industry Roundtable” (STAIR) who 
made recommendations for appropriate conduct of preclinical trials of neuroprotective agents 
using stroke/ischemic models (STAIR, 1999). The following recommendations were made by 
them: 
1. Adequate dose response curve: A full dose-response curve should be performed so 
that the minimum effective and maximum tolerated dose are clearly defined. Further, the studies 
should document that the drug in these range of concentrations is accessible to the target organ. 
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2. Therapeutic window:  There is uncertainty about the relevance of therapeutic time 
window in animals to acute clinical stroke. Yet animal models appear to be relevant to address a 
therapeutic time window for thrombolytic and neuroprotective drugs. It is recommended to use 
penumbral imaging using perfusion/diffusion MRI mismatch to help identifying the therapeutic 
window in a particular model.  
3. Outcome measures:  Multiple endpoints are important and both histological and 
behavioral outcomes should be assessed. These assessments should include studies conducted at 
least 2 to 3 weeks or longer after stroke onset to demonstrate sustained benefit with emphasis on 
functional outcome in delayed survival studies.  
4. Physiological monitoring:  In many a focal ischemia models spontaneous 
reperfusion may occur leading to infarct size variability. Basic physiological parameters such as 
blood pressure, temperature, blood gases, and blood glucose should be routinely monitored. 
Temperature should be maintained within in the normal physiological range. It is suggested to 
monitor CBF using perfusion imaging or laser Doppler flow to document adequate sustained 
occlusion and to monitor reperfusion in temporary ischemia models. 
5. Multiple species:  Treatment efficacy should be established in at least 2 species 
using both histological and behavioral outcome measures. Rodents or rabbits are acceptable for 
initial testing and gyrencephalic primates or cats are desirable as second species.  
6. Multiple models:  The ischemia is usually reversible in animal models but this 
is occasionally the case in clinical trial subjects. Hence it is recommended to test efficacy of 
neuroprotective agents in both permanent and temporary focal ischemia models, and it is desirable 
for the agent to be effective in both models.  
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7. Infarction location:  The infarction is mostly confined to the cortex in the rat 
models, while human ischemic strokes are often located in the white matter. Whether the ischemic 
area is located in grey or white matter impacts the outcome. Thus it is desirable to have 
neuroprotective agents show effectiveness for both cortical and subcortical infarctions.  
8. Multiple targets:  Protecting neurons per se is not enough. It is likely that glial 
cells and vascular elements in the brain also be protected from injury. The emerging concept of 
neurovascular unit emphasizes that all the multiple cell types in brain must be considered when 
identifying targets for developing neuroprotective agents. 
 
1.4. NEW APPROACHES IN NEUROPROTECTION  
1.4.1 Biomarker based approach 
Secondary neuronal damage is commonly observed in both stroke and cardiac arrest after 
reperfusion/resuscitation. Identifying and measuring the key mediators of injury pathways, 
especially during the delayed death phase, may be of great prognostic value to identify patients at 
risk for developing secondary neuronal damage (Turner et al., 2013). These mediators commonly 
known as “biomarkers” are classically defined as a biological component that can be tangibly 
quantified to understand normal or pathological functioning in the body (Bettermann, 2011; 
Mayeux, 2004). They are useful in diagnosis, monitoring progress of disease, identify targets for 
intervention, and assessing the risk of pathology. One example is troponin-1 well known biomarker 
used in myocardial infarction. Previous studies have demonstrated differences in various markers 
that have potential to play a role in predicting outcomes, increase our understanding of 
pathophysiology of cerebral ischemia, and possibly provide targets for therapeutic intervention 
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(Denes et al., 2011; Navarro-Sobrino et al., 2011; Qian et al., 2012; Ramos-Fernandez et al., 2011). 
Historically, biomarker based studies have focused on single marker for diagnostic/prognostic 
purpose. However, in recent times there was transition towards identifying a panel of biomarkers 
that may improve sensitivity, specificity, and predictive values over time. Multiple biomarkers 
have been identified in literature for stroke. For example, matrix metalloproteinase (MMP-9) 
(Montaner et al., 2001), glial fibrillary acidic protein (GFAP) (Hasan et al., 2012), S100B 
(Montaner et al., 2012), D-dimer (Montaner et al., 2011). A vast number of clinical trials failed 
due to how stroke research was conducted (methodology) as well as the therapeutic targets 
selected. Thus, more research on biomarkers not only serve as diagnostic/prognostic tool but will 
also help in elucidating pathophysiology of cerebral ischemic injury. 
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1.5. SUMMARY AND RESEARCH HYPOTHESIS 
Stroke and cardiac arrest are among the top three leading causes of death in adults with a 
common underlying mechanism of ischemic cell death although with differences in specific 
cellular and molecular pathways. Ischemic lesion evolution is the complex interplay of balance 
between various vasoactive factors, inflammatory mediators, and interaction between different 
injury pathways. Remarkable differences in the ischemic injury during interrupted blood flow and 
during reperfusion / resuscitation stress the need to understand these underlying pathways in order 
to design effective therapeutic strategies to minimize the debilitating consequences of stroke and 
cardiac arrest. Lipid metabolism, has taken the center stage in stroke research due to the plethora 
of actions these metabolites exert on regulation of CBF and tissue survival in a cell type specific 
manner. As discussed in this chapter, release of free fatty acids especially AA and its metabolites 
during the ischemic injury have been shown to play a critical role in the disease progression. In 
the past few decades, CYP450 enzymes have emerged as a third major pathway of AA metabolism 
with significant contribution to overall blood flow regulation in vascular beds of different organs. 
Pharmacological actions of CYP450 derived eicosanoids in different organs including kidney, 
lungs, and heart were well documented in the literature. However, interest in the delineating the 
significance of their role in cerebrovascular diseases such as stroke has gained momentum.  
 
Studies outlined throughout this review have demonstrated significance of CYP eicosanoids in 
cerebral ischemic injury. Though these CYP eicosanoids affect CBF regulation, they also exert 
cytoprotective effects directly independent of blood flow modulation. The relative contributions 
of vascular and non-vascular mechanisms of neuroprotection by CYP eicosanoids have not been 
systematically elucidated. As discussed in this chapter, use of pharmacological inhibitors to inhibit 
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one pathway of AA metabolism may change levels of AA metabolites from other pathways due to 
shunting, which may or may not contribute to the overall neuroprotective effect observed. Thus, it 
is not only important to confirm the selectivity, and specificity of the pharmacological inhibitors 
but also it is equally important to quantify a whole array of AA metabolites in order to delineate 
the specific contribution of CYP eicosanoids in neuroprotection. The advanced and sophisticated 
analytical techniques to quantify lipids and their metabolic products, an approach called lipidomics 
is gaining wide spread use in lipid research however applications of this approach specifically in 
CYP eicosanoid research has been limited.  
 
Pharmacological effects of CYP eicosanoids were traditionally evaluated from in vitro studies of 
microvessel diameter changes to in vivo studies of histological evaluation of infarct size. However, 
benefits of modulating CYP eicosanoid pathway in terms of improved outcomes was less 
emphasized. As recommended by STAIR, an assessment of short-term and long-term functional 
outcomes in addition to histological evaluation is warranted to advance pharmacological inhibitors 
of CYP eicosanoid pathway as a potential therapeutic intervention for treating cerebrovascular 
disorders like stroke. Further, understanding the relative contribution of components of 
neurovascular unit to the overall neuroprotection is important for developing therapeutic agents 
that modulate multiple targets in the neurovascular unit to achieve maximum therapeutic efficacy.    
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Figure 1-5. Schematic of research hypothesis 
Therefore, the goal of this thesis research is to systematically evaluate the effects of CYP 
eicosanoids on neuronal death, CBF, and functional outcome in the context of neurovascular unit 
in experimental models of focal and global ischemia. As shown in Figure 1-5, we hypothesize that 
inhibiting the formation of 20-HETE and metabolism of the EETs by pharmacological inhibitors 
improves functional outcome by affecting the components of neurovascular unit such as neurons, 
and cerebral vessels (blood flow).  
First objective of the study was to develop a comprehensive lipidomics analysis of tissue levels of 
prostanoids and CYP eicosanoids. This objective was achieved by using advanced analytical 
instruments and results are presented in Chapter 2. The second objective was to investigate the 
cytoprotective effects of CYP eicosanoids under normal and ischemic conditions. This objective 
was completed by using in vitro neuronal cultures and results are presented in Chapter 3. The third 
objective was to evaluate the effects of CYP eicosanoids in an experimental focal ischemia model. 
This was accomplished using advanced analytical assays, a rat MCAO model, state-of-the-art CBF 
assessment techniques, sophisticated neurobehavioral analysis, and in vitro neuronal cultures. The 
results are presented in Chapter 4. The fourth and final objective was to evaluate the CYP 
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eicosanoid effects in an experimental model of global ischemia. This was completed by using 
advanced analytical assays, pediatric asphyxial CA model, sophisticated CBF analysis, and 
neurological deficit analysis. The results are presented in Chapter 5.  
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2.0 ANALYTICAL METHOD DEVELOPMENT AND VALIDATION 
 
 
 
 
 
 
 
 
[Jafar Sadik B Shaik, Tricia M. Miller, Steven H Graham, Mioara D. Manole, Samuel M Poloyac. 
“Rapid and simultaneous quantitation of prostanoids by UPLC-MS/MS in rat brain”. Manuscript 
accepted for publication in Journal of Chromatography B] 
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2.1 INTRODUCTION 
Many pharmacological inhibitors targeting different pathways of AA metabolism were 
developed in the past as a potential therapeutic intervention to treat various neurodegenerative and 
neuroinflammatory diseases. However, these inhibitors, while decreasing metabolites from a 
specific pathway, also lead to increase in the formation of metabolites of AA from other pathways 
due to shunting. Therefore, there is a need to analytically evaluate all AA metabolites to evaluate 
the total sum effect of interventions aimed at altering arachidonic acid metabolism. Analytical 
methods play a vital supportive role in drug discovery & development process from measuring the 
concentrations of drugs in biological fluids to measuring concentrations of biomarkers of diseases 
progression. In lipid research, identifying and measuring a panel of all AA metabolites in different 
tissues and biological fluids serves two main purposes: a) quantifying specific metabolites that 
may be elevated or reduced in various disease conditions; b) quantifying metabolites of a certain 
pathway as an indicator of target engagement for confirming the selectivity of pharmacological 
inhibitors. In addition to the above advantages, lipidomics based analytical methods also offer 
rapid throughput in bioanalysis. Therefore, for the purpose of this thesis research an UPLC-
MS/MS method was developed and validated for rapid and simultaneous quantification of 
prostanoids and CYP eicosanoids in brain tissue. As discussed previously in Chapter 1, 
prostanoids are the cyclic lipid mediators produced from the cyclooxygenation of AA, a rate 
limiting step catalyzed by COX family of enzymes consisting of  a constitutive (COX-1) and an 
inducible (COX-2) isoform (Gryglewski, 2008). As shown in Figure 2-1, these and other tissue 
specific terminal synthases convert AA to family of various structurally different prostanoid 
metabolites. These prostanoids bind to classes of GPCR designated EP (PGE2), FP (PGF2α), DP 
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(PGD2), IP (PGI2), and TP (TXA2) receptors that have various effects on cAMP and intracellular 
Ca2+ mobilization.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-1. Cyclooxygenase pathway of AA metabolism. AA is converted to unstable cyclic 
endoperoxy metabolite (PGG2), which is reduced to PGH2. PGH2 is further metabolized by tissue specific 
terminal isomerases (PGD2 or PGE2), reductases (PGF2α), prostacyclin synthase (PGI2), and thromboxane 
synthase (TXA2). Hydrolysis of PGI2 and TXA2 yields inactive by-products (6-keto-PGF1α and TXB2) of 
much greater stability.  
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2.1.1. Biological significance of prostanoids in CNS: 
In previous chapter, I have discussed in detail on the biological significance of CYP 
eicosanoids in cerebral ischemia. In this section, the significance of prostanoids in various CNS 
disorders will be discussed. In the CNS, prostanoids have been implicated in various 
neuroinflammatory and neurodegenerative disorders (Lima et al., 2012). Prostanoid receptor 
signaling may elicit divergent pharmacological or pathological effects on tissue/cell viability 
depending on the type of injury. Previous studies showed that PGE2 was neuroprotective in in vitro 
neuronal cultures (Akaike et al., 1994; Takadera et al., 2002) and in in vivo animal models of focal 
ischemia (Liu et al., 2005a; McCullough et al., 2004), conversely, PGE2 was also shown to 
promote an inflammatory and neurotoxic effect in the lipopolysaccharide (LPS) model (Montine 
et al., 2002). Patients with probable Alzheimer Disease (AD) have higher CSF concentrations of 
PGE2 than age-matched control subjects (Montine et al., 1999). Similarly, Parkinson’s disease 
(PD) patients also have elevated PGE2 concentrations in CSF (Mattammal et al., 1995). In addition, 
PGD2 has been shown to be important in neuroinflammatory and neurodegenerative conditions 
(Rosenberger et al., 2004). PGD2 synthase (PGDS) expression is localized in microglial cells 
surrounding senile plaques and DP1 receptor (PGD2 receptor) expression was observed in 
microglial cells and astrocytes within senile plaques in human AD brains (Iwamoto et al., 1989; 
Mohri et al., 2007). 15-deoxy-∆12,14-PGJ2 (15d-PGJ2) and PGJ2, non-enzymatic cyclopentenone 
metabolites of PGD2, are increased in the rat brain after cerebral ischemia (Liu et al., 2011; Liu et 
al., 2013a). 15d-PGJ2 mediates its effects through PPAR γ receptors. This prostanoid has been 
shown to exert neuroprotective effects in in vitro cell cultures by reducing microglial production 
of NO, IL-6, and TNF-α induced by Aβ40 (Takata et al., 2003).  
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PGF2α has been shown to exacerbate hypoxic injury in rat primary neuronal culture (Li et al., 2008) 
as well as in in vivo models of ischemia with a FP agonist (Saleem et al., 2009). A prostacyclin 
receptor ligand has shown neuroprotective effects in a MCAO model (Takamatsu et al., 2002) and 
also in neuronal cultures by reducing expression of different inflammatory mediators such as TNF-
α (Satoh et al., 1999). In addition to their role in neuroinflammation, prostanoids such as 
prostacyclin (PGI2) and PGE2 also alter vascular smooth muscle tone (Chapple et al., 1980; 
Greenberg et al., 1982; Lippton et al., 1979). Specifically, prostacyclin (PGI2) and TXA2 are potent 
vasodilators and vasoconstrictors of cerebrovasculature, respectively (Moncada et al., 1979). 
Collectively, these studies suggest that prostanoids produce a plethora of effects on CNS and are 
important mediators in the pathogenesis of neurodegenerative and neuroinflammatory diseases. 
 
2.1.2. Analytical methods for quantifying prostanoids 
Multiple methods have been developed for the detection and quantitation of prostanoid 
metabolites. Radio-immuno assays (Hofer et al., 1993), enzyme linked immunoassays (Pradelles 
et al., 1990), HPLC methods (Henden et al., 1993; Kiss et al., 1998; Moraes et al., 2004; 
VanderNoot et al., 2002), and gas chromatography-mass spectrometry methods (Baranowski et 
al., 2002; Nithipatikom et al., 2001) have been developed in the past for the quantitative analysis 
of these metabolites from many different matrices. Though these assays are useful, limitations of 
these methods include inadequate sensitivity, limited selectivity, narrow range of metabolites, and 
cross-reactivity. A significant issue in analysis of similar isomeric metabolites from complex 
biological matrices is the specificity. High performance liquid chromatography with tandem mass 
spectrometry (HPLC-MS/MS) methods have been successfully applied to quantify these 
metabolites from different matrices including cell cultures (Martin-Venegas et al., 2011; 
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Takabatake et al., 2002), biological fluids (Chappell et al., 2011; Ferreiro-Vera et al., 2011a; 
Ferreiro-Vera et al., 2011b; Komaba et al., 2009; Unterwurzacher et al., 2008), and tissues 
(Masoodi et al., 2006) but flow rate limitation common in HPLC systems has resulted in longer 
run times making most of these methods time-consuming and expensive. The shortest run time 
reported by these methods containing at least five different prostanoids is 25 min. A more efficient 
method would be the use of ultra-performance liquid chromatography (UPLC), which offers 
greater separation efficiency, higher sensitivity, and shorter run times. 
Therefore, it was the purpose of this study to develop and validate a sensitive, accurate, and rapid 
high throughput UPLC-MS/MS method to simultaneously measure 11 prostanoid metabolites in 
rat brain tissue. In addition, we investigated the effects of the matrix on the reproducibility and 
reliability of the data as recommended by the Food and Drug Administrative (FDA) Quantitative 
Bioanalytical Methods Validation Report and other validation guidance documents (Matuszewski 
et al., 2003; Viswanathan et al., 2007). Furthermore, we applied the sample processing method 
employed in the prostanoid method development to our previously published CYP eicosanoid 
method (Miller et al., 2009) in order to measure them all from a single extracted sample of rat 
brain tissue rather than including all prostanoids and CYP eicosanoids in one single run, thereby 
compromising on sensitivity and analysis time. Therefore, development of this method is 
necessary for evaluation of these metabolites as potential quantitative biomarkers in order to 
elucidate their role in modulation of neuroinflammatory, neurodegenerative as well as vascular 
disorders.  
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2.2 EXPERIMENT AND METHOD VALIDATION 
 
2.2.1 Chemicals and reagents 
Stock standards of 6-keto-prostglandin F1α (6-keto-PGF1α), 6-keto-prostaglandin F1α-d4 
(6-keto-PGF1α-d4), 11β-prostaglandin F2α (11β-PGF2α), 11β-prostaglandin F2α-d4 (11β-PGF2α-
d4), prostaglandin F1α (PGF1α), prostaglandin F1α-d9 (PGF1α-d9), prostaglandin F2α (PGF2α), 
prostaglandin F2α-d4 (PGF2α-d4), prostaglandin E2 (PGE2), prostaglandin E2-d4 (PGE2-d4), 11-
dehydro-Thromboxane B2 (11-d-TXB2), 11-dehydro-Thromboxane B2-d4 (11-d-TXB2-d4), 
prostaglandin D2 (PGD2),  prostaglandin D2-d4 (PGD2-d4), prostaglandin A2 (PGA2), 
prostaglandin J2 (PGJ2), 15-deoxy-∆12,14-prostaglandin D2 (15-d-PGD2), 15-deoxy-∆12,14-
prostaglandin J2 (15-d-PGJ2), 15-deoxy-∆12,14-prostaglandin J2-d4 (15-d-PGJ2-d4) were 
purchased from Cayman Chemical Company (Ann Arbor, MI). High purity organic solvents were 
purchased from VWR (West Chester, PA) and all other chemicals were purchased from Sigma-
Aldrich (St. Louis, MO).  
2.2.2 Animals and treatment  
Male postnatal day (PND) 16 to 18 Sprague-Dawley rats (between 30 to 45 g) were 
maintained on a 12-h light/dark cycle. Rats were initially subjected to anesthesia with the use of a 
spontaneous inhalational anesthesia system [Surgivet (Smiths Medical, Waukesha, WI) V7216 
Isotec 4] containing 3% isoflurane / 50% N2O & oxygen until unconscious and then the trachea 
was intubated with an 18-gauge angiocatheter and mechanical ventilation was initiated. Anesthesia 
was reduced to 2.5% isoflurane/50% N2O & oxygen and femoral arterial and venous catheters 
were placed. Isoflurane was discontinued, and intravenous analgesia was initiated using fentanyl 
infusion at 50 µg/kg/h and neuromuscular blockade was obtained using vecuronium infusion at 5 
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mg/kg/h. Asphyxial cardiac arrest was induced by disconnecting the tracheal tube from the 
ventilator for 12 min. Resuscitation was initiated by reconnecting the ventilator, infusion of 
epinephrine 0.005 mg/kg and sodium bicarbonate 1 mEq/kg i.v and manual chest compressions 
until ROSC. Anesthesia and neuromuscular blockade were restarted at 30 min after ROSC. 
Animals were sacrificed by decapitation at 5 and 120 min after ROSC and brain cortical tissue was 
rapidly excised, snap frozen in liquid nitrogen and stored at -80 ºC. All animal procedures were 
approved by the University of Pittsburgh Institutional Animal Care and Use Committee.  
 
2.2.3 UPLC-MS/MS method development 
2.2.3.1 Chromatography and mass spectrometry 
2.2.3.1.1 Prostanoids: 
Liquid chromatography was performed using an Acquity ultra performance LC 
autosampler (Waters, Milford, MA). Prostanoids were separated on a UPLC BEH C-18, 1.7 µm 
(2.1 x 150 mm) reverse-phase column (Waters, Milford, MA) protected by a guard column (2.1 
mm x 5 mm; Waters, Milford, MA) of the same packing material. Column temperature was 
maintained at 55 ºC. Mobile phases, delivered at a flow rate of 0.4 ml/min, consisted of 0.005% 
acetic acid, 5% acetonitrile in deionized water (A) and 0.005% acetic acid in acetonitrile (B) at an 
initial mixture of 65:35 A and B, respectively. Mobile phase B was maintained at 35% for 7.5 min 
and then increased to 98% in a linear gradient over 1.5 min, where it remained for 0.2 min. This 
was followed by a linear return to initial conditions over 0.1 min with a 2.7 min pre-equilibration 
period prior to the next sample run. Total run time per sample was 12 min and all injection volumes 
were 7.5 µl.  
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Mass spectrometric analysis of analyte formation was performed using a TSQ Quantum Ultra 
(Thermo Fisher Scientific, San Jose, CA) triple quadrupole mass spectrometer coupled with heated 
electrospray ionization source (HESI) operated in negative selective reaction monitoring (SRM) 
mode with unit resolutions at both Q1 and Q3 set at 0.70 full width at half maximum. Quantitation 
by SRM analysis on all prostanoid metabolites was performed by monitoring their respective m/z 
transitions. The SRM conditions for these analytes and their retention times are shown in Table 
2-1. Parameters were optimized to obtain the highest [M-H]- ion abundance and were as follows: 
capillary temperature, 373 ºC, vaporizer temperature 340 ºC, spray voltage, 3500 kV, and a source 
collision-induced dissociation set at 0 V. Sheath gas, auxiliary gas, and ion sweep gas pressures 
were set at 60, 45, and 0, respectively. Scan time was set at 0.01 s and collision gas pressure was 
set at 1.5 mTorr. Analytical data was acquired and analyzed using Xcalibur software version 2.0.6 
(Thermo Finnigan, San Jose, CA). 
Table 2-1. SRM conditions for the prostanoid metabolites and the deuterated internal standards in negative 
electrospray ionization mode 
Analyte 
Precursor → Product 
(m/z) 
Collision 
Energy 
Retention 
time (min) 
6-keto-PGF1α 369.3 → 245.1 28 1.61 
6-keto-PGF1α-d4 373.2 →249.2 25 1.60 
11β-PGF2α 353.1 → 193.1 26 2.30 
11β-PGF2α-d4 357 → 197 27 2.29 
PGF1α 355.1 → 311.1 23 2.63 
PGF1α-d9 364 → 320.1 25 2.62 
PGF2α 352.9 → 309.1 23 2.68 
PGF2α-d4 357 → 313.1 23 2.66 
PGE2 351.1 → 271.1 20 2.90 
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PGE2-d4 355.1 → 275.1 19 2.88 
11-dehydro-TXB2 367 → 305.1 22 3.00 
11-dehydro-TXB2-d4 371 → 309.1 20 2.98 
PGD2 351.1 → 271.1 20 3.30 
PGD2-d4 355.1 → 275.1 17 3.29 
PGA2 333 → 271.2 19 6.00 
PGJ2 333 → 271.2 19 6.42 
15-deoxy-∆12,14-PGD2 333 → 271.2 19 9.32 
15-deoxy-∆12,14-PGJ2 316 → 272 17 9.64 
15-deoxy-∆12,14-PGJ2-d4 320 → 276 17 9.63 
 
2.2.3.1.2 CYP eicosanoids: 
CYP eicosanoids method development was described previously by our group (Miller, et al., 
2009). Briefly, CYP eicosanoids were separated on a UPLC BEH C-18 column 1.7 µm (2.1 x 100 
mm) reverse-phased column (Waters, Milford, MA) protected by a guard column (2.1 mm x 5 
mm; Waters, Milford, MA) of the same packing material. Column temperature was maintained at 
55 ºC. Mobile phases consisted of 0.005% acetic acid, 5% acetonitrile in deionized water (A) and 
0.005% acetic acid in acetonitrile (B). CYP eicosanoids were separated by delivering mobile phase 
at 0.5 ml/min at an initial mixture of 65:35 A and B, respectively. Mobile phase B was increased 
from 35% to 70% in a linear gradient over 4 min, and again increased to 95% over 0.5 min where 
it remained for 0.3 min. This was followed by a linear return to initial conditions over 0.1 min with 
a 1.5 min pre-equilibration period prior to the next sample run. Total run time per sample was 6.4 
min and injection volume was 7.5 µL. Mass spectrometric analysis of analyte formation was 
performed using a TSQ Quantum Ultra (Thermo Fisher Scientific, San Jose, CA) triple quadrupole 
mass spectrometer coupled with heated electrospray ionization (HESI) operated in negative 
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selective reaction monitoring (SRM) mode with unit resolutions at both Q1 and Q3 set at 0.70 full 
width at half maximum. Quantitation by SRM analysis on CYP eicosanoids was performed by 
monitoring their m/z transitions. Scan time was set at 0.01 s and collision gas pressure was set at 
1.3 mTorr. Analytical data was acquired and analyzed using Xcalibur software version 2.0.6 
(Thermo Finnigan, San Jose, CA). 
 
2.2.3.2 Calibration standards and quality control samples 
 A stock solution of metabolites was prepared in 80:20 methanol:water to achieve a series 
of working solutions at 1 µg/ml, 100 ng/ml and 25 ng/ml concentrations. A solution of internal 
standard (IS) consisting of PGD2-d4, 15-d-PGJ2-d4, 6-keto-PGF1-d4, 11β-PGF2-d4, PGF1-d9, 11-
d-TXB2-d4, PGE2-d4, PGF2-d4 was prepared in 80:20 methanol:water at a concentration of 1 
µg/ml. Calibration standards and quality control (QC) samples were prepared from separate stock 
solutions by spiking appropriate amounts of the working solutions into deionized water. 
Calibration standards were prepared at 0.104, 0.208, 0.417, 0.83, 1.25, 1.67, 4.17, 8.33, 12.5, 16.7, 
and 33.3 ng/ml (6.25, 12.5, 25, 50, 75, 100, 250, 500, 750, 1000, and 2000 pg on column, 
respectively). QCs were prepared at 0.667, 7.50, and 20.83 ng/ml (40, 450 and 1250 pg on column, 
respectively). 
2.2.3.3 Sample extraction procedure  
Tissue samples were homogenized in deionized water containing 0.113 mM butylated 
hydroxytoluene (BHT) and centrifuged for 30 min at 10,000 rpm. The supernatant was removed 
for analysis. The metabolite concentrations in the tissue samples as well as in the calibration and 
quality control standards were all determined using a solid phase extraction (SPE) procedure. 
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Standards and tissue supernatants were spiked with 12.5 µL (containing 12.5 ng) of internal 
standard (IS) solution consisting of PGD2-d4, 15-d-PGJ2-d4, 6-keto-PGF1-d4, 11β-PGF2-d4, 
PGF1-d9, 11-d-TxB2-d4, PGE2-d4, PGF2-d4. The spiked samples were loaded onto Oasis 
hydrophilic-lipophilic balanced (HLB) (30 mg) SPE cartridges (Waters, Milford, MA) that were 
conditioned and equilibrated with 1 ml of methanol and 1 ml of water, respectively. Columns were 
washed with three 1 ml volumes of 5% methanol and were eluted with 100% methanol. Extracts 
were spiked with 15 µL of 1% acetic acid in methanol and dried under nitrogen gas at 37°C, and 
reconstituted in 125 µl of 80:20 methanol: water for further chromatographic analysis.  
 
2.2.4 Method validation 
 Validation of the SPE assay was performed by using 11 standard concentrations of all 
prostanoid metabolites prepared in a 2 ml volume of the same deionized water used for sample 
dilution, and extracted via SPE using above method. The amount of metabolites in the standards 
ranged from 0.104 to 33.3 ng/ml (6.25 – 2000 pg on column). Four separate duplicate standard 
curves were prepared and analyzed over four consecutive days. Curves were calculated based on 
the peak area ratios between each metabolite to the IS and plotted against the amount of the 
metabolite injected onto the column.  
 
2.2.4.1 Precision and accuracy 
 Precision and accuracy of the method was determined by the analysis of QC samples. 
Metabolites were spiked into deionized water to yield low, medium, and high QCs, corresponding 
to 0.667, 7.50, 20.83 ng/ml (40, 450, 1250 pg on column), respectively. Five samples at each level 
61 
 
were analyzed for two days, followed by 10 replicates of each on the final day of validation. The 
lower limit of detection (LLOD) was determined by the minimum value with a signal-to-noise 
(S/N) ratio of ≥ 3:1. The lower limit of quantitation (LLOQ) was determined by the minimum 
value with accuracy and precision within ±15% deviation of the nominal value. Accuracy was 
determined as the relative deviation in the calculated value (E) of a standard from that of its true 
value (T) expressed as a percentage. This accuracy, or relative standard error (RE%), was 
calculated using the equation RE%=(E−T)/T×100. Precision was evaluated and expressed as 
relative standard deviation (RSD %) of the mean concentrations using the equation RSD% = 
SD/M×100. The criteria for acceptability of data included accuracy and precision within ±15% 
deviation of the nominal value.  
2.2.4.2 Analyte recovery determination 
 The extraction recovery (E.R.) efficiencies of the deuterated metabolites in deionized water 
were determined at 12.5 ng/ml (750 pg on column; n=6) by comparing the responses (area) of 
samples spiked before extraction to those spiked after extraction. The recovery samples were 
processed using SPE and concentrations of metabolites were determined by UPLC–MS/MS as 
described in section 2.2.3.3. 
2.2.4.3 Matrix effects on prostanoids and CYP eicosanoids 
 Matrix effects (ME) were evaluated using 2 ml volume of the same deionized water 
(matrix) spiked with 0.113mM BHT used for processing rat cortical tissue samples. The matrix 
was extracted via SPE using the method described above, and the eluent was spiked with 
deuterated standards of prostanoids (PGD2-d4, 15-d-PGJ2-d4, 6-keto-PGF1-d4, 11β-PGF2-d4, 
PGF1-d9, 11-d-TXB2-d4, PGE2-d4, PGF2-d4) at 12.5 ng/ml. Similarly, the matrix effects on CYP 
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eicosanoids were measured by applying the current processing conditions to previously published 
CYP eicosanoids method (Miller, et al., 2009). The matrix was extracted via SPE and eluent was 
spiked with low and high concentrations of CYP eicosanoids (12-, 15-, and 20-HETE; 8,9-, 11,12-
, and 14,15-EET; 5,6-, 8,9-, 11,12-, and 14,15-DHET) at 0.417 and 8.33 ng/ml, respectively and 
20-HETE-d6 internal standard at 12.5 ng/ml. Neat samples containing the same concentration of 
deuterated prostanoid metabolites, CYP eicosanoids and 20-HETE-d6 were prepared in 80:20 
methanol:water. Samples were analyzed using UPLC–MS/MS as described above. The ME for 
each prostanoid metabolite was calculated based on the area of the post-extraction spiked samples 
to the neat samples. The ME for each eicosanoid metabolite was calculated based on the area ratio 
(analyte/internal standard) of the post-extraction spiked samples to the neat samples. The ME 
values are expressed as average ± standard deviation (SD) with coefficient of variation (CV) (n=6). 
Values less than 1.00 indicate ion suppression and values greater than 1.00 indicate ion 
enhancement. 
 
2.2.5 Statistical analysis 
 Statistical analysis was completed using GraphPad Prism software, version 5.0 (GraphPad 
Software, La Jolla, CA). In the matrix effect studies, IS-normalized matrix effect (ME) values for 
CYP eicosanoids in buffer and deionized water were compared using unpaired t-test and a p < 0.05 
was considered significant. All data were represented as mean ± SD.  
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2.3. RESULTS 
2.3.1 Development of UPLC-MS/MS Method 
 Acetonitrile and water mobile phases with acetic acid produced optimal chromatographic 
conditions and sensitivity for prostanoids detection. Addition of 15 µL of 1% (v/v) acetic acid in 
methanol to the eluent before the evaporation and reconstitution step increased sensitivity with a 
2-fold increase in peak area. Under these experimental conditions, the representative 
chromatograms of a calibration standard at 0.417 ng/ml (25 pg on column) of prostanoids are 
depicted in Figure 2-2. The elution sequence was identified as 6-keto-PGF1α, 11β-
PGF2α, PGF1α, PGF2α, PGE2, 11-d-TXB2, PGD2, PGA2, PGJ2, 15-d-PGD2, and 15-d-PGJ2 as 
determined by comparison to injections of individual compounds and product fragments. 
2.3.2 Linearity, accuracy and precision 
 Eleven calibration standards over a range of 0.104–33.3 ng/ml (6.25 – 2000 pg on column) 
were used to construct the curves for all metabolites except for 6-keto-PGF1α, PGF2α and 11-d-
TXB2 , which ranged from 0.208 – 33.3 ng/ml. The weighting factor 1/Y typically provided the 
best fit of the plot as determined by visual inspection, correlation coefficient, and analysis of the 
residuals. All of the calibration standards fell within 15% deviation of back-calculated amounts 
from nominal spiked amounts for all levels and the correlation coefficients (R2) were > 0.99 for 
each metabolite. The intra- and inter-day accuracy and precision for the assay were evaluated at 
three levels: 0.667, 7.50, and 20.83 ng/ml (40, 450 and 1250 pg on column, respectively), using 
the QC samples within the three validation runs. Ten replicates at each concentration within a 
single day of validation were used to determine the intra-day reproducibility. Inter-day 
reproducibility was determined over three separate days using n=5 at these concentrations. 
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Calculated values of the QCs were generated using the equation of linear regression obtained from 
the calibration curves run within the same sequence. Results were evaluated and are presented in 
Table 2-2. The %RSD for all metabolites fell within 15% indicating good reproducibility of the 
assay. The LLOQ was determined to be 0.104 ng/ml for all metabolites evaluated except for 6-
keto-PGF1α, PGF2α and 11-d-TXB2, which was 0.208 ng/ml.  
2.3.3 Recovery of analytes 
 The extraction recovery efficiencies for all deuterated prostanoid metabolites were 
determined at one level, 12.5 ng/ml (750 pg on column) (Table 2-3). The recovery ranged from 
88.1 to 100.3%, with the 11β-PGF2α having the lowest recovery. Similarly the extraction 
procedure of this method was applied to our previous CYP eicosanoids method. The recovery 
values for CYP eicosanoids from phosphate buffer at low (0.417 ng/ml) and high (8.33 ng/ml) 
concentrations ranged from 85.2 to 117% and 97.1 to 108%, respectively. Under new processing 
conditions E.R values from deionized water ranged from 92.0 to 111% and 98.1 to 112% at low 
and high concentrations respectively (Table 2-5). The recovery efficiency for all metabolites 
showed good reproducibility with a %RSD below 20. 
Table 2-3 Extraction recovery efficiency of prostanoid metabolites in deionized water 
Analyte Extraction Efficiency (%) RSD (%) 
6-keto-PGF1α-d4 96.9 15.6 
11β-PGF2α-d4 88.1 15.5 
PGF1α-d9 100.3 13.5 
PGF2α-d4 93.7 14.9 
PGE2-d4 91.6 16.3 
11-dehydro-TXB2-d4 89.8 18.0 
PGD2-d4 89.5 14.6 
15-deoxy-∆12,14-PGJ2-d4 91.4 12.2 
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Figure 2-2.  Chromatographic profiles, corresponding to 25 pg on column, depicting the separation of all 
prostanoids using a UPLC tandem MS/MS triple quadrupole mass spectrometer. Separation of metabolites 
was performed on a reversed-phase Acquity BEH C-18 column (2.1 x 150 mm; 1.7 µm i.d.). Metabolites 
were eluted at a flow rate of 0.4 ml/min over 12 min run time with a gradient from 35% acetonitrile 
containing 0.005% acetic acid to 98% acetonitrile containing 0.005% acetic acid.  
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Table 2-2. Accuracy and precision of assay for 11 prostanoid metabolites extracted in deionized water.  
Analyte 
Spiked 
amount 
(pg on 
column) 
Intra-assay 
concentration 
(mean ± s.d) 
(pg on column) RE% RSD% 
Inter-assay 
concentration 
(mean ± s.d) 
(pg on column) 
RE% RSD% 
6-keto-PGF1α 40 38.7 ± 2.26 -3.01 5.82 40.7 ± 3.53 1.86 8.67 
 450 437 ± 16.7 -2.83 3.82 449 ± 25.5 -0.21 5.69 
 1250 1209 ± 34.2 -3.25 2.83 1241 ± 63.1 -0.72 5.08 
        
11β-PGF2α 40 41.2 ± 2.91 3.00 7.06 40.9 ± 4.01 2.43 9.78 
 450 435 ± 21.4 -3.12 4.91 437 ± 15.7 -2.80 3.58 
 1250 1201 ± 52 -3.88 4.33 1228 ± 57 -1.71 4.64 
        
PGF1α 40 37.7 ± 3.23 -5.72 8.56 39.5 ± 3.50 -1.28 8.86 
 450 430 ± 15.3 -4.39 3.49 438 ± 11.1 -2.56 2.54 
 1250 1216 ± 58.4 -2.68 4.80 1228 ± 64.5 -1.69 5.25 
        
PGF2α 40 38.9 ± 4.65 -2.55 11.9 38.3 ±5.41 -4.25 14.1 
 450 467 ± 47.7 3.90 10.2 455 ± 25.7 1.15 5.65 
 1250 1249 ± 131 -0.06 10.5 1221 ± 67 -2.27 5.49 
        
PGE2 40 39.6 ± 1.58 -1.00 3.99 38.9 ± 1.24 -2.71 3.19 
 450 413 ± 17.7 -8.11 4.29 439 ± 16.8 -2.23 3.83 
 1250 1175 ± 44.8 -5.99 3.81 1209 ± 52 -3.26 4.30 
        
11-dehydro-TXB2 40 35.0 ± 1.88 -12.4 5.38 38.8 ± 4.05 -2.84 10.4 
 450 407 ± 26.5 -9.41 6.50 446 ± 31.4 -0.88 7.04 
 1250 1314 ± 61.2 5.14 4.66 1363 ± 77.8 9.05 5.71 
        
PGD2 40 39.7 ± 3.12 -0.74 7.85 39.9 ± 1.89 -0.02 4.71 
 450 412 ± 5.97 -8.24 1.45 436 ± 17.8 -3.03 4.09 
 1250 1206 ± 49.2 -3.46 4.08 1238 ± 21.7 -0.91 1.76 
        
PGA2 40 37.6 ± 2.94 -5.83 7.80 39.0 ± 2.67 -2.36 6.83 
 450 409 ± 22.6 -9.03 5.53 434 ± 30.7 -3.54 7.08 
 1250 1192 ± 112 -4.57 9.41 1228 ± 69.6 -1.71 5.67 
        
PGJ2 40 41.1 ± 2.72 2.87 6.60 39.5 ± 2.09 -1.18 5.28 
 450 455 ± 11.2 1.25 2.46 443 ± 24.7 -1.38 5.57 
 1250 1267 ± 47.6 1.37 3.76 1237 ± 56.7 -1.01 4.59 
        
15-deoxy-PGD2 40 38.1 ± 4.11 -4.58 10.7 39.8 ± 2.50 -0.40 6.26 
 450 430 ± 35.5 -4.22 8.24 442 ± 28.6 -1.72 6.47 
 1250 1206 ± 113 -3.44 9.44 1249 ± 76.1 -0.02 6.09 
        
15-deoxy-PGJ2 40 42.0 ± 3.54 5.18 8.41 41.6 ± 2.96 4.11 7.10 
 450 443 ± 17.9 -1.54 4.05 449 ± 13.9 -0.08 3.10 
 1250 1216 ± 95.6 -2.72 7.86 1253 ± 40.6 0.27 3.25 
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2.3.4 Analysis of matrix effects 
2.3.4.1 Prostanoids  
The effects of the deionized water (matrix) on the reproducibility of the assay to measure 
metabolites were determined. Table 2-4 shows the coefficient of variation (CV) of the peak area 
of each deuterated metabolite of the post-extraction spike in deionized water along with the CV of 
neat samples prepared in 80:20 methanol:water (n=6). The % CV values for all metabolites were 
below 16%, demonstrating good precision and reliability of the assay. Table 2-4 also shows the 
average matrix effect (M.E.) values of each metabolite as mean and CV (n=6). The average M.E. 
ranged from 0.86 to 0.97. A M.E. of 1 signifies no matrix effects. A M.E value less than 1 signifies 
ion suppression while a value greater than 1 signifies ion enhancement or analyte loss in the 
absence of matrix. The % CV of the M.E. values for most of the metabolites was below 15%, 
which demonstrates minimal effects of the deionized water (matrix) on the precision and reliability 
of the assay. 
Table 2-4 Assessment of matrix effects of the deionized water on the reproducibility of the assay and the 
matrix effect factor for the deuterated metabolites. 
Analyte 
Precision (%CV) Matrix Effect (M.E) 
Neat Deionized Water Mean %CV 
6-keto-PGF1α-d4 1.28 15.8 0.89 14.7 
11β-PGF2α-d4 8.50 11.0 0.94 13.7 
PGF1α-d9 12.8 14.2 0.97 18.4 
PGF2α-d4 12.4 9.1 0.91 15.0 
PGE2-d4 7.03 11.7 0.94 12.7 
11-dehydro-TXB2-d4 5.38 13.8 0.86 13.9 
PGD2-d4 8.02 10.9 0.87 13.0 
15-deoxy-∆12,14-PGJ2-d4 6.16 7.61 0.93 9.96 
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2.3.4.2 CYP eicosanoids 
The matrix effects of the phosphate buffer and deionized water (matrix) on the CYP 
eicosanoids were determined at low (0.417 ng/ml) and high (8.33 ng/ml) concentrations, 
respectively. Table 2-5 shows the average IS-normalized M.E. as mean and CV (n=5). The 
average IS-normalized M.E. values in buffer ranged from 0.80 to 1.11 and 0.90 to 1.07 at low and 
high concentrations, respectively whereas in deionized water the values ranged from 0.99 to 1.17 
and 0.95 to 1.07 at low and high concentrations, respectively. The % CV of the M.E. values for all 
of the metabolites was below 18%, which demonstrates minimal effects of the deionized water 
(matrix) on the precision and reliability of the assay. Overall, matrix effect seems to be minimal 
on CYP eicosanoids when deionized water was used as compared to microsomal incubation buffer.  
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Table 2-5 Effects of deionized water on the reproducibility and extraction efficiency of CYP eicosanoids 
Medium Analyte Amt (pg) 
M.E E.R 
Mean %C.V Mean %C.V 
Buffer 20-HETE 25 0.94 11.2 113.5 18.7 
  12-HETE 25 0.80 12.2 108.4 10.1 
  15-HETE 25 0.93 8.3 85.2 12.8 
(n=5) 8,9-EET 25 1.09 13.4 98.3 16.2 
  11,12-EET 25 0.92 13.8 104.2 11.6 
  14,15-EET 25 0.91 8.5 111.4 13.7 
  5,6-DHET 25 1.03 2.4 104.0 17.6 
  8,9-DHET 25 1.01 5.9 107.0 12.6 
  11,12-DHET 25 0.97 7.3 117.0 5.2 
  14,15-DHET 25 1.11 4.8 115.7 5.9 
        
Water 20-HETE 25 1.08 5.6 104.6 10.7 
  12-HETE 25 1.06 15.6 95.8 14.7 
  15-HETE 25 1.00 8.4 92.4 10.4 
(n=5) 8,9-EET 25 1.04 10.8 104.3 10.0 
  11,12-EET 25 1.03 16.9 103.3 15.0 
  14,15-EET 25 0.99 10.8 98.7 18.2 
  5,6-DHET 25 1.02 4.5 111.2 19.7 
  8,9-DHET 25 1.17 6.3 92.0 12.5 
  11,12-DHET 25 1.01 6.6 109.5 9.9 
  14,15-DHET 25 1.06 8.9 105.4 17.0 
        
Buffer 20-HETE 500 1.04 6.0 99.2 10.6 
  12-HETE 500 0.90 14.4 103.5 10.3 
  15-HETE 500 0.93 11.7 97.6 9.8 
  8,9-EET 500 0.97 16.0 97.1 12.2 
(n=5) 11,12-EET 500 0.95 15.8 101.5 9.1 
  14,15-EET 500 0.97 14.8 99.8 12.3 
  5,6-DHET 500 0.99 15.3 105.3 12.6 
  8,9-DHET 500 0.98 10.7 106.2 9.5 
  11,12-DHET 500 1.02 12.4 106.9 12.0 
  14,15-DHET 500 1.07 7.7 108.3 6.6 
   
 
 
 
 
 
Water 20-HETE 500 0.95 7.8 103.2 5.0 
  12-HETE 500 1.06 10.8 98.1 7.0 
  15-HETE 500 1.03 7.5 98.9 7.8 
(n=5) 8,9-EET 500 1.05 6.8 101.1 6.6 
  11,12-EET 500 1.07 11.2 101.6 3.5 
  14,15-EET 500 1.03 7.6 99.4 5.2 
  5,6-DHET 500 1.02 1.1 111.0 5.6 
  8,9-DHET 500 1.03 8.1 112.1 4.5 
  11,12-DHET 500 1.06 7.9 104.6 6.3 
  14,15-DHET 500 1.07 1.9 105.5 3.3 
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2.3.5 Analysis of rat brain tissue samples 
 Rat brain cortex tissue samples (n=6) collected at 5 min post resuscitation were analyzed 
from animals subjected to 12 min of asphyxial cardiac arrest to determine prostanoid and 
eicosanoid metabolite concentrations using the standard calibration curves of each metabolite and 
results are shown in Figure 2-3 and 2-4. Quantitative amounts of all prostanoids were measured 
in these tissue samples and values ranged from 10.2 to 937 pmol/g wet tissue. The levels measured 
in the order of abundance were PGD2, PGJ2, PGE2, 15-d-PGD2, PGA2, 15-d-PGJ2, PGF2α, PGF1α, 
11β-PGF2α at 937±305, 36.9±10.7, 35.5±12.3, 32.7±14.8, 24.2±11.8, 18.4±0.80, 14.4±7, 13.9±7.7, 
10.2±3.2 pmol/gm wet tissue (Figure 3). Detectible amounts of 6-keto-PGF1α, and 11-d-TXB2 
were also seen in these samples. Similarly, quantitative amounts of all CYP eicosanoids measured 
in the same tissue sample range from 2.23 to 793 pmol/g wet tissue. The levels measured in the 
order of abundance were 12-HETE, 15-HETE, 14,15-EET, 8,9-EET, 11,12-EET, 20-HETE, 
14,15-DHET, 11,12-DHET at 793±161, 143±50.8, 44.6±3.78, 39.4±2.63, 20.8±1.46, 6.79±2.30, 
4.17±0.21, 2.23±0.16 pmol/gm wet tissue (Figure 4). Detectible amounts of 8,9- and 5,6-DHET 
were also seen in these samples. These results imply that multiple arachidonic acid metabolites 
(prostanoids and CYP eicosanoids) in rat brain cortex can be quantified reliably using this method.  
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Figure 2-3. Concentrations of prostanoid metabolites detected in brain cortical tissue of pediatric rats at 5 
min post resuscitation after being subjected to 12 min of asphyxial cardiac arrest.  
 
 
 
 
 
 
 
 
  
 
 
 
Figure 2-4. Concentrations of eicosanoid metabolites detected in brain cortical tissue of pediatric rats at 5 
min post resuscitation after being subjected to 12 min of asphyxial cardiac arrest. These CYP eicosanoids 
were analyzed from same tissue extracts used for prostanoids measurement.  
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2.4. DISCUSSION 
In this study we report a robust method to measure 11 prostanoid metabolites in rat brain 
cortical tissue. This is the first validated method reporting quantification of cyclopentenone 
metabolites in rat brain tissue. These compounds were simultaneously detected, identified and 
quantified using a validated UPLC-MS/MS method. Furthermore, we have successfully applied 
the processing conditions and extraction procedure of this method to our previously published 
method for CYP eicosanoid quantification in rat brain extracts with different MS/MS conditions 
(Miller, et al., 2009). With this approach we achieved an overall improvement in extraction 
recovery of CYP eicosanoids and reduction in matrix effects. This gave us the unique advantage 
of detecting and quantifying both the prostanoid and eicosanoid metabolites from the same 
extracted sample by two MS injections. Collectively, these results suggest that our validated 
UPLC-MS/MS method is an accurate and sensitive method and can be used successfully to 
quantify a wide range of arachidonic acid metabolites in rat brain tissue. 
 
We have performed the validation of linear calibration curves ranging from 0.104 to 33.3 
ng/ml (6.25 to 2000 pg on column) for all prostanoid metabolites except for 6-keto-
PGF1α, PGF2α and 11-d-TXB2, which ranged from 0.208 to 33.3 ng/ml (12.5 to 2000 pg). The inter-
day and intra-day variance was less than 15% with extraction efficiency greater than 88%. We 
demonstrated that matrix effect of deionized water did not significantly affect the reliability and 
reproducibility of the assay. In our previously validated CYP eicosanoid method we used 
microsomal incubation buffer as our matrix. In this study, we used the same matrix (deionized 
water) for both the prostanoid and CYP eicosanoid methods to test the extraction recovery and 
matrix effects at low and high concentrations for all CYP eicosanoids. The addition of 15 µl of 1% 
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acetic acid to the eluent before evaporation and reconstitution resulted in significant increase in 
extraction recovery for 15-HETE and significant reduction in matrix effect for 12-HETE at low 
concentrations while recovery and matrix effects largely remain unchanged at high concentrations 
for all CYP eicosanoid metabolites.  
 
 
Concentrations of prostanoid metabolites were measured in rat brain tissue extracts. These 
include PGD2, PGJ2, PGE2, 15-d-PGD2, PGA2, 15-d-PGJ2, PGF2α, PGF1α, 11β-PGF2α, 6-keto-
PGF1α, and 11-d-TXB2. Several of these metabolites have been previously detected in different 
matrices such as cell cultures (Martin-Venegas, et al., 2011; Takabatake, et al., 2002), 
plasma/serum (Ferreiro-Vera, et al., 2011a; Ferreiro-Vera, et al., 2011b; Komaba, et al., 2009), 
urine (Chappell, et al., 2011; Masoodi, et al., 2006), and rat kidney (Blewett et al., 2008). Masoodi 
et al. (Masoodi, et al., 2006) and Yue et al. (Yue et al., 2007) reported measurements of prostanoids 
in rat brain or cortical tissue. Masoodi et al. measured prostanoids in uninjured rat brain whereas 
Yue et al. measured them in sham and traumatic brain injured rats. Yue et al. reported 
concentrations of only PGE2 and PGD2 from ipsi-lateral 72 h post-injured brains as 11.3 ± 0.61 
and 4.99 ± 0.64 pmol/g tissue, respectively, and PGJ2 and PGF2α were not detected in their method. 
Although a direct methodological comparison cannot be determined given the differences in the 
animal and injury model, the levels of PGE2 measured from a 5 min post resuscitation pediatric 
rat brain cortex using our method was comparable to the results reported by Yue et al (Yue, et al., 
2007). We were able to detect all of the prostanoid metabolites of our assay, in the pediatric rat 
brain cortex post-injury indicating good specificity and sensitivity of our method. In addition, we 
successfully quantified CYP eicosanoids with different MS/MS conditions (as reported in our 
previous method) from the same tissue extracts. Together, our method is capable of measuring a 
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total of 21 arachidonic acid metabolites including prostanoids and CYP eicosanoids from a single 
extracted sample in a combined run time of 18 minutes.  
The results from our method are similar to other studies that have reported the detection of similar 
metabolites in different matrices. Ferreiro-Vera et al. described simultaneous measurement of 
different inflammation biomarkers from human serum and human plasma and reported 
concentrations of PGF2α and PGE2 as 10.3 and 0.17 ng/ml in plasma (Ferreiro-Vera, et al., 2011a), 
and 0.11 ng/ml for PGE2 (Ferreiro-Vera, et al., 2011b) in serum, which are within our standard 
calibration range of 0.104 - 33.3 ng/ml. LOQs reported in their method as 46, 138 and 188 pg (on 
column) for PGF2α, PGE2 and PGD2 were however found to be higher than our method. In addition, 
Unterwurzacher et al. described a method for measurement of hydroxyeicosatetraenoic acid, 
hydroxyoctadecadienoic acid (HODE), leukotrienes, and prostanoids by HPLC-MS/MS in human 
plasma (Unterwurzacher, et al., 2008). The LOQ from this method is reported as 0.352, 0.264, 
1.42, and 1.85 ng/ml for PGD2, PGE2, PGF2α, and 6-keto-PGF1α, respectively. Similarly, Blewett 
et al. reported simultaneous measurement of several arachidonic acid metabolites by HPLC-MS in 
rat kidney (Blewett, et al., 2008). The LOQ from this method were 14.4, 25.3, 20.6 pg (on column) 
for PGF2α, PGE2, PGD2, respectively. The LOQ for all metabolites measured in our method was 
0.104 ng/ml (6.25 pg on column) except for 6-keto-PGF1α, PGF2α and 11-d-TXB2, which was 
0.208 ng/ml (12.5 pg on column) and is comparable to the values reported by Unterwurzacher et 
al. (Unterwurzacher, et al., 2008) and Blewett et al. (Blewett, et al., 2008). Also, our UPLC-
MS/MS prostanoid method reports a shorter run time of 12 minutes as compared to the 60 and 30 
minute  run times reported by the HPLC-MS or HPLC-MS/MS methods described by Blewett et 
al. and Ferreiro-vera et al. (Blewett, et al., 2008; Ferreiro-Vera, et al., 2011b). The advantages of 
the method described in this article are: 1) the shorter run time and comparable LOQ for 
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measurement of various prostanoid metabolites in biological matrices, and 2) the ability to reliably 
quantify a wide range of physiologically important metabolites of arachidonic acid metabolism 
from COX and CYP450 pathway in a shorter run time from a single extracted sample of rat brain 
tissue. 
 
2.5. CONCLUSIONS 
 
A solid phase extraction procedure coupled with a UPLC-MS/MS method was validated, 
and successfully applied for simultaneous extraction of 11 prostanoids including cyclopentenone 
metabolites. This method was optimized to provide high resolution and sensitivity for the detection 
of these analytes in rat brain tissue with an analysis time of 12 minutes per sample. Quantitative 
amounts of majority of the prostanoids were found in rat brain cortical tissue, and they were within 
the validated linear range of 0.104 - 33.3 ng/ml. We determined that the matrix did not significantly 
affect the reliability and reproducibility of the assay. In addition, we have also demonstrated that 
applying the processing and extraction procedure of this method to our previously validated CYP 
eicosanoid method improves overall extraction efficiency and reduces matrix effects on CYP 
eicosanoids. We have successfully quantified CYP eicosanoids from the same extracted sample of 
rat brain tissue with different MS/MS conditions as reported previously.  Collectively, these data 
demonstrate that our method can be used to effectively quantitate these metabolites with reliability, 
reproducibility, and rapid analysis time. The increased throughput of analyzing these metabolites 
should help to evaluate effects of shunting on total sum arachidonic acid metabolism, and advance 
our understanding of their role as potential therapeutic targets and/or biomarkers of inflammatory 
and cerebrovascular disorders.  
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3.0 IN VITRO EVALUATION OF CYTOPROTECTIVE EFFECTS OF CYP 
EICOSANOIDS  
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3.1 INTRODUCTION 
  Previous two chapters have discussed the biological significance of CYP eicosanoids and 
prostanoids in cerebrovascular disorders evaluated in different in vitro and in vivo studies. 
Particularly, the molecular mechanisms underlying the pharmacological effects of CYP 
eicosanoids were discussed in detail in Chapter 1. In addition to their effects on cerebral 
vasculature, CYP eicosanoids also interact with different intracellular signaling pathways that may 
affect tissue/cell survival in cerebral ischemia. This is important as the neuroprotective effects of 
CYP eicosanoids may in part be mediated through both vascular as well as non-vascular effects. 
This view is supported by findings from different in vivo studies that indicated the possibility of a 
non-vascular effect of CYP eicosanoids. Inhibition of 20-HETE synthesis reduced infarct volume 
in experimental models of focal cerebral ischemia (Miyata, et al., 2005; Omura et al., 2006; 
Poloyac, et al., 2006; Tanaka et al., 2007) without producing any intra-ischemic vasodilation (Cao 
et al., 2009; Renic, et al., 2009). Further, CYP 4A expression was detected in the cortical neurons 
after ischemia (Omura et al., 2006) indicating that 20-HETE may exert effects directly on neurons, 
and contribute to the overall neuroprotection independently from the effects on CBF. Similarly, 
ischemic preconditioning protects against ischemic cell death in a MCAO model by increasing the 
expression of P450 epoxygenases in brain. Further, pharmacological inhibition of sEH has also 
shown neuroprotection against focal ischemia in the absence of changes in CBF (Zhang, et al., 
2007) suggesting that EETs may exert cytoprotective effects independent of their effects on CBF. 
Together, these findings suggest a possible role for non-vascular effects of CYP eicosanoids in the 
neuroprotection.  
 
78 
 
3.1.1 Non-vascular effects of CYP eicosanoids 
Findings from some in vitro studies have indicated the presence of a non-vascular 
mechanism of neuroprotection by CYP eicosanoids in ischemia. Renic et al, recently have shown 
that 20-HETE synthesis inhibition reduces injury from oxygen-glucose deprivation (OGD) in 
hippocampal slice cultures (Renic et al., 2012). Similarly, Terashvili et al, showed protective effect 
of 14,15-EET against hydrogen peroxide (H2O2) induced cell death in astrocyte-dopaminergic 
neurons co-culture. In the same study, they showed that neurons were more vulnerable than 
astrocytes as basal endogenous levels of 14,15-EET was higher in astrocytes than neurons. Further, 
sEH inhibition by AUDA protected cells from H2O2 induced cell death (Terashvili et al., 2012). 
In yet another study, application of exogenous EETs (Liu et al., 2005b) or overexpression of 
CYP2J2 protected rat primary astrocytes against ischemic cell death in an in vitro OGD model (Li 
et al., 2012). CYP2J2 overexpression also showed protection against hypoxia-reoxygenation 
injury in cultured bovine aortic endothelial cells. Koerner et al showed that 14,15-EET protected 
primary rat cortical neurons against ischemic cell death in an in vitro OGD model. However, this 
effect was seen only in the cultures transduced with human sEH variants expressing functional 
polymorphisms that altered enzyme’s hydrolase activity. In this study, naïve rat primary cortical 
neuronal cultures were not protected from ischemic death either by exogenous EET administration 
or pharmacological inhibition of sEH (Koerner, et al., 2007). Similar observation was made in 
another study by Fairbanks et al, who showed gender differences in neuronal susceptibility to 
ischemic cell death that are linked to sEH expression, and possibly to hydrolase activity but showed 
no protective effect of sEH pharmacological inhibition either in male or female primary rat cortical 
neurons in an in vitro OGD model (Fairbanks et al., 2012). 
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3.1.2 Rationale for the in vitro study  
The findings of recent studies detailed above do not provide conclusive evidence on the 
role of CYP eicosanoids in mediating direct cytoprotective effects in hypoxia or ischemia. To date, 
there has been only one study that reported the effects of 20-HETE under in vitro ischemic 
conditions (Renic et al., 2012) but this was evaluated in organotypic hippocampal slices. Typically, 
CYP4A expression is found high in VSM but the observation of increased CYP4A expression in 
cortical neurons after ischemia (Omura et al., 2006) still poses the question on the role of 20-HETE 
in these cortical neurons. Similarly, astrocytes and neurons both express CYP epoxygenases with 
astrocytes being major source of forming and releasing EETs. Exogenous administration of EETs 
or sEH inhibition or CYP epoxygenase expression have all shown protective effects in primary rat 
astrocyte cultures in both OGD as well as H2O2 induce cell death but protective effects of EETs 
were not seen in primary rat cortical neurons. In the studies that used cortical neurons, both EET 
and sEH inhibitor were administered at a single dose and no dose response was established. 
Further, it may be possible that sEH inhibition is protective by mitigating toxic effects of DHET. 
There was only one study that evaluated effects of 14,15-DHET on cortical neuronal survival in 
OGD model that showed no toxicity for 14,15-DHET (Koerner et al., 2007).  
 
As discussed above, many in vitro studies have used either hippocampal slices or cultures for 
studying the injury mechanisms, and evaluating protective effects of different neuroprotective 
agents under OGD induced ischemic conditions. There have been limited number of in vitro 
studies that used primary cortical neuronal cultures to evaluate neuroprotective effects of CYP 
eicosanoids under hypoxic (lack of O2) or ischemic (lack of O2 and glucose) conditions. Therefore, 
the purpose of this study is to evaluate the cytoprotective effects of 20-HETE, EETs and DHETs 
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over a wide range of concentrations in an in vitro neuron-enriched rat primary cortical neuronal 
cultures under normoxic and hypoxic conditions.  
 
3.2  EXPERIMENTAL METHODS AND PROCEDURES 
All animal studies were conducted in accordance with the principles and procedures 
outlined in the National Institutes of Health Guide for the Care and Use of Laboratory Animals 
and were approved by the University of Pittsburgh Institutional Animal Care and Use Committee. 
 
3.2.1 Rat neuronal cell culture 
 Rat primary cortical neurons were prepared as described previously (Li, et al., 2008). 
Briefly, cortical primary neuronal cultures were prepared from embryonic day 17 (E17) fetal rats 
(Sprague-Dawley, Charles River, Wilmington, MA). Brains were removed and cortices dissected 
out, freed of meninges and trypsinized for 30 min in 0.25% trypsin in Dulbecco’s modified Eagle 
medium (DMEM). After centrifuging at 1,000 x g for 3 min, the supernatant was removed and the 
tissue was triturated in culture medium to produce a single-cell suspension. The cells were then 
plated at a density of 6 x 104 cells/well in a 96-well plate coated with poly-D-lysine (100 µg/ml) 
and maintained in a humidified incubator in air with 5% CO2 (Forma Scientific, Morijetta, Ohio). 
The neurons were grown in neurobasal medium without phenol red, supplemented with 2% B27 
(Invitrogen, Carlsbad, CA), 1% Glutamax (Invitrogen), and 1% penicillin/streptomycin 
(Invitrogen). The medium was replaced the following day and every 3 days thereafter with 
Neurobasal A medium (Invitrogen). The cultures were used for experiments after 10 days as the 
cultures were considered to be mature and stable at this time. This is a neuron-enriched primary 
culture as it contains > 95% neurons.  
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3.2.2 Cell culture treatment with CYP eicosanoids 
 
 On the 11th day, neuronal cultures were used for evaluating protective effects of CYP 
eicosanoids under normoxic conditions. Stock vials of CYP eicosanoids 20-HETE, 11,12-EET, 
14,15-EET, 11,12-DHET, and 14,15-DHET (Cayman Chem, Ann Arbor, MI) were gently 
evaporated under nitrogen to remove ethanol and the residue was dissolved in phosphate saline 
buffer (PBS), pH 7.4. All working stock solutions were prepared by diluting the mother stock in 
neurobasal medium. A different plate was used for each eicosanoid. Each well (n=6/treatment) 
was added with 100 µL of medium containing CYP eicosanoids at a final concentration ranging 
from 0.05 to 50 µM as shown in the Figure 3-1. This range of concentrations were selected to 
account for possible losses due to chemical instability, degradation, metabolism during cellular 
uptake, non-specific binding to cellular components. Cultures were then incubated (Forma 
Scientific) for 24 h under normoxic conditions. Staurosporine (Sigma-Aldrich, St. Louis, MO), a 
100% cell death internal standard in which almost all cells appear dead at 24 h when observed 
under light microscopy, and MK-801 (Cayman Chem, Ann Arbor, MI), an internal cell survival 
standard in, which almost all cells survive were used as positive and negative controls in the assay. 
Cell death measurements were taken at the end of 24 h incubation. 
 
            
 
SP MK-801 Med 0.05 0.1 0.5 1.0 5 10 50 
           
          
 
          
           
          
            
 
Figure 3-1. Schematic of 96-Well Plate Design for CYP eicosanoids experiment 
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For hypoxia experiments, on the 11th day the cells were either pre-treated for one hour with vehicle 
(neurobasal medium) or with CYP eicosanoids (20-HETE, 11,12-EET, and 14,15-EET) each 
diluted in neurobasal medium at a final concentration ranging from 0.1 to 50 µM (n=6 well / 
treatment). After pre-treatment the culture plates were placed into a hypoxic glove box (Coy 
Laboratories, Grass Lake, MI, USA) and flushed for 5 min with 95% argon and 5% CO2. The 
culture medium was removed, washed twice with degassed medium and replaced with degassed 
medium containing CYP eicosanoids. The culture plates were then subjected to hypoxia for varied 
durations (for each eicosanoid) ranging from 2 to 4 h in the chamber at 37 ºC. At the end of 
hypoxia, culture plates were removed, degassed medium was replaced with pre-warmed culture 
medium, and returned to the incubator to allow reoxygenation for 24 h. This duration of anoxia 
followed by reoxygenation produces ~ 40 –60% neuronal death in untreated cultures compared to 
cultures treated with 20 µΜ Staurosporine (SP). Cell death measurements were taken at the end of 
24 h incubation. 
 
 
3.2.3 Cell death measurements 
 
Cell death was quantitatively assessed by measuring lactate dehydrogenase (LDH) release 
into the culture medium 24 h after hypoxia. LDH release signifies both cell death and loss of 
membrane integrity. LDH activity was measured from the reduction of NAD+ after the oxidative 
conversion of L-lactate to pyruvate. For LDH measurement, medium from cell culture plates was 
collected into a different plate and each well was mixed with 150 µl of reaction mixture prepared 
according to kit directions (Pointe Scientific Inc., Canton, MI). The sample plate was then 
measured at 340 nm using a plate reader (Spectramax, Molecular Devices, Sunnyvale, CA). Cell 
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death in all treatment groups was normalized to that of SP treated group and reported as % cell 
death. 
3.2.4 CYP eicosanoid measurement from medium and cell lysates 
 
 Stability of the CYP eicosanoids in the culture medium under normal incubation conditions 
was evaluated at different concentrations. At the end of incubation, cell culture medium was 
removed and cells were washed twice with PBS. The cells were then lysed with RIPA lysis buffer 
(Sigma-Aldrich, St. Louis, MO) and lysates was collected to measure the cellular uptake of CYP 
eicosanoids. Both lysates and culture medium were extracted and analyzed by UPLC-MS/MS 
method for quantifying CYP eicosanoids as follows: 
 
The cell lysates and culture medium were spiked with 12.5 µL (containing 12.5 ng) of 20-HETE-
d6 as internal standards (IS). The spiked samples were loaded onto Oasis hydrophilic-lipophilic 
balanced (HLB) (30 mg) solid phase extraction (SPE) cartridges (Waters, Milford, MA) that were 
conditioned and equilibrated with 1 ml of methanol and 1 ml of water, respectively. Columns were 
washed with three 1 ml volumes of 5% methanol and were eluted with 100% methanol. Extracts 
were dried under nitrogen gas at 37°C, and reconstituted in 125 µl of 80:20 methanol/deionized 
water for chromatographic analysis as described in Chapter 2. 
 
3.2.5. Statistical Analysis 
Significant differences between treatment groups (excluding positive and negative 
controls) were assessed by one-way ANOVA and Dunnett’s post-hoc test was used to compare 
means with control (medium) treated cells. A *p<0.05 was considered significant. All data were 
represented as mean ± SD.  
 
84 
 
3.3 RESULTS 
3.3.1 Normoxic conditions 
3.3.1.1 11,12-DHET: 
Under normoxic incubation conditions, 11,12-DHET did not show any significant decrease in cell 
death when tested at concentrations ranging from 0.05 to 1 µM. However, there was an increase 
in % cell death as the concentration was increased, and at 1 µM there was a non-significant 
decrease in cell death as compared to control (medium) treated cells (76.5 ± 7.7% vs 61.1 ± 9.3%; 
n=6; p=0.07) (Figure 3-2).  
3.3.1.2 14,15-DHET: 
Under normoxic incubation conditions, 14,15-DHET did not show any significant decrease in cell 
death when tested at concentrations ranging from 0.05 to 5 µM. There was no concentration related 
changes in cell death (Figure 3-3).  
Figure 3-2 Effect of 11,12-DHET under normoxic incubation conditions. No significant differences 
were observed between different treatment groups of 11,12-DHET when compared to control (medium) 
group (n=6 wells/treatment). 
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Figure 3-3 Effect of 14,15-DHET under normoxic incubation conditions. No significant differences 
were observed between different treatment groups of 14,15-DHET when compared to control (medium) 
group. 
3.3.1.3 20-HETE: 
20-HETE showed no significant decrease in cell death when tested at a wider concentration range 
from 0.1 to 50 µM under normoxic conditions. There was a flat concentration-effect over the tested 
range (Figure 3-4).  
Figure 3-4 Effect of 20-HETE under normoxic incubation conditions. No significant differences were 
observed between different treatment groups of 20-HETE when compared to control (medium) group. 
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3.3.1.4 11,12-EET: 
11,12-EET showed decrease in the cell death over a concentration range of 0.1 to 50 µM. At high 
concentration 10 µM, there was a non-significant decrease in cell death compared to vehicle group 
(51.3 ± 11.2% vs 34.8 ± 9.5%; n=6; p=0.059). However at even higher concentration 50 µM, there 
was a significant decrease in cell death compared to vehicle (51.3 ± 11.2% vs 31.1 ± 11.5%; n=6; 
*p<0.05) (Figure 3-5).
Figure 3-5 Effect of 11,12-EET under normoxic incubation conditions. Significant differences of 
treatment groups compared to vehicle (medium) group were denoted by *p<0.05. 
3.3.1.5 14,15-EET: 
14,15-EET showed no significant decrease in cell death when tested over a concentration range 
from 0.1 to 50 µM. There was a flat concentration-effect observed over the tested range (Figure 
3-6).  
87 
Figure 3-6 Effect of 14,15-EET under normoxic incubation conditions. No significant differences 
were observed between different treatment groups of 14,15-EET when compared to control (medium) 
group. 
3.3.2 Hypoxic conditions 
3.3.2.1 20-HETE: 
Under hypoxic conditions, 20-HETE showed an increase in the cell death over a concentration 
range of 0.1 to 50 µM. There was a non-significant increase in cell death when compared to vehicle 
group (45.7 ± 5.1%) at 5 µM (56.5 ± 6%; n=6; p=0.073). However, there was a significant increase 
in cell death compared to vehicle group (45.7 ± 5.1%) at higher concentrations 10 µM (58.8 ± 
6.1%; n=6; *p<0.05), and 50 µM (64.3 ± 12.2%; n=6; *p<0.001) (Figure 3-7). 
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Figure 3-7 Effect of 20-HETE under hypoxic conditions. Significant differences of treatment groups 
compared to vehicle group (n=6 wells/treatment) were denoted by *p<0.05, **p<0.01. 
3.3.2.2 14,15-EET: 
Under hypoxic conditions, 14,15-EET showed decrease in the cell death at 10, and 50 µM. There 
was a non-significant decrease in cell death when compared to vehicle group (48.2 ± 6.2%) at 50 
µM (36.5 ± 3.8%; n=6; p=0.079) (Figure 3-8). 
Figure 3-8 Effect of 14,15-EET under hypoxic conditions. No significant differences were observed 
between different treatment groups of 20-HETE when compared to control (medium) group. 
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3.3.2.3 11,12-EET: 
11,12-EET showed decrease in the cell death over a concentration range of 0.1 to 50 µM. There 
was a significant decrease in cell death when compared to vehicle group (51.5 ± 14%) at 5 µM 
(34.3 ± 4.3%; n=6; *p<0.05), 10 µM (35.1 ± 7.4%; n=6; *p<0.05), and 50 µM (32.9 ± 6.4%; n=6; 
*p<0.05) (Figure 3-9).
Figure 3-9 Effect of 11, 12-EET under hypoxic conditions. Significant differences of treatment groups 
compared to vehicle (medium) group were denoted by *p<0.05. 
3.3.3 Stability of CYP eicosanoids in culture medium 
As shown in Table 3-1, 20-HETE was stable in the culture medium after 24 h under 
normoxic incubation conditions (5% CO2, 37 ºC) at low, medium, and high concentrations (0.5, 
10, and 50 µM; n=6). When incubated with live cells for 24 h, 20-HETE concentrations in the 
culture medium decreased in a concentration dependent manner. 20-HETE was readily taken up 
by live cells as measured from cell lysates at the end of 24 h. 11,12-EET was relatively less stable 
than 20-HETE at medium, and high concentrations (10, and 50 µM; n=6) in the culture medium 
after 24 h under normal incubation conditions. The concentrations of 11,12-EET in the culture 
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medium decreased more rapidly than 20-HETE when incubated with live cells. However, no 
concentrations of 11,12-EET were detected in the cell lysates.  
 
Table 3-1 Stability of CYP eicosanoids under incubation conditions 
Analyte 
Conc 
(µM) 
Incubation 
Time 
Pure 
medium 
Live cells 
Culture medium Lysates 
  (min) (% rem) (% rem) (% control) 
20-HETE 
0.5 24 101.7 ± 3.6 53.8 ± 17.6 ND 
10 24 95.3 ± 5.3 36.4 ± 5.6 0.47 ± 0.02 
50 24 90.7 ± 12.2 33.2 ± 6.5 0.33 ± 0.06 
      
11,12-EET 
0.5 24 112 ± 7.7 24.5 ± 4.0 ND 
10 24 69.4 ± 7.5 7.58 ± 1.6 ND 
50 24 73.1± 5.7 19.1 ± 2.3 ND 
Conc = Concentration; ND = not detected; % rem = % remaining 
 
3.4 DISCUSSION 
 
In this study, we investigated the neuroprotective effects of CYP eicosanoids over a wider 
concentration range under normoxic and hypoxic conditions. Specifically, we found that 11,12-
EET at high concentrations is protective even under normoxic conditions. Under hypoxic 
conditions, 20-HETE was found to be toxic to neurons at high concentrations whereas 11,12-EET 
protects neurons in a dose dependent manner. Collectively, these data suggest that CYP 
eicosanoids exert a direct cytoprotective or cytotoxic effect on neurons under normal and hypoxic 
conditions.  
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In this study, we have used neuron-enriched rat primary cultures for in vitro evaluation of CYP 
eicosanoids effects. Primary neuronal cultures prepared from same source can be maintained and 
differentiated identically over long-term to examine cell death signaling mechanisms in mature, 
synaptically integrated cortical neurons. Further, potentially confounding factors such as 
neuromodulators from glial or other types of neighboring cells can be obviated making it a simple 
system to test the direct effects of hypoxia. Hypoxia of sufficient duration or severity can alter 
neuronal function and cell morphology, and can lead to cell injury or death. A number of studies 
have shown that in vitro hypoxia causes neuronal alterations that may reflect the actual processes 
under ischemia in vivo (Goldberg et al., 1986; Nieber, 1999). Indeed, the cerebral cortex has been 
shown to be more vulnerable to global ischemia and is a major site of neurodegeneration after 
hypoxia-ischemia, and stroke (Martin et al., 1998; Martin et al., 1997). Neurons of the 
hippocampus and cortex are the most vulnerable targets in the CNS to hypoxia. However, some 
studies suggested that neocortical brain regions are more vulnerable to hypoxia than the 
hippocampus (Bachevalier et al., 1996). Further, hypoxic-ischemic injury in neonatal piglets 
preferentially damages primary somatosensory and forebrain motor systems. Neocortical neurons 
in humans and rat have shown minor differences in the cellular properties and large similarities in 
cell morphology and electrophysiological properties between the two species (Jiang et al., 1992). 
Thus, neuron-enriched rat primary cortical neuronal cultures used in this study are a suitable 
system to evaluate neuroprotective effects of CYP eicosanoids under hypoxic conditions.  
 
Our findings of 20-HETE effect on toxicity of neurons under hypoxic conditions is consistent with 
the recent data reported in an OGD model of hippocampal neurons in which a 20-HETE mimetic, 
20-hydroxyeicosa-5(Z),14(Z)-dienoic acid (5,14-20-HEDE) potentiated the ischemic injury, and 
92 
 
20-HETE synthesis inhibition protected neurons from ischemic death (Renic, et al., 2012). In this 
study, for the first time we report a dose dependent increases in neuronal cell death by 20-HETE 
at high concentrations 10, and 50 µM. Interestingly, under non-hypoxic conditions, 20-HETE did 
not show any toxic effect over the same concentration range tested. Though there are differences 
in the in vitro model used in both studies, together these findings suggest that 20-HETE’s effects 
are potentiated only after a hypoxic-ischemic event and that the toxic effects are concentration 
dependent, which can be reversed by 20-HETE antagonists or synthesis inhibitors.  
 
We also found that pretreatment of 11,12-EET protected neurons from hypoxic cell death. 
Neuroprotective effects of EETs were previously reported in pure astrocytes (Terashvili, et al., 
2012), and astrocyte-dopaminergic neuron co-cultures (Liu, et al., 2005b) in both H2O2 and OGD 
models. There was one study that reported protective effects of EETs in cortical neuronal cultures 
(Koerner, et al., 2007) transduced with human sEH variants expressing functional polymorphisms 
in an OGD model. In this study, we showed for the first time that 11,12-EET protects cortical 
neurons from hypoxic cell death in a dose dependent manner. Interestingly, 11,12-EET also 
showed protection under normoxic conditions at higher concentrations. However, 14,15-EET did 
not show any protective effect at all concentrations tested either under normoxic or hypoxic 
conditions. In the study by Koerner et al., 14,15-EET did not show any protective effect in rat 
primary cortical neurons in OGD model. This could be due to increased metabolism of 14,15-EET 
by sEH during the hypoxic-ischemic event as it is a preferred substrate of the sEH. Together, these 
findings suggest that 11,12-EET, a potent regioisomer of the EETs protects different cells of CNS 
such as neurons, and astrocytes from hypoxia-ischemic as well as oxidant induced cell death.  
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In our study, we did not find any effects of DHETs on cortical neurons under normoxic and 
hypoxic conditions. We determined the stability of 20-HETE, and 11,12-EET under the normoxic 
incubation conditions and found that 20-HETE is more stable than 11,12-EET in the culture 
medium under the incubation conditions. Both 20-HETE and 11,12-EET are readily taken up by 
neurons from the culture medium however 11,12-EET concentrations declined rapidly from 
culture medium than 20-HETE. However, when we measured cellular levels of 20-HETE and 
11,12-EET at the end of incubation with exogenous administration to neurons, we only detected 
low levels of 20-HETE in cell lysates and 11,12-EET could not be detected. This could be due to 
re-esterification or rapid metabolism of these CYP eicosanoids in the neurons. Together, these data 
suggests that CYP eicosanoids can be administered exogenously to neurons for studying their 
effects in vitro under different conditions of cell death as they are relatively stable under moderate 
incubation conditions, and are readily up taken by cells. 
 
There are possible limitations to this study. We did not study the specific cellular signaling 
mechanisms activated by CYP eicosanoids after hypoxia-reoxygenation injury. As discussed in 
Chapter 1, CYP eicosanoids interact with different intracellular signaling pathways. Delineating 
specific cellular pathways involved will help gaining mechanistic insight into neuroprotective 
effects of CYP eicosanoids and also helps to validate these pathways as potential therapeutic 
targets to treat cerebral ischemic disorders. We have used one measure of cell death in this study. 
Since ischemic injury is progressive and time dependent, one type of cell death assay may not be 
representative of different modes of cells death such as apoptosis and necrosis. Hence, different 
measures of cell death or viability should be used to strengthen the findings, and also to establish 
full dose-response of the CYP eicosanoids. Though exogenous administration of CYP eicosanoids 
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are protective in hypoxic injury, these compounds are not suitable for chronic administration as 
these lipid derivatives are rapidly metabolized both in vitro and in vivo. Future studies employing 
inhibitors of formation of 20-HETE and metabolism of 11,12-EET in the in vitro cultures should 
be done to evaluate the effects of CYP eicosanoids in more severe and chronic conditions of 
hypoxia. Often, hypoxia is accompanied by lack of glucose. Glutamate-mediated neurotoxicity is 
an important factor under conditions when the neurons are deprived of both oxygen and glucose 
since removal of glucose from the medium results in a stronger hypoxic depolarization. Thus, 
further studies should be done in different models of ischemic cell death like OGD to evaluate the 
sensitivity of neurons and the potency of CYP eicosanoids in different types of ischemic injury 
that may have overlapping cellular mechanisms.  
 
3.5 CONCLUSIONS 
In summary, in the current study we have for the first time demonstrated the 
neuroprotective effects of CYP eicosanoids on rat primary cortical neuronal cultures in a hypoxia-
reoxygenation injury model. Further, we have showed dose dependent effects of 20-HETE and 
11,12-EET in hypoxic injury. We demonstrated that the CYP eicosanoids can be exogenously 
administered to neuronal cultures under hypoxic conditions as they are moderately stable, and 
readily taken up by neurons. These findings suggest a possible role of the non-vascular mechanism 
of neuroprotection mediated by CYP eicosanoids in ischemic injury. The understanding of relative 
contributions of vascular and non-vascular effects of CYP eicosanoids in mediating 
neuroprotection is critical for developing therapeutic agents that modulate cellular pathways 
specific to each mechanism in order to maximize the neuroprotective benefits of CYP eicosanoids.  
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4.1 INTRODUCTION 
 
Previous chapter has evaluated the CYP eicosanoids in in vitro cultures to test the non-
vascular mechanisms of neuroprotection. Specifically, we showed that 11,12-EET was effective 
in protecting neurons in a dose-dependent manner in hypoxia-reoxygenation injury. Together with 
their vascular and non-vascular effects, EETs appear to play a significant role in protecting cerebral 
tissue from ischemia-reperfusion injuries. This pattern of injury is produced in an experimental 
models of focal and global ischemia with subsequent reperfusion. This chapter will evaluate the in 
vivo protective effects of EETs in a focal ischemia model. Since administering EETs is not a viable 
pharmacological approach as they rapidly bind to plasma proteins or metabolized to less active 
DHETs, metabolically stable analogs of EETs were developed in the past but most widely used 
approach for studying the effects of EETs has been increasing endogenous EET levels in the tissue 
by inhibiting sEH, which is the primary route of degradation of EETs. The inhibitors of sEH have 
been shown to be neuroprotective, however no studies have evaluated if acute administration of 
sEH inhibitors can improve neurofunctional outcomes after ischemic stroke. These data are 
essential to add to the growing data to establish if sEH inhibitors meets the STAIR criteria for 
further clinical development (Fisher et al., 2009). Therefore, the primary goals of this study were 
to evaluate the effect of acute sEH inhibition by t-AUCB on infarct volume, functional outcome 
and changes in CBF using a transient MCAO model in rats.  
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4.2 EXPERIMENTAL METHODS AND PROCEDURES 
 
All animal experiments were approved by the University of Pittsburgh Institutional Animal 
Care and Use Committee (IACUC) and performed in accordance with the NIH Guide for the Care 
and Use of Laboratory Animals.  
4.2.1 Animals and experimental design 
Male Sprague-Dawley rats (250-300g) (Hilltop Laboratory Animals Inc., Scottsdale, PA) 
were maintained on a 12-h light/dark cycle and were given food and water ad libitum. The rats 
were randomly assigned to either vehicle (lyophilized hydroxypropyl-β-cyclodextrin (HPβCD), 
15%), or treatment (lyophilized t-AUCB in HPβCD, 0.5 mg) groups. MCAO was performed on 
all rats. All HPβCD lyophilized complexes (vehicle or t-AUCB) were reconstituted in PBS, 
pH=7.2, and filtered prior to administration. Treatment group rats received a single t-AUCB 0.9 
mg/Kg bolus dose via the femoral vein at the time of MCAO. As shown in the Figure 4-1, five 
experiments were performed: 1) effect of t-AUCB on cerebral infarct volume after MCAO 
(n=9/group); 2) t-AUCB inhibitory potential on brain cortical sEH activity (n=6/group); 3) acute 
t-AUCB effect on short-term behavioral outcome after MCAO (n=9/group); 4) changes in CBF 
during and after MCAO with t-AUCB treatment were determined with ASL-MRI (n=7/group); 
and 5) effect of t-AUCB on primary neuronal cultures after hypoxic injury (n=6 wells/group). A 
power analysis was conducted at β = 0.80 to detect significant difference between the treatment 
groups with an effect size of 15% (for experiments 1, 3, 4, and 5) and an effect size of  two-fold 
change in the ratio (for experiment 2). The surgeon and individuals involved in all above 
experiments were blinded to all treatment groups.  
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Figure 4-1 Schematic of the experimental design in a focal ischemia model 
 
4.2.2 Middle cerebral artery occlusion in rats 
Rats received MCAO for 90 minutes followed by reperfusion as described previously 
(Shimizu et al., 2001). Briefly, rats were anesthetized via nose cone with 1-2% isoflurane, 50/50 
N2O/O2 throughout surgery. The left common carotid artery (CCA) was exposed and the external 
common carotid artery was isolated and ligated using 5-0 silk (Ethicon). MCAO was achieved by 
inserting a 5-0 nylon suture (with tip coated with silicon ~280 µm diameter) into the internal 
carotid artery (ICA) a distance of 16 - 19 mm from the bifurcation of the CCA and ICA. The 
wound was closed and the animals were allowed to recover with the suture in place. After 90 
minutes, the rats were re-anesthetized and the suture removed, initiating reperfusion. Sham 
surgeries were performed in the same manner as MCAO surgeries but without insertion of suture. 
Throughout the surgical procedure core temperature was maintained at 37±0.5 °C using a thermo 
regulated heating pad.  
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4.2.3 Infarct volume determination 
Rats (n=9/group) were sacrificed at 24 h after reperfusion and infarct volume was assessed 
by staining with 2,3,5-triphenyl-tetrazolium chloride (TTC, Sigma, St. Louis, MO, 2% in PBS). 
Brains were placed in a rat brain matrix (ASI Instruments, Warren MI) and were sliced into 1 mm 
sections. The sections were immersed in the TTC for 30 min at room temperature. The sections 
were transferred to formalin and photographed. Infarct volume was measured using image analysis 
(MCID, St Catharines, Ontario, Canada). To minimize the effect of edema on the quantification of 
infarct size the method of Swanson et al., was used (Swanson et al., 1990). The percentage infarct 
volume was calculated by dividing infarct volume by contralateral hemisphere volume. 
 
4.2.4 Tissue extraction and chromatographic analysis of CYP eicosanoids 
Concentrations of CYP eicosanoids and prostanoids were determined from brain cortical 
tissues of vehicle and t-AUCB (0.9 mg/kg i.v; n=6/group) treated rats that underwent MCAO 
surgery using solid phase extraction, and UPLC-MS/MS analysis as described in Chapter 2 
previously.  
 
4.2.5 Functional outcome assessment 
  Functional outcome experiments were aimed at evaluating motor activity (primary motor 
cortex), and somatosensory activity of rats that underwent MCAO surgery. Behavioral deficits 
(functional outcome evaluation) in rats (n=9/group) were examined at 24 and 48 h after 
reperfusion. A simple neurological scoring system was used to assess neurological damage 
following MCAO surgery as follows: 0 = no neurological deficit; 1 = failure to extend left forepaw 
fully & torso turning to ipsilateral side when held by tail (a mild focal neurologic deficit); 2 = 
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circling to the effected side (a moderate focal neurologic deficit); 3 = unable to bear weight on the 
effected side (a severe focal deficit); 4 = no spontaneous locomotor activity. Behavioral deficits 
were determined using the arm flexion and sticky tape test as described previously (Aronowski et 
al., 1996). The arm flexure test was conducted once daily by lifting rats by their tails so that their 
ventral surface was exposed for observation. The cumulative duration of asymmetrical arm flexure 
during a ten second period after tail lifting was recorded using a stop watch. In the tape test, self-
adhesive labels (1-cm-diameter circles) were placed on each forepaw to assess the time required 
for the rat to touch and remove each label.  In addition, the order (contralateral versus ipsilateral) 
of removal was also used to determine ipsilateral asymmetry. Preference for a given wrist was 
accounted for by affixing larger labels to the wrist less preferred and correspondingly smaller 
labels to the other wrist.  The larger the ratio between surface of ipsilateral versus contralateral 
patches (from 1:1 to 1/8:15/8) the more extensive the damage (scored on a scale from 1 to 7 in the 
increasing order of severity of damage).  One trial per day was conducted at 24 hours and 48 hours 
after reperfusion.  
 
4.2.6 Cerebral blood flow assessment using ASL-MRI imaging 
CBF measurements were assessed by arterial spin labeled (ASL) MRI (Figure 4-2). Rats 
(n=7/group) underwent femoral artery catheterization and were placed in a prone position on the 
cradle. MRI was performed using a 4.7-Tesla, 40 cm bore Bruker BioSpec AVI system (Billerica, 
MA, USA), equipped with a 12-cm shielded gradient insert. A 72-mm volume coil with 2.5 cm 
actively-decoupled brain surface coil was used for imaging. Continuous ASL was used to quantify 
CBF (Detre et al., 1992; Williams et al., 1992). A single shot SE-EPI sequence was used with a 
TR = 2 s, 64 x 64 matrix, FOV = 2.3 cm, 2-s labeling pulse. The labeling pulse for the inversion 
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plane was positioned ± 2 cm from the perfusion detection plane. For each experiment, a map of 
the spin-lattice relaxation time of tissue water (T1obs) was generated from a series of spin-echo 
images with variable TR (FOV = 2.3 cm, 4 averages, 64 x 64 matrix) (Hendrich et al., 1999). CBF 
was assessed at three time points, at baseline, 70 min (during the occlusion period), and at 270 min 
(three hours after reperfusion). Blood gases were sampled at each time point and analyzed 
(Radiometer, Westlake, OH, USA). For the duration of the experiment mean arterial blood 
pressure (MABP) and EKG were continuously monitored. Rectal temperature was maintained at 
37°C using a warm air system (SA Instruments, Stony Brook NY, USA). 
 
 
 
 
 
 
 
 
 
 
Figure 4-2 ASL-MRI imaging unit 
4.2.7 Primary neuronal cultures and hypoxia study 
Rat primary cortical neurons were prepared as discussed in Chapter 2. The cultures were 
used for hypoxia experiments after 10 days. On the 11th day, the cells were either pre-treated for 
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one hour with vehicle (neurobasal medium) or t-AUCB diluted in neurobasal medium at a final 
concentration of 0.1 and 0.5 µM. These concentrations were selected to be 50 to 100 folds above 
the IC50 of t-AUCB (Tsai et al., 2010) to account for possible losses due to metabolism during 
uptake, non-specific binding to cells, degradation/instability under assay conditions. After pre-
treatment the culture plates were placed into a hypoxic glove box (Coy Laboratories, Grass Lake, 
MI, USA) flushed with argon for a period of 3 h, resulting in ~50% cell death after 24 h of 
reperfusion under normal incubation conditions. Staurosporine (20 μM) and MK801 (1 μM) were 
used as positive and negative controls respectively. Cell death was quantitatively assessed by 
CytoTox-Fluor kit (Promega, Madison, WI, USA) following manufacturer’s protocol, and by 
Propidium Iodide (PI) staining (Molecular Probes Inc., OR, USA) in two different experiments. 
For PI assay, cell were stained with 0.1 µg/mL PI (a red fluorescent dye that permeates dead cells) 
and 0.1 µg/mL Hoechst (a blue fluorescent dye that stains chromatin in live and dead cells) and 
fixed with 2% formaldehyde in PBS 24 h after hypoxia. PI and Hoechst stained cells were 
photographed with a Leica DMIRB fluorescence microscope at 20X, then counted by a blinded 
observer from 10 to 12 fields of at least three cultures. Cell death in all treatment groups was 
normalized to that of Staurosporine (SP) treated group.  
4.2.8 Statistical analysis 
Significant differences between treatment groups in experiments measuring infarct volume 
were assessed by Student’s t-test and for brain sEH activity and in vitro neuronal culture 
experiments one-way ANOVA with Dunnett’s post-hoc test was used. Significant differences for 
ASL-MRI blood flow measurements, and functional outcome assessments were determined via 
repeated measures ANOVA analysis. A *p<0.05 was considered significant. All data were 
represented as mean ± SD.  
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4.3 RESULTS 
 
4.3.1 Effect of t-AUCB on infarct volume  
The effect of acute t-AUCB pre-treatment on infarct volume after MCAO was evaluated 
and compared against vehicle. Figure 4-3 depicts representative rat brain sections stained with 
TTC. A significant reduction in percentage infarct volume was observed in t-AUCB as compared 
to vehicle treated (14.5±2.7% vs 41.5±4.5%;***p<0.001) rats (Figure 4-3). 
 
 
 
 
 
 
 
Figure 4-3 Effect of acute t-AUCB treatment on brain infarct volume after MCAO in rats. t-AUCB 
significantly reduced infarct volume upon acute administration at the time of MCAO as compared to vehicle 
treated group (n=9).  
 
4.3.2 Effect of t-AUCB administration on brain sEH activity  
The effect of acute sEH inhibition by t-AUCB in brain cortex after MCAO was assessed 
by measuring concentrations of various HETEs, EETs and DHETs as well as various PGs to verify 
the specificity of t-AUCB inhibition. A significant increase in the ratio of cumulative EETs (11,12- 
& 14,15-EET) to DHETs (11,12- & 14,15-DHET) was observed in t-AUCB as compared to 
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vehicle treated (4.40±1.89 vs 1.97±0.85;*p<0.05) rats (Figure 4-4A). No significant differences 
were observed in the concentrations of representative metabolites from the HETE and PG family 
such as 20-HETE (Figure 4-4B: vehicle: 6.39±0.92 vs t-AUCB: 6.80±1.7 pmol/gm tissue; 
p=0.62), 6-keto-PGF1α, a metabolite of prostacyclin (Figure 4-4C: vehicle: 22.3±4.35 vs t-AUCB: 
24.9±6.21 pmol/gm tissue; p=0.41), and PGF2α (Figure 4-4D: vehicle: 57.7±9.92 vs t-AUCB: 64.7 
± 13.7 pmol/gm tissue; p=0.35) in the cortex of t-AUCB and vehicle treated rats. Control values 
of these metabolites (without stroke) were also depicted in respective figures. Representative 
LC/MS chromatograms depicting the levels of EET, 20-HETE before and after treatment with t-
AUCB was shown in Figure 4-5. 
4.3.3 Effect of t-AUCB treatment on functional outcome  
The effect of t-AUCB pre-treatment on short-term behavioral deficits after MCAO was 
evaluated in arm flexion and sticky tape behavioral tests. Rats receiving t-AUCB treatment showed 
significantly improved outcome in the arm flexure test on days 1 and 2 as compared to the vehicle 
treated group (day 1: 3.28±0.5 s vs 7.50±0.9 s, ***p<0.001; day 2: 1.71±0.4 s vs 5.28±0.5 
s,***p<0.001) (Figure 4-6A). Similarly t-AUCB treatment significantly lowered neurological 
deficit scores on days 1 and 2 compared to the vehicle treated group (day 1: 1.71±0.9 vs 2.75±0.4, 
*p<0.05; day 2: 1.14±0.3 vs 2.14±0.3, ***p<0.001) (Figure 4-6B). Sticky tape tests also revealed 
a significant impact of t-AUCB on days 1 and 2 compared to the vehicle treated group (Figures 
4-6C and 4-6D). Time to remove (in sec) sticky tape from the contralateral arm was 140.4±15 s 
vs 92.8±3.5 s on days 1 and 2, respectively in the vehicle group, which was significantly reduced 
in the t-AUCB group on both days 1 and 2 (98.1±6 s, and 64.6±8 s,***p<0.001). Tape surface area 
ratio of contralateral to ipsilateral arm in the vehicle group was 6.96±0.77 vs 5.97±1.2 on days 1 
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and 2, respectively. This was significantly reduced with t-AUCB treatment on both days (2.53±0.6 
vs 1.19±0.2, ***p<0.001).  
Figure 4-4 The effect of acute t-AUCB treatment on brain cortical sEH activity after temporary MCAO in 
rats (n=6). Brain cortices were collected at 6 hours after t-AUCB dosing. Significant differences were only 
seen in the levels of cumulative EET/DHET ratio in the cortex of t-AUCB treated rats compared to vehicle. 
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Figure 4-5 Representative LC/MS chromatograms of rat brain cortical sample showing EETs, and 20-
HETE A) before and B) after treatment with t-AUCB 
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Figure 4-6 The effect of acute t-AUCB on functional outcome in a rat temporary MCAO model 
(n=9). Rats treated with t-AUCB showed significant improvement in A) arm flexure, B) 
neurological deficit score, C) time to remove tape, and D) tape surface area ratio compared to 
vehicle treated group on both days 1and 2. 
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4.3.4 Effect of t-AUCB treatment on cerebral blood flow changes  
The effect of t-AUCB treatment on changes in CBF during and after ischemic injury was 
assessed with ASL MRI. Representative brain perfusion maps of rats treated with t-AUCB or 
vehicle at three different time points are shown in Figure 4-7. There is mild to moderate 
improvement in perfusion around the infarcted tissue during the post-ischemic hypoperfusion 
period (270 min MRI scan) in t-AUCB treated rats. CBF values calculated from perfusion and 
T1obs maps, revealed no differences in the CBF values between the two groups at baseline and 
during ischemic injury (Figure 4-8). However, a non-significant increase in CBF was seen during 
the post-ischemic hypoperfusion period (180 min after reperfusion) in t-AUCB treated rats 
compared to vehicle control (Figure 4-8; t-AUCB: 73.3±35 vs vehicle: 42.2±17 ml/100 g/min; 
p=0.079). No statistically significant differences between physiological variables such as MABP, 
and pCO2 were observed between the two treatment groups (Figure 4-9).  
 
 
 
 
 
 
 
 
 
Figure 4-7 Representative brain CBF maps of rats treated with vehicle or t-AUCB before MCAO (pre), 
during MCAO (70 min) and after post-ischemic reperfusion (270 min). Dark blue regions indicate regions 
of low perfusion as seen at 70 and 270 min maps of both treatment groups.  
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Figure 4-8 Comparison of CBF values (reported as ml/100 g tissue/min) in the cerebral cortex ipsilateral 
to infarct of vehicle and t-AUCB treated rats (n=7). There was a non-significant trend towards increase in 
CBF in t-AUCB treated rats as compared to vehicle treated group. 
Figure 4-9 Comparison of physiological parameters in the vehicle and t-AUCB treated rats. No significant 
differences were observed between the physiological parameters of vehicle and t-AUCB treated rats. 
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4.3.5 Effect of t-AUCB on cytotoxicity of neuronal cultures under hypoxic conditions  
The effect of t-AUCB on cytotoxicity of rat primary cortical neuronal culture was assessed 
by treating neurons with 0.1 and 0.5µM t-AUCB followed by hypoxic injury. Pre-treatment prior 
to hypoxic injury resulted in a non-significant reduction in cell death at 0.1 µM (% cell death: 
vehicle: 67±11.6 vs t-AUCB: 56.91±7; p=0.057) and significant reduction at 0.5 µM (% cell death: 
vehicle: 67±11.6 vs t-AUCB: 48.5±9.5; **p<0.01) compared to their respective vehicle treated 
groups as assessed by the CytoTox-Fluor kit assay (Figure 4-10). Under non-hypoxic conditions 
of incubation t-AUCB did not alter neuronal survival compared to vehicle treated group (% cell 
death: vehicle: 45.6±9.4; t-AUCB0.1µM: 44.1±7.5; t-AUCB0.5µM: 52.0±6.1; p=0.124) when tested 
at the same concentration range. In another experiment, neurons treated with t-AUCB at 0.1 and 
0.5 µM prior to hypoxic injury were imaged under a fluorescent microscope for Hoechst (Blue) 
and PI (Red) staining (Figure 4-11). t-AUCB pre-treatment prior to hypoxic injury resulted in 
significant reduction in cell death in a concentration-dependent manner (% PI positive cells: 
vehicle: 70.9±7.1 vs t-AUCB0.1µM: 58±5.11; vs t-AUCB0.5µM: 39.9±5.8; ***p<0.001) compared to 
the vehicle treated group (Figure 4-12).  
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Figure 4-10 The effect of t-AUCB on cytotoxicity of primary rat cortical neuronal cultures. % Cell 
death with t-AUCB or vehicle treatment under hypoxic and non-hypoxic conditions. t-AUCB showed 
significant reduction in cell death at 0.5 µM under hypoxic conditions as compared to vehicle group. 
Figure 4-11 Representative images of rat primary cortical neuronal cultures imaged under fluorescence 
microscope after Hoechst (Blue) and PI (Red) staining.  
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Figure 4-12 The effect of t-AUCB on cytotoxicity of primary rat cortical neuronal cultures. Cytotoxicity 
assessment after hypoxic injury by PI staining. t-AUCB treatment showed concentration-dependent 
decrease in cell death as compared to medium treated group.  
 
4.4 DISCUSSION 
In this study, we investigated the neuroprotective effects of acute sEH inhibition with a 
single low dose, t-AUCB (0.9 mg/kg, iv) in focal ischemic stroke and the factors contributing to 
the neuroprotection. Specifically we have established causative relationship between acute sEH 
inhibition, EETs concentrations and neuroprotection. Furthermore, this study is the first to report 
the impact of acute sEH inhibition on behavioral performance using a comprehensive behavioral 
tests evaluating motor and somatosensory activity. The major findings of this study are that a single 
low dose administration of t-AUCB i) significantly decreases infarct volume and elevates brain 
cortical EETs concentrations, ii) significantly improves short-term functional outcome, iii) does 
not significantly alter CBF as determined by ASL-MRI, and iv) significantly increases neuronal 
survival under hypoxic conditions. Collectively, these data suggest that acute inhibition of sEH by 
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t-AUCB offers neuroprotection primarily through a direct cytoprotective effect on neurons with a 
minor contribution from alterations in CBF.  
Our finding of significant reduction in infarct volume after MCAO is consistent with the previous 
data reported using urea-based derivative 12-(3-adamantan-1-yl-ureido)-dodecanoic acid butyl 
ester (AUDA-nBE) in a mouse (10 mg/kg,ip) (Dorrance, et al., 2005; Iliff, et al., 2009a; Zhang, et 
al., 2007), and rat (2 mg/day) (Simpkins, et al., 2009) model of ischemic stroke. Also our results 
are consistent with other non-urea based sEH inhibitors such as 4-Phenyl Chalcone Oxide (4-PCO) 
that have been shown to produce neuroprotection in stroke models (Iliff, et al., 2010). This study 
with the urea based inhibitor for the first time showed that infarct volume reduction was associated 
with a two-fold elevation of the cumulative EETs/DHETs ratio in brain cortex with t-AUCB 
treatment. Analysis of brain cortices by our validated UPLC-MS/MS method demonstrated no 
significant changes in the levels of metabolites produced from CYP4A, CYP4F, and the COX 
pathway, thereby indicating the specificity and selectivity of sEH inhibition by t-AUCB. Together, 
these findings suggest that low dose t-AUCB selectively alters EETs concentrations and 
significantly reduces infarct volume after a single dose administration in the rat MCAO model.  
 
Based on these results, we delineated the impact acute sEH inhibition had on behavioral 
performance. Our findings suggest that acute administration of t-AUCB significantly improved 
behavioral performance following post-ischemic reperfusion. Behavioral tests used in this study 
are relevant to evaluate the damage produced by MCAO. MCA, the largest branch of the internal 
carotid, supplies a portion of the frontal lobe and the lateral surface of the temporal and parietal 
lobes, including the primary motor and sensory areas of the face, throat, hand and arm. Therefore, 
we have used behavioral tests that evaluate motor and sensory systems deficits. Further, these 
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behavioral tests to assess MCAO damage have been shown to correlate with the duration of 
ischemia and relate to the degree of behavioral deficit (Aronowski, et al., 1996). Acute treatment 
with t-AUCB at the time of ischemic injury exerted beneficial effects on days 1 and 2 following 
reperfusion. The data from these behavioral performance tests suggest that the extent of cortical 
damage was more severe in vehicle treated rats after MCAO when compared with t-AUCB treated 
animals, and that the rats recovered significantly from cortical damage and sensory neglect after 
acute t-AUCB administration. Taken together, these data demonstrate that selectively increasing 
brain cortical EETs concentrations by acute sEH inhibition may not only reduce infarct volume, 
but also improves the neurofunctional outcome in rats after MCAO, thereby providing additional 
evidence in support of sEH inhibitors as potential therapeutic intervention for neuroprotection after 
ischemic injury. 
 
The data from infarct volume and behavioral performance assessments led us to investigate the 
factors contributing to the neuroprotective effects of t-AUCB. We employed a non-invasive ASL-
MRI imaging technique to evaluate real-time CBF analysis. We found that acute t-AUCB 
treatment produced a non-significant trend towards improved CBF around the infarcted area 
during the post-ischemic hypoperfusion period with no major differences in CBF observed either 
during or after ischemia. Our findings after ischemic injury were similar to the results reported 
previously showing no significant differences in regional CBF rates as measured by [14C] 
iodoantipyrene [IAP] autoradiography between AUDA-nBE and vehicle treated groups (Zhang, et 
al., 2007). Conversely, in another study, Zhang, et al reported that brain tissue perfusion was 
significantly higher in sEH null mice (sEH-/-) compared to WT mice during and after vascular 
occlusion by Laser-Doppler perfusion and [14C] IAP autoradiography (Zhang, et al., 2008b). One 
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of the likely explanations for the contradictory findings between sEH-/- phenotype and chemical 
sEH inhibition is related to acute chemical sEH inhibition versus chronic loss of activity in sEH-/- 
mice producing differential effects on CBF. It is also possible that developmental differences or 
loss of phosphatase activity in the sEH-/- animals may explain the observed CBF effects. 
Interestingly, this discrepancy in the pharmacological inhibition versus gene deletion of sEH is not 
unique to CBF effects as several studies have reported differences in other phenotypes that are 
independent of CBF effects. For example, in a study Keseru et al., observed increased right heart 
hypertrophy and pulmonary artery muscularization in sEH-/- mice subjected to chronic hypoxia 
than the wild type mice treated chronically with sEH inhibitors (Keseru et al., 2010). Similarly, 
Fairbanks et al. also reported gender differences in neuronal susceptibility to ischemic cell death 
in in vitro OGD model and linked it to sEH expression and possibly to hydrolase activity. In this 
study of primary cortical neuronal cultures made from male and female rats, acute sEH inhibition 
by 4-PCO did not abolish the gender differences in ischemic death but knock out of sEH eliminated 
differences in sensitivity to OGD between neurons from male and female mice (Fairbanks, et al., 
2012). Collectively, these studies support that the phenotype differences exist between sEH 
chemical inhibition and sEH-/- animals. More studies focusing on CBF changes should be 
completed to elucidate the underlying mechanisms of these phenotypic differences and to better 
understand the degree to which changes in CBF within microvessels contribute to overall 
neuroprotection within the neurovascular unit.  
 
Given that acute administration did not significantly affect CBF in the rat MCAO model, we sought 
to determine if t-AUCB directly protects neurons from ischemic damage in vitro. Our in vitro 
experiments with naïve rat primary cortical neurons showed that t-AUCB significantly reduced 
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neuronal cell death in a concentration-dependent manner after hypoxic injury, thereby suggesting 
a direct neuroprotective effect of t-AUCB treatment under hypoxic conditions. In our assay, 
negative control MK-801, a potent NMDA receptor antagonist prevented neuronal death 
significantly after hypoxic injury, suggesting that involvement of excitotoxic mechanisms for 
neuronal death, however it is unknown if the protective mechanisms of the EETs are identical in 
vivo vs in vitro. Future studies comprehensively evaluating the protective mechanisms will help 
understand the similarity of in vitro protective mechanisms to the in vivo mechanisms. In a study, 
Koerner, et al reported protective effects of exogenous administration of 14,15-EET or sEH 
inhibition by 4-PCO at low concentration in an in vitro OGD study with primary rat cortical 
neurons transduced with human sEH variants expressing functional polymorphisms that alter 
hydrolase activity of sEH (Koerner, et al., 2007). However, these protective effects were not 
observed in naïve rat cortical neurons. In this study, for the first time we reported significant 
neuroprotective effects of sEH inhibition by t-AUCB in rat primary cortical neurons after hypoxia-
reoxygenation injury. Though in this experiment we did not measure cellular levels of EETs after 
sEH inhibition, our findings of protective effect of exogenous 11,12-EET administration from 
Chapter 3 indicate that EETs exert direct neuroprotective effects in ischemic injury. In addition 
to the protective effect on neurons, EETs also appear to exert beneficial effects on other brain cells 
in ischemia as reported by Liu et al who showed cytoprotective effects of exogenous 
administration of EETs on cortical astrocyte culture in an OGD model (Liu, et al., 2005b).  
Although, we studied the neuroprotective mechanisms in vitro and CBF changes in vivo, we 
observed significant improvements in infarct volume reduction and behavioral performance in the 
absence of a significant CBF improvement suggesting that the protective effects may be due to 
both direct effect on neurons and additional contributions from CBF changes. Future studies 
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evaluating EET agonists and antagonists that evaluate microvascular flow will aid in the 
elucidation of the mechanisms of neuroprotection. Furthermore, evaluating the effect of sEH 
inhibition on oxidative stress and inflammation accompanying ischemic damage of cerebral tissue 
will elucidate underlying effector mechanisms involved in the pathogenesis. Although we did not 
observe significant changes in the levels of key prostaglandin metabolites across treatment groups, 
future studies evaluating the levels of key oxidative stress markers such as 8-isoprostane will help 
in elucidating the underlying mechanisms of pathogenesis of ischemic injury. Collectively, these 
data suggest that altering EETs levels by acute inhibition of sEH is likely to produce the largest 
benefits by affecting multiple components of neurovascular unit such as astrocytes, neurons, and 
microvascular flow. 
 
There are possible limitations to this study. One of the limitations is the administration of t-AUCB 
at the time of initiation of ischemia. Due to the difficulty in administering t-AUCB post ischemic 
injury in our MCAO model in CBF assessment experiments by ASL-MRI, we administered t-
AUCB immediately prior to initiation of ischemic injury in all of our experiments.  Future direction 
of our work includes evaluating the neuroprotective effects of t-AUCB administered with the same 
dosing regimen (0.9 mg/Kg, i.v) during the post-ischemic reperfusion period. A second limitation 
is that we evaluated the protective effects after acute administration of a single dose of t-AUCB. 
Additional studies are need in future to establish a dose-response curve as t-AUCB has favorable 
pharmacokinetic profile due to good solubility and permeability across tissues, and longer half-
life (Tsai, et al., 2010), and to evaluate the impact of chronic administration during the post-
ischemic reperfusion phase on the regional CBF and long-term functional outcome. Third 
limitation of our study was that in our in vitro cell culture experiments, we used high 
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concentrations of t-AUCB (0.5 µM) to account for possible loss due to non-specific binding to 
cells and metabolism after uptake. This concentration may not be reflective of intracellular 
concentrations achieved with our dosing regimen (Tsai, et al., 2010). Future goals of our work will 
aim at assessing the in vitro neuroprotective efficacy of t-AUCB over a wider concentration and 
time exposure range. Fourth limitation of our study was that t-AUCB neuroprotection was 
evaluated in male rats alone. A previous study has showed that sEH expression in females was 
lower than males and that the gene deletion of sEH did not reduce infarct volume in females 
presumably due to lower sEH expression (Zhang et al., 2009). Additional studies in future 
evaluating acute and/or chronic sEH inhibition in female rats will help to understand if gender 
difference plays a crucial role in sEH mediated neuroprotective effects. 
 
4.5 CONCLUSIONS 
In summary, in the current study we have demonstrated the neuroprotective effects of t-
AUCB in a rat MCAO model at a low dose and have produced the first evidence that t-AUCB 
alters EETs/DHETs ratio without significant changes in other AA metabolites from CYP4A, 
CYP4F, and COX pathways. In addition, these data are first to demonstrate improved short-term 
behavioral performance by t-AUCB; thereby, providing evidence that sEH inhibitors meet the 
STAIR criteria of improved functional outcome in the rat. Further, we demonstrated that the 
neuroprotection by t-AUCB is likely due to direct neuronal effects with minor contributions from 
alterations in CBF. Chronic sEH inhibition by pharmacological inhibitors is an area of the future 
study to better elucidate long-term behavioral performance and evaluate sEH inhibitors as a 
potential novel intervention for focal ischemic insults. 
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5.1 INTRODUCTION 
  Previous chapter has investigated the effects of CYP eicosanoids on neuroprotection, CBF 
changes and short-term functional outcomes in focal ischemia model. As mentioned in the earlier 
chapter, CBF dysregulation is commonly observed after reperfusion from ischemic stroke or 
cardiac arrest (CA). In the introduction, I’ve discussed on adult and pediatric CA. Ventricular 
fibrillation is main cause of adult CA. In children common cause for CA is respiratory failure due 
to asphyxiation with 10 – 15% cases attributed to ventricular fibrillation. In addition to poor 
prognosis and clinical outcomes after CA in children, limited knowledge of the developmental 
differences in ion channels, receptor subtype expression in pediatric population curtails our 
understanding of pathophysiology of global ischemic injury in pediatric CA as compared to adult 
CA. Further, these developmental differences in ion channels could raise an issue in using general 
anesthetics blocking GABA with high risk for excitotoxicity. For this reason, we chose pediatric 
asphyxial CA model to elucidate the pathophysiology of global ischemic injury after CA in 
pediatrics. Like in focal ischemic models, resuscitation after CA may produce secondary neuronal 
damage as a result of global ischemic brain injury (Buunk et al., 2000). Thus, restoration of CBF 
following CA is critical in determining neuronal survival. (Manole et al., 2008; Shaffner et al., 
1999; Xu et al., 2002b). The CBF derangements after CA are well documented in adult animals 
describing a typical phasic pattern. During the first phase that corresponds to the CPR maneuvers 
there is no flow, followed by low flow at the end of CPR. Immediately after reperfusion there is a 
transient global increase in CBF (hyperemia) (Fischer et al., 1995; Shaffner et al., 1998) followed 
by a prolonged post-ischemic hypoperfusion (hyporemia) (Liachenko et al., 2001). In a clinically 
relevant pediatric rat asphyxial CA model, similar pattern of CBF changes after CA were observed 
with a transient hyperemia in subcortical regions followed by prolonged hypoperfusion in cortical 
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regions (Manole et al., 2009; Manole et al., 2012). There have been conflicting opinions regarding 
the relationship between CBF changes, and neurological outcome after CA. It was hypothesized 
that early hyperemia after CA is beneficial and hypoperfusion is detrimental for neuronal survival 
(Della Corte et al., 1993; Snyder et al., 1975); however, other studies indicated that early 
hyperemia may lead to poor neurological outcome (Cohan et al., 1989; Pignataro et al., 2008). 
Currently there are no therapeutic treatments that have shown efficacy in improving neurological 
outcomes after CA except for hypothermia (Bernard et al., 2002; Weigl et al., 2005). The 
mechanisms implicated in the pathogenesis of CBF derangements after resuscitation from CA are 
not fully elucidated. Increases in the levels of endogenous catecholamines, nitric oxide production 
in cerebral vessels are attributed to early hyperemia post ROSC. Other mechanisms such as 
vascular resistance, cerebral edema, coagulation, lipid peroxidation and neuronal apoptosis or 
necrosis are also attributed to the ischemia / reperfusion injury (Gando et al., 1997; Nitatori et al., 
1995; Traystman et al., 1991). Therefore, a thorough pathophysiological investigation of regional 
dynamic changes in CBF during the early and late period after resuscitation should be done to gain 
insight into the mechanisms leading to secondary neuronal damage.  
 
Ischemic injury following CA increases PLA2 mediated release of AA into the cytosol, which is 
metabolized further to form prostanoids, CYP eicosanoids, and leukotrienes. Prostanoids are 
potent regulators of vascular tone and mediate their effects through various membrane receptors 
of GPCR family (Wright et al., 2001). Specifically, prostacyclin (PGI2) and TXA2 are potent 
vasodilator and vasoconstrictor of cerebral vasculature. Other prostanoids such as PGE2, and 
PGF2α also induce either vasoconstriction or vasodilation depending on the type of receptor 
activated (Moncada, et al., 1978). As discussed in Chapter 1, CYP eicosanoids are also potent 
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regulators of cerebrovascular tone and blood flow. Thus, an imbalance in the levels of prostanoids, 
and CYP eicosanoids may serve to limit the CBF recovery during the reperfusion phase after CA. 
Role of prostanoids in the ischemic brain damage has been well characterized and studied. The 
neuroprotective effects of different prostanoids in in vitro and in vivo models of ischemia were 
summarized in Chapter 2. Similarly, role of CYP eicosanoids in the pathogenesis of ischemic 
injury after focal ischemia (Iliff, et al., 2009a; Miyata, et al., 2005; Omura, et al., 2006; Poloyac, 
et al., 2006; Zhang, et al., 2007) is well characterized. However, their role in global ischemia is 
poorly understood. Hitherto, there is only one published report that investigated the role of 20-
HETE in global ischemia or neonatal hypoxia-ischemia (Yang et al., 2012). Therefore, the primary 
goals of this study were to measure the brain tissue levels of CYP eicosanoids and prostanoids, to 
evaluate the changes in CBF, and to evaluate the effect of acute inhibition of 20-HETE synthesis 
by HET0016 on CBF, and functional outcome in a pediatric rat asphyxial cardiac arrest model.  
 
5.2 EXPERIMENTAL METHODS AND PROCEDURES 
 
All animal experiments were approved by the University of Pittsburgh Institutional Animal 
Care and Use Committee (IACUC) and performed in accordance with the NIH Guide for the Care 
and Use of Laboratory Animals.  
5.2.1 Animals and experimental design 
Mixed litter, male PND 16 to 18 Sprague-Dawley rats (30 to 45 g) were used. The rats 
were randomly assigned to receive either 9 min or 12 min of asphyxial arrest or sham surgery. 
Sham control rats underwent anesthesia and surgery without asphyxial arrest or resuscitation. 
Initial experiments were performed to assess CBF changes at serial time intervals (5, 10, 30 and 
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60 min) following resuscitation from CA. Rats were sacrificed by decapitation at 5 and 120 min 
after ROSC, and brain tissue was rapidly excised, snap frozen in liquid nitrogen and stored at -80 
ºC until further analysis to measure levels of CYP eicosanoids and prostanoids in the cortex and 
the midbrain. In a separate study, rats were randomly assigned to either vehicle (lyophilized 
HPβCD, 15%), or treatment (lyophilized HET0016 in HPβCD, 0.5 mg) groups. All rats were 
subjected to either sham surgery or 12 min of CA. All HPβCD lyophilized complexes (vehicle or 
HET0016) were reconstituted in PBS, pH=7.2, and filtered prior to administration. Four 
experiments were performed: 1) effect of HET0016 on cerebral blood flow changes after CA 
(n=6/group); 2) CYP eicosanoids and prostanoids levels in the cortex and the midbrain at 5 min 
after ROSC following HET0016 or vehicle treatment (n=6/group); 3) acute HET0016 effect on 
short-term neurological deficits at 24 and 48 h after resuscitation from CA (n=6/group); and 4) 
effect of HET0016 on neuronal survival after CA (n=6/group). For experiments 1and 2 a single 
bolus dose of HET0016 at 0.9 mg/Kg was administered via the femoral vein at the time of 
resuscitation from CA. For experiments 3 and 4 multiple doses of HET0016 at 0.9 mg/Kg were 
administered intravenously at every 6 hours over a period of one day since the time of resuscitation. 
Sample size was determined based on the power analysis of detecting a significant difference 
between treatment groups with an effect size of 20% and 2 fold increase in the ratios at 80% power. 
The surgeon and individuals involved in all above experiments were blinded to all treatment 
groups.  
 
5.2.2 Asphyxial cardiac arrest in pediatric rats 
Rats underwent asphyxial CA for 9 or 12 minutes followed by resuscitation as described 
previously (Fink et al., 2004). A schematic diagram illustrating the CA model was shown in Figure 
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5-1. Briefly, the rats were initially anesthetized via nose cone with 3% isoflurane, 50/50 N2O/O2 
in a Plexiglas chamber until unconscious and then the trachea was intubated with an 18-gauge 
angiocatheter and mechanical ventilation was initiated. PaCO2 was maintained between 35 to 45 
mm Hg by adjusting ventilation rate and tidal volumes. During surgery, anesthesia was reduced to 
2.5% isoflurane, 50/50 N2O/O2 & oxygen and femoral arterial and venous catheters were placed. 
Isoflurane was discontinued and intravenous analgesia was initiated using fentanyl infusion at 50 
µg/kg/h and neuromuscular blockade was obtained using vecuronium infusion at 5 mg/kg/h. Prior 
to recording baseline CBF, a 30 min duration of isoflurane washout was performed to minimize 
the effect of inhaled anesthetics on CBF. Asphyxial cardiac arrest was induced by disconnecting 
the tracheal tube from ventilator and maintained until 9 or 12 min. Resuscitation was initiated by 
reconnecting the ventilator, infusion of epinephrine 0.005 mg/kg and sodium bicarbonate 1 
mEq/kg i.v., and manual chest compressions until ROSC. Anesthesia and neuromuscular blockade 
were restarted at 30 min after ROSC until the end of experiment. MABP and heart rate were 
continuously monitored via femoral arterial and venous catheters. Arterial blood gases were 
measured at baseline, during CA and post resuscitation till the end of experiment. Rectal 
temperature was continuously monitored and maintained at 37 ºC via a heater water blanket system 
throughout the surgery. 
 
 
 
 
Figure 5-1 A schematic diagram illustrating the asphyxial CA model in pediatric rats. 
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5.2.3 Tissue extraction and chromatographic analysis of AA metabolites 
Concentrations of various metabolites including CYP eicosanoids, and prostanoids were 
determined from cortex and midbrain of vehicle and HET0016 (0.9 mg/kg i.v; n=9/group) treated 
rats that underwent either sham surgery or asphyxial cardiac arrest using solid phase extraction 
and UPLC-MS/MS analysis as described in Chapter 2.  
5.2.4 Cerebral blood flow assessment using laser-speckle photometry 
Cortical CBF was measured using laser-speckle photometer from Perimed (PeriCam PSI, 
Perimed, Switzerland) (Figure 5-2). During anesthesia, rats were placed into a standard stereotaxic 
frame and the skull was exposed with a midline scalp incision skin. The skull area was cleaned to 
remove any traces of blood. Rats were placed under a PeriCam PSI system, which utilizes a built-
in 70 mW laser diode to illuminate the cortical surface. PeriCam PSI laser head was adjusted to a 
distance of 15 cm and at an angle of 90 degree to the imaging plane such that the laser beam falls 
in the center of the imaging area. The Imaging area was set to 2 X 2 cm. The perfusion imaging 
was recorded continuously at a frame rate of 10 images/sec and resolution of 0.14 mm throughout 
the experiment. Measurement events were marked at regular intervals starting from baseline, 
during CA, after CA till the end of the experiment. CBF perfusion maps were obtained at baseline 
and at 5, 10, 30, 60 min after ROSC. CBF perfusion values in the regions of interest (ROI) in 
cortex were computed from perfusion images using PIMSoft software (Perimed, Switzerland).  
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Figure 5-2 Perimed laser speckle perfusion imaging unit 
5.2.5 Neurological deficit assessment 
 Neurological deficits in rats (n=6/group) from vehicle, and HET0016 groups at 3, 24, and 
48 h after resuscitation from CA or from sham group were examined by a modified neurological 
deficit score (NDS) system as described previously (Neumar et al., 1995). Parameters assessed in 
in the NDS were listed in Table 5-1. Briefly, various parameters including general consciousness, 
cranial nerves, motor, sensory, and coordination response were each scored individually. 
Cumulative score obtained is normalized to maximum test score and represented as % NDS score. 
A NDS score of 0-10% is considered normal and 100% is considered maximum neurological 
damage.  
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Table 5-1 Neurologic deficit scoring system for assessing behavioral performance of pediatric rats 
subjected to asphyxial CA 
Parameter Score scale 
General 
Consciousness 0 / 50 / 100 
Respiration 0 / 50 / 100 
Total points 200 
Clinical nerves 
Olfactory 0 / 10 / 20 
Vision 0 / 10 / 20 
Corneal reflex 0 / 10 / 20 
Whisker movement 0 / 10 / 20 
Hearing 0 / 10 / 20 
Total points 100 
Motor 
Left forepaw 0 / 5 / 10 
Right forepaw 0 / 5 / 10 
Left hindpaw 0 / 5 / 10 
Right hindpaw 0 / 5 / 10 
Tail 0 / 5 / 10 
Total points 50 
Sensory 
Left forepaw 0 / 5 / 10 
Right forepaw 0 / 5 / 10 
Left hindpaw 0 / 5 / 10 
Right hindpaw 0 / 5 / 10 
Tail 0 / 5 / 10 
Total points 50 
Coordination 
Travel ledge 0 / 5 / 10 / 15 / 20 / 25 
Placing test 0 / 15 / 25 
Righting reflex 0 / 15 / 25 
Stop table edge 0 / 15 / 25 
Total points 100 
Total Score 500 
Percent NDS 0 – 100 % 
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5.2.6 Neuronal survival assessment after global ischemic injury 
Effect of acute HET0016 treatment on neuronal survival after asphyxial CA was assessed 
by FluoroJade-B (Schmued et al., 1997), and hematoxylin and eosin (H&E) staining. At 48 h from 
resuscitation after CA, rats receiving either HET0016 or vehicle treatment were anesthetized with 
3% isoflurane and 50% N2O / balance O2 followed by transcardial perfusion with 250 mL of ice-
cold heparinized saline and 250 ml of 4% paraformaldehyde. The brains were removed and fixed 
in 4% paraformaldehyde. Coronal sections of the paraffin embedded brains were cut at 5 µm using 
a cryotome, and 5 to 6 systematic random sections were obtained. Separate sections were further 
processed and stained with FluoroJade-B for identifying degenerating neurons, and with H&E for 
evaluating gross ischemic cellular changes.  
 
For FluoroJade-B staining, coronal sections were washed sufficiently with xylene to remove 
paraffin, then immersed in 100% ethanol and 1% sodium hydroxide for 90 sec, followed by another 
30 sec treatment with 70% ethanol. Slides with coronal brain sections were mixed with 0.06% 
potassium permanganate for 10 min on a shaker and subsequently washed in distilled water before 
immersion in a 0.006% working solution of Fluoro-Jade B with 4,6-diamidino-2-phenylindole 
(DAPI) for 30 min. Slides were then washed with distilled water multiple times, drained and placed 
on a slide warmer at 50°C for 10 min, then cover-slipped with DPX mounting medium. Cells 
stained positively in the primary motor and sensory cortex were counted under microscope from 
multiple sections by an observer blinded to experimental condition.  
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5.2.7 Statistical analysis 
Primary hypothesis in the experiments with HET0016 was to evaluate changes in the levels 
of 20-HETE with or without HET0016 administration. Hence, primary statistical comparisons 
were done to evaluate significant changes in 20-HETE levels with subsequent secondary analysis 
performed to evaluate significant changes in other metabolites. Significant differences between 
treatment groups in experiments measuring CYP eicosanoid and prostanoid levels, and neuronal 
survival one-way ANOVA with Dunnett’s post-hoc test was used. Significant differences between 
groups in CBF changes at regular intervals after ROSC, neurological deficit assessments, and 
physiological variables were determined via repeated measures ANOVA analysis. A *p<0.05 was 
considered significant. All data were represented as mean ± SE.  
 
5.3 RESULTS 
5.3.1 Effect of CA duration on CBF in the cortex in pediatric rat asphyxial cardiac arrest 
model 
 Changes in the cortical blood flow during early and late reperfusion period after asphyxial 
cardiac arrest were evaluated in a 9 and 12 min CA models. Blood flow changes in the cortex, 
represented as % of baseline, throughout the reperfusion phase exhibited same pattern in both 
models of CA with a rapid decline until 30 min and sustained low flow till 120 min (Figure 5-3). 
However there was significant decrease in CBF early at 5 min after ROSC in 12 min group (77.8 
± 1.7%) as compared to 9 min CA (86.3±1.2%; *p<0.05). During the late reperfusion period, CBF 
in 12 min CA group was significantly low at 60 (56±2.5% vs 63.1±1.2%; *p<0.05) and 120 min 
(55.4±1.8% vs 64.4±2.7%; *p<0.05) after ROSC as compared to 9 min CA group. 
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Figure 5-3 Effect of duration of CA on cortical blood flow after resuscitation from CA. CA (independent 
of duration) produced a trend of initial steep decrease in CBF followed by sustained low flow post 
resuscitation. 12 min CA showed significant reduction in CBF at 5, 60, and 120 min compared to 9 min CA 
in the post-ischemic reperfusion period.   
 
5.3.2 Effect of CA duration on the prostanoid levels in the cortex after ROSC in pediatric 
asphyxial cardiac arrest 
Prostanoid levels in the cortex at 5 and 120 min after ROSC were evaluated in both 9 and 
12 min CA models. In 9 min CA model, 5 min after ROSC significant increases in the levels 
(pmol/g tissue) of 6-Keto-PGF1α (3.22±0.2 vs 2.24±0.2; *p<0.05), 11β-PGF2α (16.1±2.2 vs 
3.34±0.71; *p<0.001), PGF2α (58.5±10.9 vs 15.8±1.92; *p<0.001), PGE2 (122±20.9 vs 12.8±2.0; 
*p<0.001), 11-d-TXB2 (11.7±2.3 vs 1.37±0.4; *p<0.01), PGD2 (1029±82 vs 351±90.7; *p<0.001), 
15-d-PGD2 (34.2±5.7 vs 27.6±7.9; *p<0.05), 15-d-PGJ2 (53.0±9.4 vs 12.8±2.2; *p<0.01), and 
significant decrease in the levels of PGF1α (3.3±0.7 vs 16.5±2.2; *p<0.001) were observed in 
cortex as compared to sham rats (Table 5-2). However fold changes in the levels of PGE2 with 
respect to sham were higher than all other metabolites. At 120 min after ROSC, concentrations of 
131 
 
most of the metabolites decreased to sham or below sham levels. In 12 min CA model, during the 
early reperfusion at 5 min, significant increases in the levels of 6-Keto-PGF1α (14.5±1.9 vs 
2.24±0.2; *p<0.001), 11β-PGF2α (10.2±1.3 vs 3.34±0.7; *p<0.001), PGF2α (131±12.5 vs 15.8±1.9; 
*p<0.001), PGE2 (35.5±5.0 vs 12.8±2.0; *p<0.001), PGD2 (937±125vs 351±90.7; *p<0.001), 15-
d-PGJ2 (18.4±0.4 vs 12.8±2.2; *p<0.05) and significant decreases in the levels of PGF1α (2.6±0.39 
vs 16.5±2.2; *p<0.05) were observed in cortex as compared to sham rats. However fold change in 
the levels of 6-Keto-PGF1α, and PGF2α relative to sham in the early phase of reperfusion was higher 
in 12 min CA as compared to 9 min CA. At 120 min the levels of 6-Keto-PGF1α (13.5±1.67 vs 
2.24±0.2; *p<0.001) was still significantly higher than sham whereas PGJ2 (1.81±0.43 vs 36.9 ± 
4.80; *p<0.001), 15-d-PGD2 (2.06± 0.4vs 27.6±7.9; *p<0.01), and 15-d-PGJ2 (5.36±1.1vs 
12.8±2.2; *p<0.01) have decreased significantly compared to sham rats. In contrast to 9 min CA 
model, levels of PGA2 were not detected at either 5 or 120 min after ROSC in the 12 min CA 
model. Fold changes in the levels of all prostanoids in the cortex with respect to sham at 5 and 120 
min after ROSC in 9 and 12 min CA was depicted in a polar plot (Figure 5-4). Each spike 
represents a prostanoid, and the radius of the circle represents fold changes normalized to sham. 
Prostanoids with significant changes compared to sham were separately shown in Figure 5-5.  
 
5.3.3 Effect of CA duration on the prostanoid levels in the midbrain after ROSC in 
pediatric asphyxial cardiac arrest 
 Prostanoid levels in the midbrain at 5 and 120 min after ROSC were evaluated in both 9 
and 12 min CA models. In 9 min CA significant increases were only observed in the levels of 
PGF2α (39.5±3.4 vs 20.8±2.1; *p<0.001) whereas significant decreases were observed in the levels 
of 11β-PGF2α (10.3±1.8 vs 21.9±4.8; *p<0.05), PGF1α (3.58±0.4 vs 20.9±2.9; *p<0.001), PGA2 
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(2.37±0.91 vs 18.4±4.6; *p<0.001),15-d-PGD2  (25.6±5.1 vs 62.2±0.8; *p<0.001) at 5 min after 
ROSC in the midbrain compared to sham rats (Table 5-3). At 120 min, significant increases were 
only seen in the levels of PGF1α (12.0±1.70 vs 20.9±2.97; *p<0.05) whereas significant decreases 
were observed in the levels of 11β-PGF2α (9.41±2.12 vs 21.9±4.81; *p<0.05), PGF2α (8.66±0.77 
vs 20.8±2.1;  *p<0.001), PGD2 (171±36 vs 479±147; *p<0.05), PGJ2 (8.02±1.8 vs 22.7±4.5; 
*p<0.05), 15-d-PGD2  (16.9±2.9 vs 62.2±0.85; *p<0.001) compared to sham rats. In 12 min CA 
model, during the early reperfusion at 5 min, significant increases in the levels of 6-Keto-PGF1α 
(7.83±0.71 vs 1.80±0.5; *p<0.001), PGF2α (57.8±5.4 vs 20.8±2.1; *p<0.001) and significant 
decreases in the levels of PGF1α (1.31±0.21 vs 20.9±2.97; *p<0.001), PGE2 (19.8±2.37 vs 
159±35.7; *p<0.05), 11-d-TXB2 (1.55±0.3 vs 7.68±1.7; *p<0.01), 15-d-PGD2 (16.7±1.41 vs 
62.2±0.85; *p<0.001), 15-d-PGJ2 (10.7±1.4 vs 44.8±6.6; *p<0.001) were observed in the midbrain 
compared to sham rats. At 120 min, the levels of 6-Keto-PGF1α was still significantly higher 
whereas PGE2, 11-d-TXB2, PGD2, PGJ2, 15-d-PGD2, and 15-d-PGJ2 were still significantly lower 
compared to sham rats. At 120 min, there were no levels of 11β-PGF2α, PGF1α, and PGA2 detected 
in the midbrain. Fold changes in the levels of all prostanoids in the midbrain with respect to sham 
at 5 and 120 min after ROSC in 9 and 12 min CA was depicted in a polar plot (Figure 5-6). Each 
spike represents a prostanoid, and the radius of the circle represents fold changes normalized to 
sham. Prostanoids with significant changes compared to sham were separately shown in Figure 5-
7. 
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 Table 5-2 Effect of CA duration on temporal profile of prostanoid levels (pmol/g tissue) in brain cortex 
after ROSC. Five minutes after ROSC there were significant increases in the prostanoids which returned to 
sham or below sham levels at 120 min after ROSC.  
Analyte 
CA Sham 9 min 12 min 
ROSC(min)        5 120 5 120 
6-Keto-PGF1α  2.24 ± 0.2 3.22 ± 0.2* 2.68 ± 0.3 14.5 ± 1.9* 13.5 ± 1.7* 
11β-PGF2α  3.34 ± 0.7 16.1 ± 2.2* 3.61 ± 0.8 10.2 ± 1.3* 1.37 ± 0.3 
PGF1α  16.5 ± 2.2 3.3 ± 0.7* 7.4 ± 1.4* 2.6 ± 0.4* - 
PGF2α  15.8 ± 1.9 58.5 ± 11* 13.2 ± 1.8 131 ± 12.5* 13.2 ± 2.3 
PGE2  12.8 ± 2.0 122 ± 20.9* 88.8 ± 23.9* 35.5 ± 5.0* 9.71 ± 2.2 
11-d-TXB2  1.37 ± 0.4 11.7 ± 2.3* 3.93 ± 1.1 1.25 ± 0.2 0.86 ± 0.2 
PGD2  351 ± 90.7 1029 ± 82* 180.3 ± 41.4 937 ± 125* 57.4 ± 12.4 
PGA2  24.2 ± 5.3 20.8 ± 4.8 3.53 ± 0.4* - - 
PGJ2 36.9 ± 4.8 50.6 ± 10.8 11.9 ± 2.1 33.8 ± 5.3 1.81 ± 0.4* 
15-d-PGD2 27.6 ± 7.9 34.2 ± 5.7 9.33 ± 2.1 27.0 ± 2.5 2.06 ± 0.4* 
15-d-PGJ2 12.8 ± 2.2 53.0 ± 9.4* 20.2 ± 4.1 18.4 ± 0.4* 5.36 ± 1.1* 
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 Table 5-3 Effect of CA duration on temporal profile of prostanoid levels (pmol/g tissue) in the midbrain 
after ROSC. Five minutes after ROSC there were significant increases in the prostanoids which returned to 
sham or below sham levels at 120 min after ROSC 
Analyte 
CA Sham 9 min 12 min 
ROSC(min)        5 120 5 120 
6-Keto-PGF1α  1.80 ± 0.5 1.50 ± 0.2 2.66 ± 0.4 7.83 ± 0.7* 9.90 ± 1.2* 
11β-PGF2α  21.9 ± 4.8 10.3 ± 1.8* 9.41 ± 2.1* 5.62 ± 0.7* - 
PGF1α  20.9 ± 2.9 3.58 ± 0.4* 12.0 ± 1.7* 1.31 ± 0.2* - 
PGF2α  20.8 ± 2.1 39.5 ± 3.4* 8.66 ± 0.7* 57.8 ± 5.4* 7.16 ± 0.9* 
PGE2  159 ± 35.7 88.6 ± 17.4 84.9 ± 12.2 19.8 ± 2.4* 6.02 ± 0.8* 
11-d-TXB2  7.68 ± 1.7 9.16 ± 1.6 9.43 ± 2.1 1.55 ± 0.3* 1.43 ± 0.2* 
PGD2  479 ± 147 569 ± 53 171 ± 36* 522 ± 53.9 28.4 ± 4.04* 
PGA2  18.4 ± 4.6 2.37 ± 0.9* 2.94 ± 0.7* - - 
PGJ2 22.7 ± 4.5 31.7 ± 4.2 8.02 ± 1.8* 18.0 ± 2.2 1.13 ± 0.1* 
15-d-PGD2 62.2 ± 0.8 25.6 ± 5.1* 16.9 ± 2.9* 16.7 ± 1.4* 2.10 ± 0.4* 
15-d-PGJ2 44.8 ± 6.6 55.7 ± 7.3 49.5 ± 8.1 10.7 ± 1.4* 3.22 ± 0.7* 
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Figure 5-4 Polar plot representing changes in prostanoid levels of cortex normalized to sham at 5 and 120 
min after ROSC in 9 and 12 min CA models. Significant changes were observed in the cortical levels of 
prostanoids at 5 min after ROSC in both 9 and 12 min CA groups. At 120 min majority of the prostanoids 
returned to sham or below sham levels in both groups.  
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Figure 5-5 Significant changes in the prostanoids levels in the cortex at 5 and 120 min after ROSC in 9 and 
12 min CA models. At 5 min ROSC 6-keto-PGF1α, and PGF2α significantly increased in 12 min CA group 
whereas PGE2, and 15-d-PGJ2 levels decreased significantly. At 120 min majority of prostanoids decreased 
significantly in 12 min CA group except 6-keto-PGF1α.  
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Figure 5-6 Polar plot representing changes in prostanoid levels in midbrain normalized to sham at 5 and 
120 min after ROSC in 9 and 12 min CA models. Significant changes were observed in the levels of 
prostanoids in midbrain at 5 min after ROSC in 9 min CA group. At 120 min majority of the prostanoids 
returned to sham or below sham levels in both groups. 
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Figure 5-7 Significant changes in the prostanoids levels in the midbrain at 5 and 120 min after ROSC in 9 
and 12 min CA models. At 5 min ROSC 6-keto-PGF1α, and PGF2α significantly increased in 12 min CA 
group whereas PGE2, PGF1α, and 15-d-PGD2 levels decreased significantly. At 120 min majority of 
prostanoids decreased significantly in 12 min CA group except 6-keto-PGF1α. 
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5.3.4 Effect of CA duration on the CYP eicosanoid levels in the cortex after ROSC in 
pediatric asphyxial cardiac arrest 
CYP eicosanoid levels in the cortex and midbrain at 5 and 120 min after ROSC were 
evaluated in both 9 and 12 min CA models. In 9 min CA model, 5 min after ROSC significant 
increases in the levels (pmol/g tissue) of 20-HETE (6.79±1.4 vs 3.78±0.4; *p<0.05), 8,9-EET 
(39.3±9.3 vs 2.66±0.34; *p<0.01), 14,15-EET (44.6±13.3 vs 7.43±2.8; *p<0.01) and the 
corresponding DHET metabolites 8,9-DHET (1.31±0.2 vs 0.86±0.1; *p<0.05), 14,15-DHET 
(4.17±0.7 vs 1.41±0.2; *p<0.001) were observed in cortex as compared to sham rats (Table 5-4). 
However fold changes in the levels of 8,9-EET and 14,15-EET with respect to sham were higher 
than that of 20-HETE. At 120 min after ROSC, 20-HETE levels decreased whereas 15-HETE 
levels (291±51 vs 173±27; *p<0.05) significantly increased in cortex as compared to sham rats. 
Though 8,9-EET and 14,15-EET levels decreased at 120 min they were still higher than sham but 
were not statistically significant. In 12 min CA model, during the early reperfusion at 5 min, 
significant increases in cortex were only observed in the levels of 20-HETE (12.8±2.8 vs 
3.78±0.41; *p<0.01), and 14,15-DHET (3.39±0.73 vs 1.41±0.2; *p<0.05) as compared to sham 
rats. However, fold change in 20-HETE levels relative to sham in the early phase of reperfusion 
was higher in 12 min CA as compared to 9 min CA. At 120 min, there were no significant increases 
in the levels of any metabolites. Fold changes in the levels of all CYP eicosanoids in the cortex 
with respect to sham at 5 and 120 min after ROSC in 9 and 12 min CA was depicted in a polar plot 
(Figure 5-8). Each spike represents a CYP eicosanoid, and the radius of the circle represents fold 
changes normalized to sham. CYP eicosanoids with significant changes compared to sham were 
separately shown in Figure 5-9.  
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5.3.5 Effect of CA duration on the CYP eicosanoid levels in the midbrain after ROSC in 
pediatric asphyxial cardiac arrest 
Similarly, in 9 min CA no significant increases in 20-HETE levels were observed at 5 min 
after ROSC in the midbrain but an increase in 8,9-EET (80.3±21.1 vs 2.31±0.5; *p<0.01), 14,15-
EET (46.5±12.8 vs 14.6±6.0; *p<0.05), and 8,9-DHET (4.14±0.9 vs 1.59±0.3; *p<0.05) were 
observed as compared to sham rats (Table 5-5). At 120 min, only 15-HETE (375±44 vs 154±14; 
*p<0.05) levels significantly increased in the midbrain. No significant changes in the levels of any 
metabolites were observed in midbrain in 12 min CA. Fold changes in the levels of all CYP 
eicosanoids in the midbrain with respect to sham at 5 and 120 min after ROSC in 9 and 12 min 
CA was depicted in a polar plot (Figure 5-10). Each spike represents a CYP eicosanoid, and the 
radius of the circle represents fold changes normalized to sham. CYP eicosanoids with significant 
changes compared to sham were separately shown in Figure 5-11. 
Table 5-4 Effect of CA duration on temporal profile of CYP eicosanoid levels (pmol/g tissue) in brain 
cortex after ROSC 
Analyte 
CA Sham 9 min 12 min 
ROSC(min)        5 120 5 120 
20-HETE  3.78 ± 0.4 6.79 ± 1.4* 4.14 ± 0.5 12.8 ± 2.8* 5.35 ± 0.6 
15-HETE  173 ± 27.2 143 ± 19.2 291 ± 51.1* 211 ± 31.5 171 ± 61.6 
12-HETE  1649 ± 366 793 ± 61 1379 ± 191 1732 ± 275 1453 ± 478 
8,9-EET  2.66 ± 0.3 39.3 ± 9.3* 15.9 ± 6.6 2.74 ± 0.3 2.81 ± 0.6 
11,12-EET  11.8 ± 4.3 20.9 ± 5.2 13.9 ± 4.9 3.79 ± 0.3 5.18 ± 0.8 
14,15-EET  7.43 ± 2.8 44.6 ± 13.3* 17.8 ± 6.7 5.78 ± 1.6 3.86 ± 0.6 
5,6-DHET  0.63 ± 0.05 1.10 ± 0.1 0.82 ± 0.1 0.84 ± 0.2 0.91 ± 0.2 
8,9-DHET  0.86 ± 0.1 1.31 ± 0.2* 0.95 ± 0.1 1.03 ± 0.1 0.81 ± 0.1 
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11,12-DHET 1.29 ± 0.2 2.23 ± 0.6 1.18 ± 0.2 1.90 ± 0.1 1.34 ± 0.4 
14,15-DHET 1.41 ± 0.3 4.17 ± 0.7* 1.36 ± 0.3 3.39 ± 0.7* 1.38 ± 0.3 
 
 
Table 5-5 Effect of CA duration on temporal profile of CYP eicosanoid levels (pmol/g tissue) in the 
midbrain after ROSC  
Analyte 
CA Sham 9 min 12 min 
ROSC (min)        5 120 5 120 
20-HETE  4.58 ± 0.8 6.34 ± 1.0 5.05 ± 0.6 7.75 ± 0.8 6.30 ± 1.2 
15-HETE  154 ± 14 258 ± 39 375 ± 44* 144 ± 20 119 ± 35 
12-HETE  1440 ± 170 974 ± 79 1263 ± 346 1207 ± 173 1141 ± 307 
8,9-EET  2.31 ± 0.5 80.3 ± 21* 41.1 ± 7.93 3.27 ± 0.6 3.05 ± 0.4 
11,12-EET  20.2 ± 7.7 51.4 ± 15.1 35.1 ± 6.6 4.48 ± 0.8 3.66 ± 0.9 
14,15-EET  14.6 ± 6.0 46.5 ± 12.8* 33.4 ± 5.7 4.19 ± 0.7 2.53 ± 0.2 
5,6-DHET  1.11 ± 0.1 1.88 ± 0.3 1.33 ± 0.2 1.32 ± 0.1 1.15 ± 0.13 
8,9-DHET  1.59 ± 0.3 4.14 ± 0.9* 3.20 ± 0.5 1.18 ± 0.2 1.13 ± 0.04 
11,12-DHET 1.89 ± 0.5 2.94 ± 0.6 4.07 ± 0.9 1.42 ± 0.2 1.32 ± 0.1 
14,15-DHET 2.56 ± 0.3 2.40 ± 0.2 2.79 ± 0.5 2.32 ± 0.3 1.71 ± 0.5 
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Figure 5-8 Polar plot representing changes in CYP eicosanoid levels of cortex normalized to sham at 5 and 
120 min after ROSC in 9 and 12 min CA models. 8,9-EET and 14,15-EET levels were significantly elevated 
in 9 min CA at 5 min ROSC which decreased at 120 min.  In 12 min CA group 20-HETE levels were 
significantly elevated compared to 9 min CA group and the levels were still above sham levels at 120 min 
ROSC. 
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Figure 5-9 Significant changes in the CYP eicosanoids levels in the cortex at 5 and 120 min after ROSC 
in 9 and 12 min CA models. At 5 min ROSC 20-HETE levels significantly elevated in 12 m CA as compared 
to 9 min whereas 8,9-EET and 14,15-EET were significantly elevated in 9 m CA group. At 120 min ROSC 
EET levels significantly decreased in 12 min group whereas 20-HETE levels were above sham.  
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Figure 5-10 Polar plot representing changes in CYP eicosanoid levels of midbrain normalized to sham at 
5 and 120 min after ROSC in 9 and 12 min CA models. EETs and DHETs were significantly elevated at 5 
min ROSC in 9 min CA group which decreased significantly in 12 min CA. 20-HETE levels were 
significantly elevated in 12 min CA group at 5 min ROSC. At 120 min ROSC, EET levels returned to 
normal in 12 min CA group whereas they were above sham levels in 9 min CA group.  
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Figure 5-11 Significant changes in the CYP eicosanoids levels in the midbrain at 5 and 120 min after ROSC 
in 9 and 12 min CA models. At 5 min ROSC 8,9-EET, 14,15-EET, and 8,9-DHET levels were significantly 
elevated in 9 min CA group and decreased significantly in 12 min CA group. At 120 min ROSC, EET and 
DHET levels were above sham levels in 9 min CA group whereas they decreased to sham levels in 12 min 
CA group.  
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5.3.6 Effect of HET0016 treatment on cerebral blood flow in cortex after ROSC in pediatric 
asphyxial cardiac arrest 
The effect of acute HET0016 treatment on CBF at 5, 10, 30, and 60 min after ROSC in a 
12 min CA was evaluated and compared against vehicle. Cortical CBF in vehicle treated rats 
rapidly declined to 77.8 ± 4.2% of baseline at 5 min post resuscitation and continued to decline 
sharply till 30 min to 56.1 ± 2.5 % of baseline and sustained from there onwards till 60 min (Figure 
5-12). A significant increase in the cortical CBF was observed at 5 min and 10 min after 
resuscitation from 12 min CA in HET0016 as compared to vehicle treated rats (% CBF at 5 min: 
101 ± 12.5% vs 77.8 ± 4.2%; at 10 min: 91.6 ± 14.2% vs 69.5 ± 4.6%; *p<0.05) rats.  
 
 
 
 
 
 
 
 
 
 
Figure 5-12 Effect of HET0016 treatment on cortical blood flow after ROSC in 12 min CA. Acute 
HET0016 administration significantly increased CBF at 5 and 10 min post resuscitation as compared to 
vehicle treated group.  
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5.3.7 Effect of HET0016 treatment on CYP eicosanoid and prostanoid levels in cortex and 
midbrain after ROSC in pediatric asphyxial cardiac arrest 
The effect of acute dosing of HET0016 at the time of resuscitation on the levels of CYP 
eicosanoids and prostanoids in cortex and midbrain was evaluated at 5 min after ROSC in a 12 
min CA model. HET0016 treatment significantly reduced 20-HETE levels (1.99 ± 0.20 vs 8.06 ± 
1.33 pmol/g tissue; *p<0.001) in cortex and midbrain (3.18 ± 0.22 vs 6.44 ± 0.89 pmol/g tissue; 
*p<0.05) but did not change the levels of other eicosanoid metabolites as compared to vehicle 
treated group (Table 5-6). Fold changes in the levels of all CYP eicosanoids after HET0016 
treatment in the cortex with respect to sham at 5 min after ROSC in 12 min CA was depicted in a 
polar plot (Figure 5-13). HET0016 treatment did not change the levels of the prostanoids in the 
cortex and midbrain as compared to vehicle treated group (Table 5-7). A summary of the 
physiological variables (mean arterial pressure, paCO2, pO2 and pH) at baseline and post 
resuscitation in rats treated with either vehicle or HET0016 is presented in Table 5-8. Treatment 
of HET0016 itself did not significantly change the physiological variables when compared to 
vehicle group at each time point after resuscitation. 
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Table 5-6 Effect of HET0016 treatment on the levels of CYP eicosanoids (pmol/g tissue) in the cortex and 
the midbrain at 5 min after ROSC in 12 min CA model 
Analyte 
CA (12 min) 
Cortex Midbrain 
Vehicle HET0016 Vehicle HET0016 
20-HETE 8.06 ± 1.3 1.99 ± 0.2* 6.44 ± 0.9 3.18 ± 0.2* 
15-HETE 473 ± 118 352 ± 42 495 ± 125 336 ± 78 
12-HETE 3698 ± 725 2953 ± 251 3932 ± 965 2753 ± 539 
8,9-EET 6.24 ± 1.0 5.66 ± 1.0 5.62 ± 0.7 6.82 ± 0.8 
11,12-EET 4.32 ± 0.6 4.39 ± 0.4 3.56 ± 0.4 4.70 ± 0.6 
14,15-EET 6.93 ± 0.9 6.55 ± 0.7 5.65 ± 0.8 6.64 ± 0.5 
5,6-DHET 0.64 ± 0.1 0.67 ± 0.1 0.98 ± 0.1 0.93 ± 0.1 
8,9-DHET 1.89 ± 0.2 2.00 ± 0.3 2.56 ± 0.3 2.08 ± 0.4 
11,12-DHET 1.82 ± 0.1 1.54 ± 0.1 2.09 ± 0.2 2.00 ± 0.2 
14,15-DHET 2.88 ± 0.4 2.15 ± 0.2 3.09 ± 0.2 2.29 ± 0.1 
 
 
Table 5-7 Effect of HET0016 treatment on the levels of prostanoids (pmol/g tissue) in the cortex and the 
midbrain at 5 min after ROSC in 12 min CA model 
Analyte 
CA (12 min) 
Cortex Midbrain 
Vehicle HET0016 Vehicle HET0016 
6-Keto-PGF1α 11.5 ± 0.9 11.9 ± 1.3 7.78 ± 0.7 7.32 ± 1.1 
11β-PGF2α 11.2 ± 1.2 12.4 ± 1.9 11.4 ± 1.1 9.75 ± 1.3 
PGF1α 1.88 ± 0.3 1.7 ± 0.3 1.92 ± 0.2 1.51 ± 0.2 
PGF2α 113 ± 10 116 ± 12 79.2 ± 7.9 71.1 ± 7.6 
PGE2 20.7 ± 2.6 19.1 ± 2.6 12.1 ± 0.7 11.2 ± 1.5 
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11-d-TXB2 0.50 ± 0.1 0.42 ± 0.1 0.93 ± 0.2 0.71 ± 0.1 
PGD2 820  ± 81 834 ± 88 661 ± 53 630 ± 51 
PGA2 0.73 ± 0.1 0.82 ± 0.1 1.16 ± 0.3 1.22 ± 0.1 
PGJ2 27.8 ± 5.2 20.49 ± 3.6 17.8 ± 2.3 20.2 ± 5.3 
15-d-PGD2 20.1 ± 2.1 14.2 ± 1.4 18.3 ± 1.6 15.0 ± 1.8 
 
 
Table 5-8 Physiological variables after treatment with either vehicle or HET0016 12 min CA model 
 Baseline 10 min 30 min 60 min 
MAP     
Vehicle 72.2 ± 4.7 84.7 ± 4.8 57.5 ± 3.7* 69.2 ± 5.2 
HET0016 71.0 ± 4.2 79.0 ± 4.8 50.0 ± 2.2* 58.3 ± 2.5 
     
PaCO2     
Vehicle 33.9 ± 1.7 31.5 ± 4.3 30.03 ± 1.9 36.4 ± 1.9 
HET0016 32.5 ± 0.8 28.6 ± 1.8 29.7 ± 1.9 41.9 ± 2.1* 
     
PaO2     
Vehicle 209 ± 12 432 ± 19* 443 ± 11* 378 ± 53* 
HET0016 224 ± 1.9 423 ± 12* 402 ± 25* 414 ±20* 
     
pH     
Vehicle 7.42 ± 0.01 7.29 ± 0.05* 7.46 ± 0.01 7.46 ± 0.03 
HET0016 7.43 ± 0.01 7.31 ± 0.02* 7.41 ± 0.03 7.40 ± 0.03 
MAP, Mean arterial pressure 
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Figure 5-13 Polar plot representing changes in CYP eicosanoid levels in the cortex normalized to sham at 
5 min after ROSC in 12 min CA model. Significant changes in the CYP eicosanoids levels are shown in 
separate plot (bottom panel). HET0016 administration significantly reduced cortical 20-HETE levels at 5 
min after ROSC as compared to vehicle treated group in a 12 min CA model.  
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5.3.8 Effect of HET0016 treatment on neurological deficit after asphyxial cardiac arrest 
The effect of acute HET0016 treatment on short-term neurologic deficits were evaluated 
at 3, 24, and 48 h after resuscitation from 12 min CA and compared against vehicle and sham 
groups. There was a time and treatment effect on the neurological outcome in vehicle and 
HET0016 treatment groups. At 3 h after ROSC there was moderate to severe neurological damage 
in rats receiving vehicle, which was significantly reduced by HET0016 treatment (52.2 ± 4.8% vs 
37.5 ± 9.9%; **p<0.01).  Rats in both treatment groups showed recovery from neurological 
damage over time. At 24 h vehicle treated rats showed mild neurological damage as compared to 
HET0016 group, which was significantly reduced by HET0016 (10.4 ± 4.9% vs 2.8 ± 0.8; 
**p<0.001). At 48 h vehicle treated rats still exhibited residual neurological damage whereas 
HET0016 treated rats did not show any signs of neurological damage indicating full recovery 
(Figure 5-14). Rats receiving sham surgery showed no signs of any neurological damage except 
very little at 3 h. 
Figure 5-14 Effect of HET0016 treatment on short-term neurologic deficit after 12 min CA. HET0016 
administration significantly decreased neurological deficit at 3 and 24 h after reperfusion as compared to 
vehicle treated group in a 12 min CA model.  
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5.3.9 Effect of HET0016 on neuronal death after asphyxial cardiac arrest 
The effect of HET0016 treatment on neuronal survival at 48 h after ROSC from 12 min 
CA was evaluated by FluoroJade-B and H&E staining. The 12 min CA induced significant 
neuronal death in vehicle treated rats as compared to sham operated rats (average no.of FluoroJade 
+ve cells: 41.4±9.6 vs 4.6±2.0; ***p<0.001), which was significantly reduced by HET0016 
treatment (22.8±6.9; **p<0.01). Similarly, H&E staining also revealed significant neuronal death 
in vehicle treated rats compared to sham (average no.of H&E +ve cells: 45.2±9.8 vs 5.0±1.8; 
***p<0.001), which was significantly reduced by HET0016 treatment (24.8±7.2). (Figure 5-15). 
Representative sections of brain from vehicle and HET0016 treated rats photographed under 
microscope with FluoroJade-B (green) and H&E staining (purple red) were also depicted (Figure 
5-15).  
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Figure 5-15 Effect of HET0016 treatment on neuronal death at 48 h after ROSC in a 12 min CA model. 
Top panel (A) shows degenerating neurons stained positively by Fluorojade-B and bottom panel (B) shows 
cells stained with H&E. Acute administration of HET0016 significantly decreased degenerating neuronal 
population as measured at the end of 48 h after reperfusion from 12 min CA when compared to vehicle 
treated group.  
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5.4 DISCUSSION 
The major findings of this study are i) reduction in the cortical CBF post resuscitation from 
cardiac arrest during both early and late reperfusion period increases significantly with the duration 
of the cardiac arrest, ii) significant changes in the levels of vasoconstrictive and vasodilatory 
prostanoids and CYP eicosanoids occurred in the early reperfusion period after 9 and 12 min CA, 
iii) acute administration of HET0016 significantly increased cortical CBF in the early reperfusion 
period after 12 min CA by significantly decreasing 20-HETE levels in the cortex, iv) 
administration of HET0016 significantly decreased neuronal death and increased short-term 
functional outcome following resuscitation from a 12 min CA. Collectively, these data suggest 
that CBF dysregulation in the cortex after resuscitation is dependent on the duration of ischemic 
injury and is related to the imbalance in the levels of vasoactive AA metabolites in cortex and that 
the acute administration of 20-HETE synthesis inhibitor, HET0016 improves short-term functional 
outcome by significantly increasing CBF.  
 
In previously reported experimental studies of CA, various techniques such as 
microspheres, Laser Doppler Flow (LDF) technology (Brown et al., 1986; Nozari et al., 1999; 
Nozari et al., 2000), Xenon-washout (Cohan, et al., 1989), MRI (Manole, et al., 2009; Xu, et al., 
2002b), and PET imaging (Heiss et al., 1998; Mortberg et al., 2007) were used to measure CBF 
before and after ROSC. LDF is not suitable to study inter-regional or global CBF, microspheres 
have disadvantage of non-homogenous mixing in blood, MRI, and PET are expensive and time 
consuming. In this study we measured CBF by laser speckle photometry, which is relatively 
inexpensive, fast, and allows accurate measurements of regional blood flow in the cortex. Our 
findings of CBF measurement with this technique suggest that CBF dysregulation during 
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reperfusion after global ischemic injury is dependent on the duration of the injury itself. 
Specifically, we observed that longer duration of asphyxia leads to immediate or delayed 
hypoperfusion in the cortex without any hyperemia. Further, we observed prolonged exposure of 
decreased CBF beginning as early as 30 min after resuscitation from CA in both 9 and 12 min CA 
models with the latter exhibiting significant reduction in CBF in the low perfusion phase compared 
to the 9 min injury. Previous studies in experimental animal models investigating reperfusion 
patterns after CA produced variable results with regards to hyperemia in cortex. While some 
studies indicated the presence of early hyperemia in cortex after CA in adult rats (Liachenko, et 
al., 2001), and young pigs (Mortberg, et al., 2007) other studies indicated absence of hyperemia in 
new born pigs (Goplerud et al., 1989; Leffler et al., 1989). The pattern of CBF changes after CA 
in pediatric rats is consistent with previously published data reporting hyperemia in subcortical 
structures and hypoperfusion in the cortex (Manole, et al., 2009; Manole, et al., 2012). This 
observation of post-ischemic hypoperfusion is consistent with previous animal studies in adult rats 
(Bottiger et al., 1997; Liachenko et al., 1998), young pigs (Mortberg, et al., 2007), and dog 
(Shaffner, et al., 1998). Together, these findings suggest the presence of a delayed post-ischemic 
hypoperfusion in cortex that is dependent on the severity of ischemic injury. 
 
Based on our findings from CBF analysis, we set out to investigate the vascular pathways 
of pathological CBF changes after resuscitation. Therefore, we quantified regional (cortex and 
midbrain), and temporal (5 and 120 min after ROSC) profile of prostanoids and CYP eicosanoids 
levels in the post-ischemic brain following CA. We have employed a lipidomics approach using 
our validated UPLC-MS/MS method to quantify a panel of various vasoactive AA metabolites. 
Our lipidomics analysis showed that both moderate and severe CA significantly increased the 
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concentrations of majority of prostanoids in the cortex at 5 min after reperfusion as compared to 
sham rats. However, concentrations in the midbrain were significantly lesser compared to sham 
rats at 5 min after reperfusion. In both regions, concentrations decreased at 120 min after 
reperfusion. However, 12 min CA has produced rapid decline in prostanoid levels than 9 min CA 
group at 120 min after reperfusion. The most abundant prostanoid in the cortex and midbrain of 
control rats in this study was PGD2, which increased following ischemic injury. This is consistent 
with the previous findings reporting prostaglandin concentrations in the ischemic brain of rat and 
gerbil (Kempski et al., 1987; Narumiya et al., 1982). Also, the order of the abundance of prostanoid 
levels measured in control rats in this study is consistent with the recent data measuring prostanoids 
at different intervals in hippocampus and cortex of sham pediatric rats (Liu et al., 2013b). Together, 
these data shows that ischemia and reperfusion injury produces differential changes in prostanoid 
levels that are region, time dependent, and prostanoid-specific.  
 
The effects of prostanoids on CBF regulation under normal and pathophysiological 
conditions are more complex to delineate as the net resultant effect depends not only on local 
concentrations but also on receptor subtype expression in the cerebral vasculature and the 
interaction with other vasoactive factors with overlapping signaling mechanisms. However, in this 
study changes in cortical blood flow during early and late reperfusion period after CA were 
correlated with ratio of cumulative vasoconstrictive (11β-PGF2α, PGF1α, PGF2α, 11-d-TXB2, 
PGA2) to vasodilatory (6-keto-PGF1α, PGE2, PGD2, PGJ2, 15-d-PGD2, 15-d-PGJ2) prostanoids in 
the cortex. We found that moderate CA (9 min) favored a shift towards a net vasodilatory effect at 
5 min after reperfusion although no hyperemia was observed whereas more severe CA (12 min) 
abolished such response in the cortex. This is consistent with our CBF findings observed at 5 min 
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after reperfusion where 12 min CA has significantly lower CBF than the 9 min CA group. This is 
further supported by steep increases in the vasodilatory PGD2, PGE2 prostanoids at 5 min after 
reperfusion in 9 min CA compared to 12 min CA. However, at 120 min after reperfusion there was 
a shift towards net vasoconstrictive effect, which was more pronounced in 12 min CA group as 
compared to 9 min CA. This is consistent with CBF response at 120 min, which is significantly 
lower in 12 min CA group. This is supported by rapid decline in the concentrations of prostanoids 
in 12 min CA than in 9 min. Though we did not measure blood flow in subcortical regions, our 
observation of prostanoid changes at 5 and 120 min in both 9 and 12 min CA groups are supportive 
of the findings of CBF in the thalamus as measured by ASL-MRI (Manole, et al., 2009). In this 
study Manole et al, reported hyperemia in the thalamus at 5 min after reperfusion and 
hypoperfusion at 120 min. Consistent with this findings, we found a decrease in the ratio of 
vasoconstrictor to vasodilatory prostanoids indicating a shift towards net vasodilatory effect at 5 
min and an increase in the ratio at 120 min indicating a shift towards net vasoconstrictive effect. 
Together, these findings suggest that CBF dysregulation in the post-ischemic phase are in part 
related to the imbalances in the ratio of vasoactive prostanoids that are injury severity, and 
reperfusion time dependent.  
 
Prostanoids exert diverse array of pharmacological actions sometimes functionally 
antagonizing depending on the membrane receptor they bind to and activate. For example, PGE2 
induces vasoconstriction through EP1 and EP3 receptors but induces vasodilation through EP2 
and EP4 receptors. This explains the PGE2 induced vasoconstriction and relaxation effects on 
MCA of adult baboon, adult cat basilar and MCA, and adult human pial and basilar arteries (Jadhav 
et al., 2004). (Thornhill et al., 1999). Further, vascular responses to PGE2 seems to be age 
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dependent as the expression of EP receptor subtypes may vary. For example, in newborn pigs, 
PGE2 dilates pial and intraparenchymal microvessels but in adults the same are constricted 
(Armstead et al., 1989; Li et al., 1994) whereas in premature and newborn baboons, PGE2 relaxes 
MCA, but in adults the same are constricted (Hayashi et al., 1985). Thus, PGE2 response seems to 
be preferential vasodilation in the new born, and a preferential vasoconstriction in adults. In our 
study, we found significant increases in the PGE2 levels in the cortex of PND 17 rats following 
ischemic injury. It may be possible that PGE2 in these rats exert vasodilatory effects preferentially 
but such conclusions need further investigations of receptor subtype expression in these rats under 
normal and ischemic conditions. Another surprising finding in our study was the levels of 6-keto-
PGF1α, a stable metabolite of prostacyclin (PGI2) in the cortex and midbrain of especially 12 min 
CA group where the levels were significantly higher at both 5 and 120 min post reperfusion. It 
would be expected that vasodilatory effects of prostacyclin dominate the net response but 
interestingly CBF in 12 min CA group at both 5 and 120 min are significantly lesser than 9 min 
CA group. One possible explanation suggested for this could be activation of IP and TP 
(thromboxane receptor) receptor by prostacyclin, which are functionally antagonistic. In a recent 
study, Liu et al described that COX-1 generated endothelial PGI2 dilator activity mediated by IP 
receptors can be compromised by a concomitant TP receptor activation (Liu et al., 2012). It may 
be possible that high concentrations of prostacyclin as seen in the cortex and midbrain in our study, 
activate both IP and TP receptors thus diminishing the overall dilatory effect of prostacyclin. 
Further investigations are needed to thoroughly understand relative contributions of specific 
receptor subtypes of prostanoids and the net effect on the cerebral vasculature under physiological 
and pathophysiological conditions.  
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The findings from prostanoid analysis suggest that an imbalance in tissue levels of these 
vasoactive prostanoids may be associated with the observed hypoperfusion during the post-
ischemic reperfusion phase. However, caution need to be exercised in extrapolating these findings 
to correct the CBF dysregulation using COX or specific prostanoid receptor inhibitors. Many 
different studies have evaluated the neuroprotective effects of COX or specific prostanoid receptor 
inhibitors in different ischemic models with contradictory findings on CBF enhancements. For 
example, prostacyclin infusion given at 2 h after reperfusion did not improve global CBF as 
measured by 133Xe clearance during the delayed post-ischemic hypoperfusion in a cat global 
cerebral ischemia model (van den Kerckhoff et al., 1983). In another study, inhibition of 
thrombaxane synthase did not decrease the hypoperfusion in the post-ischemic brain after global 
ischemia. Interestingly, TXA2 inhibition increased production of PGI2 in post-ischemic cerebral 
blood vessels (Prough et al., 1986). These studies concluded that PGI2 and TXA2 may not play a 
significant role in hypoperfusion after global ischemia and that further increasing the physiological 
levels of PGI2 may not dilate the cerebral vessels. In another study, Nishida et al reported that 
COX inhibitor diclofenac modulated fetal CBF response to hypoxia through systemic changes by 
decreasing MAP rather than affecting CVR and cerebral vascular tone (Nishida et al., 2006). 
However, administration of indomethacin along with the infusion of PGI2 attenuated the post-
ischemic hypoperfusion in a dog model of global ischemia (Hallenbeck et al., 1982). On the other 
hand, PGD2 DP1 receptor knockout mice showed increased infarct size in a focal cerebral ischemia 
model however, no differences in CBF (measured by LDF) were observed during ischemia or 1 h 
post reperfusion between WT and DP1-/- mice. In yet another study, EP1 receptor knockout mice 
has significantly improved CBF in vivo after focal ischemia and increased neuronal survival in in 
vitro neuronal cultures (Saleem et al., 2007). Though we found association between imbalances in 
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vasoactive prostanoids, and CBF dysregulation in the post-ischemic brain cortex, together these 
findings suggest that prostanoids alone may not explain all of the observed phenotype of 
hypoperfusion in the cortex after CA. This is could likely be due to more prominent effects of 
prostanoids on larger cerebral arteries with minimal effects on the resistance vessels, and the total 
CVR. Vasoactive properties of prostanoids in general on cerebral vasculature was largely 
evaluated in large cerebral arteries such as MCA, basilar, and pial arteries of different species. 
However, their effects on resistance microvessels, total CVR, and changes in CBF during 
pathological conditions such as ischemia needs further investigation in order to fully elucidate the 
role of prostanoids in pathophysiological regulation of CBF. 
 
We further quantified the CYP eicosanoids from the same tissue used for prostanoids 
measurement. Our lipidomics analysis showed that the vasoactive CYP eicosanoids are formed 
early after CA and returned to normal levels during the late reperfusion period in both 9 and 12 
min CA. Specifically, we observed that during early reperfusion period there is prominent 
increases in vasodilatory EET metabolites and their breakdown products DHETs in the brain 
cortex of rats subjected to shorter duration of asphyxia and prominent increase in vasoconstrictive 
20-HETE in longer duration of asphyxia. The ratio of 20-HETE and EETs indicated that in the 
early reperfusion period eicosanoid equilibrium is shifted towards a vasodilatory effect in shorter 
ischemic insult and towards a vasoconstrictive effect in longer ischemic insult. This is consistent 
with CBF observation in 12 min CA, which is significantly lower than in 9 min CA group. 
Interestingly, there was no hyperemia observed in the cortex with shorter asphyxial arrest even 
though EETs levels were elevated higher than that of 20-HETE. This could be due to the rapid 
degradation of EETs to DHETs as evident in 9 min CA group. In the midbrain, during the early 
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reperfusion period after 9 min CA there was massive increase in the levels of EETs in the absence 
of any changes in 20-HETE, favoring towards a significant vasodilatory effect. This is consistent 
with the findings of Manole et al., who reported hyperemia in the thalamus at 5 min after 
reperfusion as measured by ASL-MRI (Manole, et al., 2009). During late reperfusion period, 
concentrations of most of the metabolites in cortex and midbrain returned to at or below baseline 
levels irrespective of duration of asphyxia with the exception of 15-HETE, which was significantly 
elevated in the cortex and midbrain of rats subjected to 9 min CA. This could be likely due to 
either substrate or enzyme depletion, or further metabolism to other substances. Hypoperfusion in 
the cortex was seen in both 9 and 12 min CA with the effect being more pronounced in longer 
insult. This phenomenon is consistent with previously published data from different animal models 
(Bottiger, et al., 1997; Liachenko, et al., 1998; Mortberg, et al., 2007; Shaffner, et al., 1998). 
Together, these findings suggest that vasculature in the cerebral cortex may be especially 
vulnerable to impaired vascular patency in global ischemia and that no-reflow phenomenon can 
occur as a result of impaired vascular patency, which is in turn dependent on the duration of the 
global ischemia (Fischer, et al., 1995; Kagstrom et al., 1983b). It has been shown previously that 
cerebral cortex is more vulnerable to global ischemia (Geraghty et al., 2006; Martin, et al., 1997). 
In a study by Buunk et al, they reported high endothelin levels, decreasing nitrate levels, increasing 
cGMP levels in comatose patients resuscitated from cardiac arrest suggesting the presence of 
active cerebral vasoconstriction due to an imbalance in local vasoconstrictors and dilators (Buunk 
et al., 1996). In yet another study, CBF was improved by abolishing the abnormal vasoconstriction 
using endothelin type-A antagonist in a rat CA model (Krep et al., 2000; Krep et al., 2003). To our 
knowledge, there is no study published so far evaluating the impact of vasoconstrictors of 
microvasculature on the CBF changes during the reperfusion phase in a global ischemic brain 
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injury model. The preset findings of our study produce the first evidence of an imbalance in the 
levels of vasoconstrictive and vasodilatory CYP eicosanoids and their possible link to the delayed 
hypoperfusion in the cortex after global cerebral ischemia.  
 Our findings from CBF assessment and CYP eicosanoid levels measurement suggested a 
prominent role of vasoconstriction in the early and delayed hypoperfusion in a 12 min CA model. 
Thus, we set out to delineate the role of 20-HETE by using synthesis inhibitor HET0016 on CBF 
changes in a 12 min CA model. Our results showed that acute treatment of low dose HET0016 at 
the time of resuscitation significantly increased CBF in the cortex consistent with the significant 
reduction of 20-HETE levels during the early reperfusion period when compared to vehicle 
treatment. There was no change in the levels of other CYP eicosanoids and prostanoids due to 
HET0016 treatment as compared to vehicle indicating the specificity of the inhibition at the given 
dose. Further, HET0016 treatment did not significantly change physiological variables such as 
MAP, paCO2, pO2, and pH at any time after resuscitation when compared to vehicle treated group. 
Our findings of HET0016 effect on CBF is similar to our previous data showing significant 
reduction in the attenuation of CBF in post-ischemic hypoperfusion phase in a rat focal ischemia 
model (Poloyac, et al., 2006) but contradictory to the data by Yang et. al, (Yang, et al., 2012) who 
reported no significant changes in CBF measured by LDF in a neonatal piglet hypoxia-ischemia 
model. This could be due to different reasons such as i) different animal model, ii) difference in 
the CBF measurement technique, iii) different time of administration of HET0016 (during 
resuscitation versus 5 min after resuscitation), and v) different doses of HET0016 (0.9 mg/kg vs 
10 mg/kg). In our study we observed significant elevation of 20-HETE at 5 min after resuscitation 
and corresponding significant decreasing in CBF, thus we chose to administer HET0016 during 
resuscitation. Further, higher dose of HET0016 may produce concentrations in brain beyond its 
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selectivity index for CYP4A/4F enzymes, inhibiting CYP2C/2J enzymes that form vasodilatory 
EETs. Thus, we acutely administered a lower dose of HET0016 in our pediatric rat asphyxial CA 
model. Together, these findings suggest that HET0016 significantly improves cortical CBF during 
early reperfusion phase after 12 min CA by significantly reducing 20-HETE levels in the cortex.  
 
 The findings of HET0016 treatment on cortical CBF and eicosanoid levels in the cortex 
led us to investigate the impact of HET0016 on neuronal survival and short-term functional 
outcome. Our data indicated that the 12 min CA produced moderate to severe neurological damage 
during early reperfusion phase, which was significantly reduced by HET0016. Rats showed 
recovery from damage over time, however, HET0016 showed full recovery by 48 h after 
reperfusion whereas vehicle treated rats still exhibited residual neurological damage as assessed 
by functional outcome experiments. Further, staining of brain sections collected at 48 h from 
reperfusion by FluoroJade-B for degenerating neurons (green) indicated that our injury model 
produced moderate neuronal death, which was significantly reduced by HET0016 treatment. Our 
findings of neuroprotective effects of HET0016 are consistent with the data published by Yang et 
al in a neonatal piglet hypoxic-ischemia model. Further, Yang et al, showed that 20-HETE 
increases the phosphorylation of NMDA receptor NR1 subunit selectively at protein kinase-C 
sensitive sites indicating a direct effect of 20-HETE in mediating excitotoxicity (Yang, et al., 
2012). Our studies showed the evidence of increased CBF after HET0016 treatment indicating a 
possible role of vascular mechanism whereas data from Renic et al, on protective effect of 
HET0016 on hippocampal slice cultures from oxygen-glucose deprivation (Renic, et al., 2012), 
neuronal localization of CYP4A in putamen of pig (Yang, et al., 2012), and in post-ischemic 
cortical neurons of adult rat (Omura, et al., 2006) suggest possible activation of neuronal signaling 
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cascade indicating role of a non-vascular mechanisms of neuroprotection. Future studies need to 
be completed evaluating the degree to which microvascular flow changes contribute to 
neurovascular protection in global cerebral ischemia. Together, these data suggest that 
neuroprotection by 20-HETE inhibition may likely be mediated by both blood flow changes and 
direct cytoprotective effects on neurons.  
 
There are possible limitations to this study. One of the limitations is that regional and temporal 
distribution of CYP eicosanoids and prostanoids was done over relatively shorter duration of post-
ischemic reperfusion period. Future studies will include temporal profiling of AA metabolites from 
different brain regions over longer time intervals extending into one week after ischemic injury for 
fully characterizing the time they peak and return to basal levels. This will help in determining the 
therapeutic window of time for administering small molecule inhibitors like HET0016, which has 
relatively shorter half-life in vivo (Mu et al., 2008). In this study, we administered HET0016 
acutely as it has shorter half-life and at low dose as high concentrations can inhibit EET synthesis. 
A future direction of this study includes continuous infusion of low dose HET0016 at different 
intervals during post-ischemic reperfusion to achieve target concentrations in the selectivity range 
in order to evaluate effects of chronic inhibition on long-term functional outcomes, and on the 
regional CBF in the extended period of post-ischemic reperfusion. Additional studies with the 
antagonists of 20-HETE will confirm if the protective effects of HET0016 are direct or mediated 
through 20-HETE inhibition. Another future direction includes administering COX inhibitor 
individually and along with HET0016 to elucidate the relative contributions of prostanoids and 
CYP eicosanoids on pathological CBF regulation in the cortex during post-ischemic reperfusion. 
A second limitation is that we did not evaluate the direct neuroprotective effects of HET0016 in 
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in vitro neuronal cultures. Future studies will evaluate the neuroprotective efficacy of HET0016 
over a wider concentration under ischemic conditions.  
 
5.5 CONCLUSIONS 
In summary, in the current study we have described the pattern of CBF dysregulation 
during the post-ischemic reperfusion phase after different durations of CA and first time reported 
full profile of regional and temporal distribution of CYP eicosanoids and prostanoids in the rat 
brain after global ischemic injury. Further, we have produced the first evidence of an imbalance in 
the tissue levels of vasoactive CYP eicosanoids and their relationship to pathological changes in 
cortical blood flow during post-ischemic reperfusion. Further, we have showed that HET0016 
improves cortical CBF during the early reperfusion phase after 12 min CA by selectively inhibiting 
20-HETE levels in the cortex. In addition to CBF improvements, we showed significant reduction 
in neuronal death and improved short-term behavioral performance after a single low dose 
administration of HET0016.  
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6.0 CONCLUSIONS AND FUTURE DIRECTIONS 
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6.1 Summary and conclusions 
The main objective of this research was to investigate the role of CYP eicosanoids in the 
cerebral ischemic injury. This was achieved by studying the effect of CYP eicosanoids on the 
individual components of neurovascular unit in in vitro and in vivo models of ischemia by using 
small molecule pharmacological inhibitors. In order to systematically evaluate the effects, in vitro 
primary neuronal cultures, a focal and global ischemic rat models were utilized. In addition, 
advanced analytical assays and sophisticated blood perfusion imaging systems were used in this 
research to further understand the relationship between CYP eicosanoids, and CBF changes. 
Finally, modulation of specific CYP eicosanoid pathways by pharmacological inhibitors were 
assessed for their potential impact on improving neurofunctional outcome, a necessary criteria 
suggested by STAIR for translating preclinical findings from a relevant animal model to clinical 
stroke research. Several key findings are made from this research, which are summarized in the 
following section.  
 
In the first part of this research, we have developed and validated a robust and rapid UPLC-MS/MS 
assay for quantitating a wide range of AA metabolites including CYP eicosanoids and prostanoids 
from same tissue extract. Further, this is the first validated method to report quantification of 
cyclopentenone prostanoid metabolites (PGA2, PGJ2, 15-d-PGJ2) in rat brain tissue. In this and 
other Chapters of this research, we have successfully applied this method not only to profile 
regional and temporal distribution of the AA metabolites in the rat brain after cerebral ischemic 
injury but also to test the specificity of the pharmacological inhibitors. This lipidomics based 
method offers a potential advantage in identifying potential biomarkers that may be critical in 
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disease progression and may be viable therapeutic targets for mitigating secondary neuronal 
damage after ischemic injury. 
 
In the second part of this research, we evaluated the neuroprotective effects of CYP eicosanoids 
over a wide concentration range in in vitro rat primary cortical neuronal cultures under normoxic 
and hypoxic conditions. We verified that the CYP eicosanoids are relatively stable and readily 
taken up by neurons under the incubation conditions and that they can be exogenously 
administered to neuronal cultures. We demonstrated three novel findings from this study. First, 
11,12-EET is protective even under normoxic conditions at relatively high concentrations. Second, 
20-HETE exhibited concentration dependent toxic effects and these effects are potentiated only 
after a hypoxic-ischemic event. Third, 11,12-EET showed concentration dependent 
neuroprotective effects in hypoxic injury. These findings from Chapter 3, suggest a possible role 
for the non-vascular mechanism of neuroprotection by CYP eicosanoids in ischemic injury. 
 
In the third part of the study, we have evaluated the in vivo protective effects of CYP eicosanoids 
in a focal ischemia model of rat MCAO using t-AUCB, a pharmacological inhibitor of sEH. We 
have demonstrated the neuroprotective effects of t-AUCB at a low dose. This study is the first to 
report that acute t-AUCB administration increases cumulative EETs/DHETs ratio in the cortex 
and is associated with the observed neuroprotective effects. Further, we have applied our 
lipidomics method and showed that t-AUCB did not change the levels of other AA metabolites 
from CYP4A, CYP4F, and COX pathways indicating the specificity of sEH inhibition. In addition, 
these data are the first to demonstrate improved short-term behavioral performance by t-AUCB by 
evaluating motor and somatosensory behavior. Functional outcome improvements is one of the 
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important criteria suggested by STAIR for successfully translating preclinical drug candidates to 
further clinical development in stroke research, and our findings provide evidence that t-AUCB 
meets this criteria. We have also demonstrated for the first time that exogenous t-AUCB 
administration to primary cortical neuronal cultures significantly increases their survival in a 
concentration dependent manner in a hypoxia-reoxygenation injury model. Further, we have 
showed that acute sEH inhibition by t-AUCB has marginal improvements in CBF around the 
infarcted area during the post-ischemic hypoperfusion period. These findings from Chapter 4 
suggest that altering EETs levels by acute inhibition of sEH is likely to produce the largest benefits 
by affecting multiple components of neurovascular unit. 
 
In the final part of this study, we have evaluated the in vivo protective effects of CYP eicosanoids 
in a global ischemia model of pediatric asphyxial CA using HET0016, a pharmacological inhibitor 
of CYP4A/4F. We have described the pattern of CBF dysregulation during the post-ischemic 
reperfusion phase after different durations of CA. We have for the first time described a 
comprehensive profile of regional and temporal distribution of CYP eicosanoids and prostanoids 
in the rat brain after global ischemic injury. Further, we have produced the first evidence of an 
imbalance in the tissue levels of these vasoactive AA metabolites and their possible association 
with pathological changes in CBF in the cortex post resuscitation from different durations of CA. 
We have selected HET0016, inhibitor of synthesis of 20-HETE, a potent constrictor of 
microvasculature and showed that acute HET0016 administration improves cortical CBF during 
the early reperfusion phase after 12 min CA by selectively inhibiting 20-HETE levels in the cortex. 
We confirmed the selectivity of this inhibition using our validated analytical method. In addition 
to CBF improvements, we showed significant reduction in neuronal death and improved short-
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term behavioral performance after low dose administration of HET0016. These findings from 
Chapter 5 suggest that correcting the imbalance in the tissue levels of vasoactive CYP eicosanoids 
improves CBF at least during the initial phase of reperfusion and improves short-term functional 
outcome. 
 
6.2 Clinical relevance 
 
1) Several clinical studies have shown that polymorphisms in the genes encoding CYP 
enzymes that result in altered levels of AA metabolites are associated with increased risk 
for stroke in some specific patient population. The findings of this study also showed that 
modulation of CYP pathway of AA metabolism in ischemic injury by small molecule 
inhibitors affects multiple components of neurovascular unit and improves functional 
outcome. These findings help us to gain a better insight into the role of brain CYP450 
enzymes in endogenous fatty acid metabolism particularly of AA and their relationship to 
cerebrovascular diseases such as stroke.  
 
2) This research facilitates the understanding of the CYP eicosanoids role in the progression 
of cerebral ischemic injury. We showed that duration and severity of CBF reduction in the 
cortex of post-ischemic brain is dependent on the tissue levels of CYP eicosanoids. Several 
clinical studies have also shown the evidence of increased levels of AA and CYP 
eicosanoids in the CSF of stroke patients.  Thus, CYP eicosanoids can serve as potential 
biomarkers for assessing the severity of CBF reductions during the reperfusion phase of 
the post-ischemic brain and thereby identifying patients at risk for secondary neurological 
complications of stroke.  
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3) In the last two decades of stroke research, several therapeutic agents have failed in the 
clinical trials. From the drug development perspective, the failures could be ascribed to the 
lack of efficient target engagement due to poor permeability across BBB and/or to the lack 
of assessing target engagement. The research paradigm applied in this study addresses the 
first problem by improvising drug delivery using formulations made of HPβCD, and the 
second problem by using lipidomics analysis to quantify an array of biomarkers to ensure 
target engagement. This approach has potential clinical value in designing therapeutic 
strategies for optimum dosing in order to maximize the efficacy of the therapeutic agents 
by achieving relevant drug concentrations in the brain.  
 
6.3 Future directions 
 The findings of this work provides the basis and foundation for future preclinical studies 
and opens up avenues to further investigate the mechanistic underpinning of the CYP eicosanoids 
effects in cerebral ischemia. These future studies can generate additional evidence in support of 
the primary findings of this research. There are several future directions to this body of work, 
which are listed in the following section.  
 
The lipidomics method developed and used in this work is applicable to measure tissue levels of 
CYP eicosanoids and prostanoids. However, additional studies are needed in future to develop and 
validate the method for measuring these metabolites in biological fluids such as plasma or CSF in 
order to extend its scope for clinical applications. We have performed in vitro evaluations in pure 
neuronal cultures alone under hypoxic conditions. However, further studies in pure astrocytes or 
mixed neuron-astrocytic cultures are needed in future to evaluate the neuroprotective effects of 
CYP eicosanoids in the context of neurovascular unit. For example, adding the media from 
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astrocyte cultures treated with CYP eicosanoids to neuronal cultures will help in teasing out the 
effects of CYP eicosanoids on individual cell types and/or in mixed cultures. Additionally, more 
in vitro studies are warranted to investigate the signaling pathways activated by CYP eicosanoids 
after ischemic injury. For example, electrophysiology experiments evaluating direct effect of 
individual CYP eicosanoids on different ion channels that are linked to excitotoxicity and Ca2+ 
overload will help in differentiating the protective mechanisms of CYP eicosanoids. At present, a 
putative 20-HETE or EET receptor has not been identified. Thus, there is need for identifying CYP 
eicosanoid receptor in order to gain an insight into the molecular mechanisms of neuroprotection.  
 
Throughout this study, ischemia was assessed by measuring CBF changes alone after the stroke 
and/or CA. However, it is observed that oxygen and glucose extraction increase as the blood flow 
is reduced. So the decrease in the oxidative metabolism can be less than the fall in CBF, which 
means even during the hypoperfusion period neurons in selective regions might survive as long as 
the oxidative metabolism remains above a certain threshold. Thus, another future direction to this 
work includes cerebral metabolic rate of oxygen (CMRO2) assessments along with CBF 
measurements to better serve as a predictor of neuronal survival after ischemic injury. Additional 
studies assessing the extent of autoregulatory dysfunction after ischemic injury in global and focal 
ischemia models will aid in developing small molecule inhibitors that can restore autoregulation 
of CBF. 
 
Reperfusion after initial ischemic event burdens the system with free radicals increasing the 
oxidative stress and initiating inflammatory response. Thus, another future direction to this work 
includes measurement of the markers of oxidative stress such as 8-isoprostanes and pro-
inflammatory cytokines such as IL-6 to elucidate underlying effector mechanisms involved in the 
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pathogenesis of ischemic damage. The regional and temporal distribution of CYP eicosanoids and 
prostanoids was done over relatively shorter duration of post-ischemic reperfusion period. Further 
studies are needed to describe temporal profile of AA metabolites from different brain regions over 
longer time intervals extending as long as one week after ischemic injury for characterizing the 
time they peak and return to basal levels. In addition, CBF measurement should be taken over the 
same interval in order to correlate with tissue levels.  
 
In this work acute administration of low doses of HET0016 and t-AUCB were individually 
evaluated for their protective effects in different animal models of ischemia. Though both 
HET0016 and t-AUCB showed neuroprotection in this study, HET0016 showed evidence of 
neuroprotection through both vascular and non-vascular mechanisms. Also, sEH inhibitors may 
not be preferable to use in chronic conditions with comorbid diseases such as cancer due to the 
potential angiogenic effects of EETs. Thus their use may be limited to acute applications.  Thus, 
HET0016 appears to be a good candidate for further clinical development. A future direction of 
this work includes administering the inhibitor at different intervals after reperfusion to establish 
the therapeutic time window of neuroprotection. Additional studies are warranted for establishing 
a dose-response curve and chronic dosing to evaluate the impact on the regional CBF in the 
extended post-ischemic reperfusion phase and on long-term functional outcome. Another possible 
future direction to this work includes, a synergistic combination of both pharmacological inhibitors 
to maximize the neuroprotection however the dosing strategy must be optimized to ensure that 
there is no cross-inhibition to nullify the protective effects of each other. Another future direction 
includes antagonists of CYP eicosanoids to confirm if the protective effects of these inhibitors are 
direct or mediated through CYP eicosanoids. Another potential strategy in the development of 
pharmacological inhibitors would be repurposing clinically approved medicines for other 
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indications with potential effect on CYP eicosanoid system. For example, Fingolimod, a 
sphingosine-1-phosphate receptor modulator is clinically used for treating multiple sclerosis. 
Fingolimod is a major substrate for CYP4F2 which could probably be used as a competitive 
inhibitor of AA metabolism to reduce 20-HETE levels. Such approaches will help in advancing 
clinical development of pharmacological inhibitors of CYP eicosanoid pathway.  
 
Some of the major disadvantages of pharmacological inhibitors are that sometimes they may not 
offer required selectivity at the in vivo concentrations achieved, and may exert off-target effects 
that are unavoidable. Genetic tools such as transgenic mice overexpressing a particular CYP or 
knockout animals devoid of a particular CYP are indispensable tools to investigate the underlying 
molecular mechanisms of CYP enzymes in cerebral ischemic injury. We have created a humanized 
mouse overexpressing CYP4F2 under the Tie2 promoter of vascular endothelium. Initial 
experiments of functional characterization were performed. Future in vivo studies with these 
transgenic animals are needed to be done to investigate the role of 20-HETE produced from 
CYP4F2 in cerebral ischemia after stroke or cardiac arrest. These studies will corroborate the 
findings from pharmacological inhibitor studies and also give more insight into the effects of 
overexpressed CYP4F2 and its AA metabolite 20-HETE under normal and ischemic conditions. 
Further, these transgenic animals could also be used to investigate the role of CYP4F2 generated 
20-HETE in other diseases of cardiovascular, and renal system.   
 
In conclusion, the results of the work performed throughout this thesis research could have 
important clinical implications, since altered tissue levels of CYP eicosanoids are related to CBF 
dysregulation, ischemic brain injury, and worse functional outcomes. Pharmacological inhibitors 
could potentially mitigate or reduce the ischemic injury and associated long-term complications. 
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Further research is warranted in order to design an optimum dosing strategy for single or 
combination small molecule inhibitors of CYP eicosanoid pathway to rectify the CBF 
dysregulation, and improve long-term functional outcomes after stroke injury. 
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APPENDIX A: 
 
Tie2-CYP4F2 transgenic mice functional characterization  
 
A.1 Tie2-CYP4F2 vector creation:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig A-1:  Map of Tie2-CYP4F2 insert in pBSK(+) vector. CYP4F2 is expressed in vascular 
endothelium under Tie2 promoter with full enhancer sequence. Transgenic mice were 
created on C57BL/6 strain.  
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A.2 CYP4F2 mRNA expression in the Tie2-CYP4F2 transgenic mice: 
Fig A-2:  mRNA expression levels of CYP4F2 in different tissues of WT and 
heterozygous transgenic mice from different lines. Highest expression was 
observed in lung, brain followed by kidney. 
178 
A.3 Microsomal yield from different batches of transgenic mice: 
Table A-1: Protein estimation of microsomes from batch-1Tie2-CYP4F2 mice 
Liver Kidney Lung Heart Brain 
Wt (g) 
Conc. 
Wt (g) 
Conc. 
Wt (g) 
Conc. 
Wt (g) 
Conc. 
Wt (g) 
Conc. 
S.No Sample Gender GT (µg/µL) (µg/µL) (µg/µL) (µg/µL) (µg/µL) 
1 4T1-7 F Het 0.336 2.20 0.082 1.13 0.035 0.212 0.049 3.57 0.1813 10.40 
2 4T2-3 F Het 0.324 3.35 0.096 1.35 0.029 0.334 0.047 4.05 0.1669 10.47 
3 4T2-4 F Het 0.383 5.05 0.106 1.49 0.027 0.389 0.033 2.59 0.1976 10.44 
8 T492 M Het 0.437 2.69 0.111 2.13 0.059 0.659 0.041 4.38 NA - 
10 3468-08 M Het 0.273 2.75 0.137 2.79 0.0790 1.062 NA - 0.2067 10.50 
4 4T2-5 F WT 0.397 3.50 0.103 1.56 0.032 0.383 0.048 4.03 0.1963 10.76 
5 4T2-6 F WT 0.399 3.51 0.092 1.38 0.029 0.248 0.038 3.01 0.1930 10.91 
6 4T3-4 F WT 0.344 2.88 0.114 1.64 0.038 0.352 0.064 5.18 0.1931 10.55 
7 4T3-5 F WT 0.295 3.04 0.119 1.84 0.044 0.464 0.042 5.44 0.2439 10.27 
9 MH78-2 M WT 0.332 2.88 0.115 2.12 0.096 1.003 0.044 4.66 NA - 
GT: genotype; Het: heterozygous; WT: Wild type 
179 
A.3 Microsomal yield from different batches of transgenic mice: 
Table A-2: Protein estimation of microsomes from batch-2 Tie2-CYP4F2 mice 
Liver Kidney Lung Brain Heart 
Wt (g) 
Conc. 
Wt (g) 
Conc. 
Wt (g) 
Conc. 
Wt (g) 
Conc. 
Wt (g) 
Conc. 
S.No Sample Gender GT (µg/µL) (µg/µL) (µg/µL) (µg/µL) (µg/µL) 
1 4T12-6 F WT 0.1120 3.03 0.0588 3.28 0.0393 1.65 0.2625 6.48 0.0565 10.87 
2 4T13-1 M Het 0.0838 2.86 0.0756 3.43 0.0416 1.64 0.3020 6.88 0.0614 13.08 
3 4T13-2 M WT 0.1534 4.52 0.1030 3.88 0.0438 1.95 0.3359 6.98 0.0626 20.62 
4 4T13-3 F Het 0.1529 3.51 0.0615 2.12 0.0400 1.75 0.3326 6.78 0.0743 13.74 
5 4T13-4 F Het 0.1596 3.45 0.0736 4.15 0.0394 1.86 0.3535 9.85 0.0643 18.62 
6 4T13-5 F WT 0.1471 3.72 0.0578 2.60 0.0344 1.89 0.3574 9.09 0.0443 12.04 
GT: genotype; Het: heterozygous; WT: Wild type 
180 
A.4 Functional activity evaluation of different batches of transgenic mice: 
Table A-2: Functional activity evaluation in different tissues of from batch-1 Tie2-CYP4F2 mice 
Liver Kidney Lung Brain Heart 
20-HETE 20-HETE 20-HETE 20-HETE 20-HETE 
Velocity 
(pmol/mg/min) 
Velocity 
(pmol/mg/min) 
Velocity 
(pmol/mg/min) 
Velocity 
(pmol/mg/min) 
Velocity 
(pmol/mg/min) 
S.No Line Gender GT Avg SD 
% 
C.V Avg SD 
% 
C.V Avg SD 
% 
C.V Avg SD 
% 
C.V Avg SD 
% 
C.V 
1 4T1-7 F Het 217.7 26.2 12.0 19.4 2.3 11.7 5.0 3.40 0.41 12.1 0.6 0.04 8.0 
2 4T2-3 F Het 243.6 7.9 3.2 13.2 0.5 3.8 14.1 0.3 2.4 2.27 0.26 11.6 0.4 0.02 5.2 
3 4T2-4 F Het 217.1 33.8 15.6 12.5 1.1 8.6 7.8 1.6 20.7 2.53 0.24 9.4 0.4 0.01 2.8 
4 4T2-5 F WT 219.5 25.1 11.4 2.9 0.8 26.8 7.6 1.0 13.0 3.05 0.16 5.3 NF 
5 4T2-6 F WT 355.5 27.8 7.8 10.7 1.3 12.1 14.5 2.43 0.44 18.0 NF 
6 4T3-4 F WT 266.7 13.4 5.0 15.4 0.7 4.5 13.4 1.4 10.5 1.87 0.14 7.7 0.3 
7 4T3-5 F WT 265.2 27.0 10.2 11.8 0.7 6.2 12.5 1.3 10.6 2.26 0.08 3.7 NF 
8 T492 M Het 203.4 18.2 8.9 18.8 0.5 2.7 34.4 1.5 4.3 
Not collected 
0.4 0.1 4.0 
9 MH78-2 M WT 289.3 31.1 10.7 16.1 1.5 9.5 27.1 1.8 6.5 NF 
10 P3468-8 M Het 188.1 23.8 12.6 40.0 3.9 9.9 18.1 1.1 6.2 5.26 0.90 17.19 Not collected 
GT: genotype; Het: heterozygous; WT: Wild type 
20-HETE formation was highest in liver, followed by kidney, and lungs and brain. 20-HETE detection was negligible in heart microsomes of WT 
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A.4 Functional activity evaluation of different batches of transgenic mice: 
Table A-3: Functional activity evaluation in different tissues of from batch-2 Tie2-CYP4F2 mice 
Liver Kidney Lung Brain Heart 
20-HETE 20-HETE 20-HETE 20-HETE 20-HETE 
Velocity 
(pmol/mg/min) 
Velocity 
(pmol/mg/min) 
Velocity 
(pmol/mg/min) 
Velocity 
(pmol/mg/min) 
Velocity 
(pmol/mg/min) 
S.No Line Gender GT Avg SD 
% 
C.V Avg SD 
% 
C.V Avg SD 
% 
C.V Avg SD 
% 
C.V Avg SD 
% 
C.V 
1 4T12-6 F WT 612.3 42.4 6.9 83.7 16.0 19.1 12.0 1.6 13.0 2.75 0.27 9.8 NF 
2 4T13-2 M WT 459.2 42.3 9.2 156.4 3.6 2.3 6.6 0.0 0.1 1.62 0.20 12.5 NF 
3 4T13-5 F WT 499.3 68.1 13.6 39.5 1.1 2.7 6.8 2.1 31.7 1.87 0.23 12.2 NF 
4 4T13-1 M Het 506.7 70.0 13.8 120.1 11.1 9.2 18.1 0.0 0.0 4.00 0.54 13.5 0.05 0.004 8.66 
5 4T13-3 F Het 525.1 49.2 9.4 51.6 0.7 1.3 14.8 2.5 16.6 2.01 0.30 14.9 0.07 0.002 3.20 
6 4T13-4 F Het 588.8 30.3 5.1 36.1 1.2 3.3 14.6 2.0 13.9 1.62 0.04 2.6 0.05 0.000 0.00 
GT: genotype; Het: heterozygous; WT: Wild type 
20-HETE formation was highest in liver, followed by kidney, and lungs and brain. 20-HETE formation was not detected in WT heart microsomes 
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